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Fibroblasts are abundant mesenchymal cells present in all tissues in a quiescent state, 
which contribute to wound healing when activated. Cytokine transforming growth 
factor-β1 (TGF-β1) stimulates fibroblast-myofibroblast differentiation, which induces 
extracellular matrix secretion, tissue contraction and promotes cancer cell migration. 
Hence, chronic activity of stromal myofibroblasts correlates with a poor prognosis for 
cancer and organ fibrosis patients. Therefore, modulating myofibroblast activity may 
reduce the severity of these diseases. Previous research suggests blockade of 
transmembrane integrin receptors expressed by fibroblasts prevents TGF-β1-
induced differentiation, indicating integrins are attractive therapeutic targets. 
However, fibroblasts derived from different organs exhibit heterogeneity, although 
their integrin expression and integrin-regulated differentiation has not been directly 
compared. The aim of my research was 1) to understand and compare how integrins 
regulate TGF-β1-induced activation of fibroblasts derived from normal skin, lung and 
breast tissue; 2) to examine the global gene expression of TGF-β1-treated lung 
fibroblasts; 3) to identify novel therapeutic targets that modulate TGF-β1-induced 
activation of lung fibroblasts using a drug library.  
qPCR showed skin, lung and breast fibroblasts differentially expressed TGF-β1-
induced activation markers, including ACTA2, FN1, TIMP3, CTGF and SERPINE1, in 
addition to integrin genes for α1, α4, α11 and β3. Small-molecule inhibitors of αv 
integrins only reduced the invasion of TGF-β1-exposed skin fibroblasts, but not lung 
or breast fibroblasts. siRNA against α11, β3 and β5 decreased TGF-β1-induced 
collagen contraction and activation marker expression in skin and lung fibroblasts, 
while α1 siRNA prevented collagen contraction by breast fibroblasts only. RNA 
sequencing of TGF-β1-treated lung fibroblasts revealed pro-inflammatory and pro-
fibrotic pathways were significantly enriched, while screening TGF-β1-treated lung 
fibroblasts with a FDA-approved drug library identified 46 hits that significantly 
reduced α-smooth muscle actin and fibronectin expression.  
Overall, genes are differentially expressed in TGF-β1-treated skin, lung and breast 
fibroblasts, while different integrins in each fibroblast appear to regulate invasion, 
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TGF-β1-induced collagen contraction and gene expression. RNA sequencing revealed 
TGF-β1 promotes the expression of a pro-tumour signature in lung fibroblasts and 
several novel therapeutic targets that modulate the activation of lung fibroblasts 
have been identified. Understanding these integrin-dependent and independent 
mechanisms will facilitate the generation of myofibroblast-targeted treatments for 
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CHAPTER I. INTRODUCTION 
1.1. Fibroblast biology 
Fibroblasts are mesenchymal, spindle-shaped cells that are present in a quiescent 
state in most mammalian tissues. In response to various cytokines and changes in 
stiffness of their surrounding environment, fibroblasts differentiate into 
myofibroblasts[1], where they coordinate the synthesis, organisation and 
maintenance of the extracellular matrix, which functions as a scaffold that binds 
together organ tissue. Myofibroblasts maintain tissue homeostasis and hence, 
demonstrate prominent roles during embryonic development and wound repair, but 
also undergo activation in pathological states, such as cancer and organ fibrosis[2]. 
1.1.1. The role of fibroblasts during wound healing  
The term ‘myofibroblast’ was originally suggested after the discovery that fibroblasts 
located within a newly secreted matrix of a healing wound, named granulation tissue, 
displayed distinct contractile apparatus within the cell cytoplasm. These consisted of 
densely packed bundles of actin stress fibres that were organised into 
microfilaments, indicating cells had adopted a contractile phenotype[3]. These 
findings were further illustrated by plating human skin fibroblasts obtained from 
healing wounds on to collagen gels, which were contracted to 50% of their original 
size within 24-hours. This was in contrast to healthy dermal fibroblasts derived from 
non-wounded skin, where prominent actin stress fibres were absent and cells took 
at least three times longer to achieve the same level of contraction, demonstrating 
fibroblasts undergo phenotypic changes during wound healing[4].  
Universally, α-smooth muscle actin (α-SMA), which is a constituent of these stress 
fibres is predominantly used as a molecular marker of fibroblast-to-myofibroblast 
differentiation[1]. However, the identification of myofibroblast-specific markers is 
required, as smooth muscle cells and contractile cells surrounding vasculature called 
pericytes may also express α-SMA[5].  
Wound healing is a dynamic process involving multiple stages and cellular 
contributions. In brief, this process has three primary stages: inflammation, 
granulation tissue formation and regeneration. Initial tissue injury causes damaged 
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capillaries to activate circulating platelets, which initiate the formation of a fibrin-
based blood clot. Platelets release cytokines and chemotactic factors, such as 
transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor (PDGF) 
which recruit inflammatory cells, including neutrophils, to remove debris from the 
site of injury and circulating monocytes, which mature into macrophages after 
infiltrating the wound from the local tissue and blood supply[6]. Macrophages are an 
additional source of TGF-β1 and PDGF, which promote endothelial cell recruitment 
and fibroblast proliferation and migration into the wound site, as displayed in Figure 
1.1a[7]. The importance of this cytokine environment is typified by macrophage 
ablation in mice, which display defective wound repair[8].         
The second stage of wound repair involves the formation of new blood vessels at the 
site of injury and the differentiation of recruited fibroblasts into α-SMA-expressing 
myofibroblasts, which generate granulation tissue by secreting extracellular matrix 
proteins to stabilise the wound, 3-4 days after injury[6]. The predominant 
extracellular matrix (ECM) component deposited in the initial fibrin clot is 
myofibroblast-secreted fibronectin that constitutes the scab covering the wound 
site[9]. This provides a framework for myofibroblast-secreted collagen type III fibrils 
that are gradually replaced by collagen type I to facilitate rebuilding of the wound 
space, which is a key structural component of dermal tissue[10]. 
Myofibroblasts then contract this underlying connective tissue to bring wound 
margins closer together[11]. Fibroblasts are mechanoresponsive cells as increases in 
the tension of granulation tissue also promotes α-SMA expression, which 
corresponds with the level of contractility. This phenomenon was demonstrated by 
Hinz and colleagues, who subjected tissue strips from wound sites to tension, which 
correlated with higher expression of α-SMA and fibronectin splice variant ED-A, 
compared to control tissue strips exhibiting lower levels of tension[12]. Contraction 
of the granulation tissue permits re-epithelialization, whereby local keratinocytes 
migrate along the wound edge and begin to proliferate (Figure 1.1b). Previous 
studies demonstrate that double paracrine signalling occurs between keratinocytes 
and fibroblasts, whereby IL-1 secreted from these epidermal cells stimulates the 
release of cytokine IL-6 from fibroblasts, which promotes keratinocyte 
16 
 
proliferation[13]. Moreover, wounds of IL-6 knockout mice exhibit less infiltrating 
leukocytes and angiogenesis culminating in delayed wound closure[14, 15]. 
 
 
A) The initial phase of wound healing results in fibrin clot formation and 
infiltration of inflammatory cells, which stimulate and recruit local fibroblasts. B) 
Remodelling of the wound involves production of proteases such as matrix 
metalloproteinases (MMPs) and urokinase/tissue plasminogen activator 
(uPA/tPA) by epidermal cells and granulation tissue formation and contraction by 
fibroblasts, which facilitates re-epithelialisation and angiogenesis. TGF-β: 
Transforming growth factor-β. PDGF: Platelet derived growth factor. FGF-2: 
Fibroblast growth factor. Image adapted from Bissell and Radisky, 2001. 
 




In the final phases of wound healing the mechanical tension is lowered, which 
induces a reduction of myofibroblast numbers by apoptosis[5], although it is 
unknown whether myofibroblasts can revert into quiescent non-α-SMA-expressing 
fibroblasts[6].  
The process of wound healing encapsulates key functions of myofibroblasts, 
including migration, the production of inflammatory mediators and the secretion and 
contraction of the extracellular matrix. Many of these functions, begin with TGF-β1 
stimulation, which is a potent inducer of this active phenotype.   
 
1.2. TGF-β1 activation  
TGF-β1 is a pleiotropic cytokine with wide ranging biological effects, including cell 
proliferation, differentiation and apoptosis[16]. It is a component of the TGF-β 
superfamily of related signalling molecules, which contain common features such as 
the positioning of 7 cysteine residues in their core structure. This family includes 3 
TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3), Activins, Nodal and bone 
morphogenetic proteins (BMPs), each with differential effects[17]. As TGF-β1 is the 
more abundant isoform and a potent inducer of fibroblast-to-myofibroblast 
differentiation[18], it was solely used in this study, therefore following literature is 
focused on this isoform. 
TGF-β1 is secreted by damaged epithelial cells, immune cells, myofibroblasts and 
tumour cells[19], though it is initially translated as a precursor protein that is 
intracellularly processed via proteolytic cleavage into a latent form. This comprises 
homodimeric TGF-β1 that is non-covalently bound to the amino-terminal of ‘latency-
associated peptide’ (LAP) and latent TGF-β binding protein (LTBP)[16, 20], which is 
secreted in this inactive complex that binds fibrillin-1 and fibronectin in the ECM 
(Figure 1.2A)[21]. Active TGF-β1 is then released from matrix-bound LAP-LTBP via 
various mechanisms, including proteolytic degradation of LAP via proteases localised 
to the cell surface of epithelial cells, particularly matrix metalloproteinase-2 (MMP-
2)[22] and MMP-9[23] and myofibroblast-mediated contraction of the matrix, which 
primes latent-TGF-β1 for activation. In 2014, Klingberg and colleagues demonstrated 
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that when myofibroblasts contract the ECM, they reorganise LTBP-fibronectin into 
dense fibrils, whereas undifferentiated fibroblasts are unable to do so. This appears 
to facilitate more efficient activation and hence, higher levels of active TGF-β1 are 
generated by myofibroblasts[24]. Transmembrane integrin receptors also represent 
a key mechanism by which epithelial cells and fibroblasts bind and activate latent 
TGF-β1, as further detailed in section 1.3. 
1.2.1. TGF-β receptor signalling in fibroblasts     
Once released from its latent complex, active TGF-β1, -2 and -3 are each capable of 
binding to the type II TGF-β receptor expressed by fibroblasts, epithelial cells, 
inflammatory cells and endothelial cells. This dimeric receptor exists as a 
constitutively active serine-threonine kinase, and upon binding the cytokine, 
dimerises with the type I receptor dimer, inducing autophosphorylation (Figure 
1.2B)[16]. This permits the recruitment and activation of canonical TGF-β signalling 
proteins, namely receptor-activated Smad2 and Smad3, that when phosphorylated 
bind Smad4 (Figure 1.2C) and translocate to the nucleus, to induce the transcription 
of various genes[25].  
In addition, several positive and negative regulatory proteins also exist, including 
Smad anchor for receptor activation (SARA), which facilitates the binding of Smad2 
to TGF-β receptors, and inhibitory Smad7, which interferes with the phosphorylation 
of Smad2/3 and mediates TGF-β receptor degradation[26], preventing downstream 
signalling. To induce transcription of key TGF-β1 target genes, the complex of 
Smads2/3 and Smad4 bind to Smad-binding elements in DNA, though they require 
synergy with additional transcription factors. These include AP-1 or TFE3, which bind 
to specific DNA sequences within TGF-β response elements and initiate transcription 
of key myofibroblast genes, such as protease inhibitor plasminogen activator 
inhibitor-1 (SERPINE1)[27]. Another key set of genes induced by TGF-β1 stimulation 
are the cell surface receptors, integrins, whereby TGF-β1 also signals via integrins to 























1.3. The role of integrins in cell biology 
1.3.1. Integrin composition  
Integrins are major adhesion receptors expressed on the plasma membrane of many 
cell types, including fibroblasts. They are heterodimers that consist of one α- and one 
β-subunit, whereby 18 α- and 8 β-subunits have been previously identified (Figure 
1.3). Twenty-four combinations of heterodimers exist and some display restricted 




Fibronectin- and fibrillin-bound latency-associated peptide (LAP) and latent 
TGF-β-binding protein (LTBP) keep the TGF-β homodimer in an inactive complex 
(A). Various mechanisms release TGF-β, which binds to the corresponding type 
I and type II receptor, which undergo autophosphorylation (B). Smad anchor for 
receptor activation (SARA) promotes Smad2/3 phosphorylation, while Smad7 
prevents this action. Phosphorylated Smad2/3 (C) binds to Smad4 and 
translocates to the nucleus to bind Smad-binding elements (SBE) in DNA. 
Recruitment of transcription factors (TF) to the T-box binding element (TBE) 
permits the transcription of target genes. Image from Hayashi and Sakai, 2012. 
Figure 1. 2. Latent-TGF-β1 activation and TGF-β receptor signalling. 
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by leukocytes, while αIIbβ3 integrins are restricted to platelets[29]. To note, there 













In addition, each integrin binds particular extracellular ligands, as listed in Table 1.1. 
For example, ECM proteins, such as collagens are ligands for integrins α1β1, α2β1 
and α11β1, or cell surface proteins, such as intracellular adhesion molecules (ICAMs) 
expressed by endothelial and inflammatory cells bind to αLβ2 integrins on 
leukocytes[30].  
Integrins bind to corresponding ligands through the recognition of particular amino 
acid sequences. For example, collagens exhibit the GFOGER motif[31], while the 
arginine-glycine-aspartic acid (RGD) motif is expressed by many glycoproteins, in 
addition to fibronectin and the latency-associated peptide of TGF-β1[32]. The RGD 
sequence is recognized by eight integrins, including α5β1[33] and all αv-containing 
integrins, including αvβ3 and αvβ5, which are expressed by TGF-β1-activated 
fibroblasts[34]. It has previously been established that epithelial αvβ6 is a key 
Integrin α- & β-subunits form heterodimers in various combinations to form 
receptors for particular ligands, e.g. collagen and laminin. RGD receptors are 
integrins that bind to proteins containing an arginine-glycine-aspartic acid 
sequence. Integrins can also exhibit restricted expression to certain cell types, 
e.g. only white blood cells express β2, β7. Image from Hynes et al, 2002. 
 
Figure 1. 3. Mammalian integrin subunit binding partners. 
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activator of latent TGF-β1, which physically binds to the RGD sequence and induces 
a conformation change in LAP by exerting force generated intracellularly, thereby 
releasing the TGF-β1 cytokine[35]. This function is particularly notable in damaged 
and cancerous tissues, where αvβ6 expression is upregulated[36]. In addition, αvβ8 
displays a similar role using protease MMP-14 to release TGF-β1 by cleaving LAP in 
cerebral tissue[22] and regulatory T-cells[37], though its expression has not been 
extensively studied in fibroblasts. Sheppard and colleagues also recently 
documented αvβ1, which is expressed by lung fibroblasts and hepatic stellate cells, 
also directly binds and activates latent TGF-β1[38]. 
In addition, prior evidence suggests fibroblast integrins prime latent TGF-β1 for 
activation. Earlier studies by Wipff and colleagues suggested αvβ5, and to a lesser 
extent αvβ3 and β1 integrins expressed by myofibroblasts mediate TGF-β activation 
by contracting the matrix, which transmits conformational changes to ECM-bound 
















Table 1. 1. Overview of the regulation of integrin expression by TGF-β. 
Integrin Main ligand Effect of TGF-β Cell type Context 
α1β1 Collagens, 
Laminins 






Keratinocytes, fibroblasts Collagen remodelling and contraction, myofibroblast 
differentiation, re-epithelialization  
α3β1 Laminins Upregulation, 
downregulation 
Keratinocytes, fibroblasts, 
carcinoma cells, alveolar cells 
Re-epithelialization during wound healing, EMT, 
cancer cell migration and invasion 
α5β1 Fibronectin Upregulation Keratinocytes, fibroblasts, 
carcinoma cells, endothelial cells 
Re-epithelialization, EMT, migration and invasion, 
endothelial cell migration and tube formation 
α6β1 Laminins Upregulation Carcinoma cells, alveolar epithelial 
cells, leukaemia cells 




Upregulation Fibroblasts, vascular smooth 
muscle cells 
Myofibroblast differentiation, vascular smooth 
muscle cell contraction 
α11β1 Collagens Upregulation Fibroblasts, mesenchymal stem cell Myofibroblast differentiation, contraction 
αvβ3 RGD, 
fibronectin 
Upregulation Fibroblasts, carcinoma cells, 
endothelial cells 
Myofibroblast differentiation, angiogenesis, 
carcinoma cell migration and invasion 
αvβ5 RGD, 
vitronectin 
Upregulation Keratinocytes, fibroblasts Myofibroblast differentiation, re-epithelialization, 
EMT, cancer cell migration and invasion 
αvβ6 RGD, 
fibronectin 
Upregulation Keratinocytes, carcinoma cells, Re-epithelialization during wound healing, EMT, 
cancer cell migration and invasion 
EMT, epithelial-to-mesenchymal transition; ICAM1, intercellular adhesion molecule 1; RGD, arginine–glycine–aspartate; TGF-β, transforming 
growth factor-β. Adapted from Margadant and Sonnenberg, 2010. 
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1.3.2. Integrin structure and activation 
Generally, the α- and β-subunits are transmembrane-localised glycoproteins, with an 
extracellular ectodomain, a transmembrane domain and a short cytoplasmic tail. In 
2001, breakthrough electron microscope imaging of the αvβ3 crystal structure 
revealed different conformations of ligand-free and ligand-bound integrins[40], 
which displayed similarity to integrins αIIbβ3 and αxβ2. The current models of 
integrin activation propose that integrins exist in an inactive bent configuration, 
where the ligand binding site is near the plasma membrane and cell receptor 
stimulation induces the formation of an upright higher affinity structure of integrins 
(Figure 1.4). Furthermore, experimentally locking integrins in a bent state by inducing 
disulphide bonds prevented ligand binding by αvβ3 and αIIbβ3 integrins[41]. In 
addition, the upright extended configuration exists in a closed and open state, 
whereby the open state exhibits the highest affinity for ligand binding. The rationale 
for this conformation is best characterized by platelets, where integrins expressed by 
circulating cells are inactive to avoid potentially detrimental attachment and 
accumulation in blood vessels. In 2016, these various integrin configurations were 
also extended to α5β1 integrin, which only adhered to fibronectin in the extended-
open conformation, but not while bent or extended-closed, demonstrating similarity 
to the mechanism of β2 and β3-containing receptors[42]. This concept is aptly named 
the ‘switchblade’ model and encompasses these 3 key states of integrin 
activation[43]. An alternative hypothesis named the ‘deadbolt’ model suggests more 
modest changes occur around the bent conformation, which can bind potentially 
ligands, although due to technical difficulties investigating the arrangement of 
solubilised integrins, the details of this model have yet to be defined. Nevertheless, 
the flexibility afforded to integrins derives from individual domains that comprise 
each α- and β-subunit.  
The α-chain consists of 4-5 units; a 7-bladed ‘β-propeller’, which contains a calcium 
ion binding site that modulates ligand binding, a ‘thigh’ and 2 ‘calf’ domains, as 
shown in Figure 1.4. Furthermore, 50% of integrins display an additional small ‘α-I’ 
domain that sits within the β-propeller. There are two chief regions of inter-domain 
flexibility, one is the linker between the β-propeller and the thigh and the second is 
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the bend between the thigh and calf-1 domain (the ‘genu’), mirroring a similar region 
in the integrin β-subunit. The β-subunit consists of 7 domains; a β-I domain 
containing a significant α7 helix, a ‘hybrid’, a ‘plexin-semaphorin-integrin’ (PSI), 4 
epidermal growth factor (EGF) modules and a β-tail that lacks enzymatic activity, 
though creates a platform where multiple signalling molecules interact and initiate 
downstream signalling cascades[44].  
Extracellular ligand binding takes place at the interface between the α- and β-
subunits. Binding is dependent on the conformation of the β-I head domain, as a 
downward movement of its α7 helix (visible in the β-I domain of the extended-closed 
and open structure in Figure 1.4) reveals the presence of metal ion-binding sites for 
magnesium and manganese cations, which promote ligand binding. There is also a 














Three conformational states of integrins are shown during ligand binding (i, ii, 
iii). Ligand binding occurs when integrins display the extended-open 
conformation, where the α- and β- transmembrane domains are separated (iii). 
(iii) shows the name of each domain composing the α and β subunits. TM; 
transmembrane. Image adapted from Luo and Springer, 2006.  
Ligand 
Figure 1. 4. The structure and activation of integrin heterodimers. 
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1.3.3. Integrin-mediated outside-in signalling  
Extracellular ligand binding to integrins is associated with the recruitment of several 
cytoplasmic proteins to the short integrin β-tail[45]. In 2015, Horton and colleagues 
conducted data mining studies to identify proteins that constitute the integrin 
‘adhesome’ when various cells lines, including foreskin and renal fibroblasts were 
plated on fibronectin. By integrating the proteome data from separate cell lines, they 
found 2,412 proteins were implicated in integrin adhesion complexes, where 60 
proteins comprised a core signature in at least 5 cell types and included novel 
proteins in addition to well-known integrin-associated factors. These included 
kindlin, talin and vinculin[46], whereby previous studies have demonstrated kindlin 
and talin are important for mediating β1 and β3 integrin activation in platelets and 
fibroblasts[47, 48]. Talin and kindlin each bind to particular motifs in cytoplasmic 
integrin β-tails. This is supported by evidence of talin-bound integrins, which display 
extended structures, as opposed to bent, suggesting talin is associated with the 
activated heterodimer. In addition, vinculin[49] and talin[49] contain multiple actin-
binding sites, enabling integrins to mechanically link proteins in the extracellular 
space to the intracellular actin cytoskeleton, which allows integrins to regulate cell 
shape and contractility.  
Individual integrins exhibit weak interactions with the ECM and constitute ‘nascent 
adhesions’, which mature into larger focal adhesions containing clustered integrins, 
reinforcing adhesion sites[50]. This creates a hub for recruited intracellular signalling 
molecules, such as tyrosine kinase focal adhesion kinase (FAK)[51], which undergoes 
autophosphorylation or TGF-β1-mediated phosphorylation, and subsequently 
activates tyrosine kinase Src[52], facilitating the activation of various downstream 
signalling cascades, as displayed in Figure 1.5. This process is referred to as ‘outside-
in’ signalling, where short-term changes induce cytoskeletal reorganisation to adapt 
cell shape and prepare for cellular migration, while long-term signalling (60 minutes 
plus) may affect the expression of genes that regulate survival, differentiation and 
growth of cells[45]. The Ras-ERK (extracellular signal-regulated kinase) pathway is a 
key cascade activated by the FAK-Src complex, which is implicated in regulating 
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transcription in myofibroblasts, while FAK was identified as a key protein involved in 
mediating TGF-β1-induced fibroblast α-SMA expression[28].  
Depending upon the particular ECM protein and integrin engaged, integrins are 
capable of activating particular intracellular pathways. For example, when rat cardiac 
fibroblasts were plated on fibronectin, α4-, α5- and RGD integrins mediated the 
activation of ERK2 in response to stretch, whereas binding of integrins to vitronectin 
or laminin contributed to the activation of the c-Jun NH2-terminal kinase (JNK1) 
pathway [53]. Consequently, downstream transcription factors induce gene 
expression in fibroblasts, indicating integrin signaling, as well as the TGF-β1 pathway 










1.3.4. Inside-out signalling  
Integrins are unusual as transmembrane receptors as they can signal bidirectionally. 
Inside-out signalling is important during embryonic development and in response to 
vasculature injury and inflammation[56]. This type of signalling is initiated by 
Tissue stiffness, matrix proteins and growth factor receptor (GFR) signalling 
promote integrin activation and several downstream signalling pathways that 
regulate cellular functions. Phosphatidyinositol-4,5-bisphosphate 3-kinase 
(PI3K), integrin-linked kinase (ILK), focal adhesion kinase (FAK), extracellular 
signal regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK). Image from 
Ledgate et al, 2009. 
Figure 1. 5. Key downstream signalling pathways activated by integrins. 
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cytokine and G-protein coupled receptor stimulation[57], producing intracellular 
signals that promote binding of cytosolic proteins, such as talin, kindlin and FAK to 
the integrin cytoplasmic β-tail. The talin head domain disrupts bonds between the α- 
and β-transmembrane domains, inducing separation that causes a conformational 
change to push integrins into a highly adhesive state, from the inside-outwards[58]. 
Moreover, kindlin contains similar structural domains to talin and supports talin-
mediated integrin activation, by binding NXXY motifs in β1, β2 and β3 integrin tails, 
thereby functioning as a co-activator[59]. This inside-out-in signalling activates 
various intracellular signalling pathways to regulate a variety of cell functions 
summarised in Figure 1.5. 
 
1.4. The role of integrins in TGF-β1-induced fibroblast activation and activity  
1.4.1. Fibroblast differentiation  
Previous studies have shown that TGF-β1 stimulation of human lung fibroblasts up-
regulated specific integrin subunits, including α1, α2, α3, α5 and β1, which enabled 
regulation of cell adhesion and positioning[60]. Moreover, matrix stiffness may also 
promote integrin upregulation, as mechanical strain and TGF-β1 stimulation of 
mouse embryonic fibroblasts resulted in a 2-fold and 8-fold increase in α11 
expression, respectively[61].  
Localised scleroderma is a skin connective tissue disorder characterised by an 
abundance of collagen, where dermal fibroblasts derived from these tissues express 
a higher number of αvβ5 integrins, which enhance autocrine TGF-β1 signalling[62]. 
Endogenously secreted TGF-β is kept inactive by a latent complex and Asano and 
colleagues suggested that this latent complex is removed via an αvβ5-mediated 
pathway in dermal fibroblasts, which resulted in the release of active TGF-β into the 
ECM. Therefore, when an anti-αvβ5 antibody was applied in vitro, TGF-β1 remained 
inactive and myofibroblast activation was reduced, as noted by decreased type I 
procollagen, MMP-1 and Smad3 expression[63].  
Integrin intracellular signalling is also a key mechanism of TGF-β1-induced 
differentiation. The administration of siRNA to collagen-binding integrin α11 in the 
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presence of active TGF-β1, prevented α-SMA expression by 50% in human corneal 
fibroblasts[61]. In fibroblasts derived from human oral mucosa and dermal tissue, 
anti-αvβ3 and anti-αvβ5 antibody blockade inhibited the expression of α-SMA and 
collagen gel contraction. Moreover, this also occurred in the presence of 
supplementary active TGF-β1, suggesting factors downstream of integrins were 
necessary to transmit TGF-β1 signals[64].  
Thannickal and colleagues observed that TGF-β1-induced lung myofibroblast 
differentiation was prevented in non-adherent cells, suggesting integrin-dependent 
signalling was required. FAK was identified as a key signal transduction protein as 
inhibition of FAK’s key phosphorylation site, tyrosine-397, prevented TGF-β1’s ability 
to promote α-SMA expression and stress fibre formation. In addition, there was a 
correlation between TGF-β1-induced up-regulation of integrin subunits α4, α5 and 
β5 and the autophosphorylation of FAK, which was not observed when fibroblasts 
were plated on a non-integrin binding matrix[28]. In a separate study it was revealed 
that TGF-β1-mediated FAK phosphorylation was Smad3-dependent, while treatment 
of lung fibroblasts with an RGD-containing integrin inhibitor partially attenuated 
phospho-FAK expression after TGF-β1 stimulation[65]. Meanwhile, integrin β3 siRNA 
led to reduced phospho-FAK levels, while the addition of a FAK inhibitor to 3T3 
murine fibroblasts culminated in significantly less type I collagen and connective 
tissue growth factor (CTGF)[66]. These studies suggest that TGF-β1 signals lead to 
phosphorylation of FAK and integrins enhance this phosphorylation, perhaps by 
creating docking sites for various signalling complexes.  
Another key signalling component is integrin-linked kinase (ILK), a scaffold protein 
that can directly bind integrins or indirectly via kindlin-2, forging a link between 
integrins and the actin cytoskeleton[47]. ILK inactivation results in smaller focal 
adhesion sites, lower α-SMA and significantly inhibited collagen gel contraction. ILK-
deficient dermal fibroblasts are unable to undergo differentiation into 
myofibroblasts in response to TGF-β1 and display impaired activity of TGF-β 
canonical and non-canonical signalling pathways, as observed by reduced 
phosphorylation of Smad2 and ERK, respectively[67]. Together, these data suggest 
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that integrin engagement is required for promoting TGF-β1-induced fibroblast 
differentiation. 
1.4.2. Fibroblast-mediated contraction and invasion 
Fibroblast-mediated remodelling and invasion are key functions during wound repair 
and constitute important measurements of myofibroblast activity. A key mediator of 
fibroblast contraction is GTPase RhoA, which is activated by both TGF-β1[68] and 
downstream of integrin-FAK interaction (Figure 1.5). RhoA activates Rho kinase 
(ROCK), which increases phosphorylation of the light chain of myosin II that is 
connected with the cell’s actin filaments, forming an actomyosin network[69]. TGF-
β1 contributes to this network by promoting stress fibre formation, while integrins 
are important for mechano-transduction activity, as the tension generated by a 
fibroblast’s intracellular actin, including α-SMA, can be transmitted by integrins at 
focal adhesion sites, which pull on the outside ECM to aid contraction[70]. 
Furthermore, the continuous turnover of actin filaments at focal adhesion sites, 
allows integrins to sustain cell contraction[69].  
As mentioned previously, integrin knockdown or blockade corresponds to a 
reduction in matrix contraction. The key contribution of non-canonical signalling was 
also recently demonstrated using tamoxifen, which impaired collagen contraction in 
TGF-β1-treated primary human skin and breast fibroblasts. The authors found that 
tamoxifen did not affect Smad-mediated signalling, but instead reduced ERK1/2 
expression and downstream transcription factor AP-1, which significantly decreased 
the expression of α-SMA, actin-myosin regulator calponin and actin-crosslinker 
SM22α; each of which contribute to force generation in fibroblasts[71]. 
Separate integrins appear to regulate ECM remodelling depending on which matrix 
protein they detect. Huhtala and colleagues found that when fibroblast α5β1 bound 
intact fibronectin, MMP secretion was increased, though binding of α4β1 to a domain 
of fibronectin named connecting segment-1 (CS-1) suppressed the secretion of 
collagenase MMP-1 [72]. In addition, when breast fibroblasts were plated on collagen 
type I gels, they enhanced secretion of protease procathepsin B, which was mediated 
by collagen-binding integrins α1β1 and α2β1, as secretion was downregulated by 
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50% when these integrins were inhibited [73]. Furthermore, the knockdown of 
integrin α11 in periodontal ligament fibroblasts reduced their capacity to contract 
collagen gels by up to 40%. This capacity was partially dependent on MMP-13 
expression, as α11 silencing resulted in more than 80% decline in MMP-13, while the 
application of an MMP-13 inhibitor to wild-type fibroblasts notably reduced 
contraction [74]. These studies suggest integrins regulate protease expression by 
processing cues from their immediate environment.  
The actin-myosin machinery of fibroblasts also regulates cell migration and invasion, 
and expectedly, integrins are also key contributors to this process. Although there 
are few studies directly linking TGF-β1 to fibroblast invasion, TGF-β1 stimulation of 
fibroblasts may increase proteases that are required for ECM breakdown during cell 
invasion[68]. One example is MMP-2, which is localised to α6β1 on fibroblasts and 
mediates proteolysis of basement membrane protein collagen type IV. Moreover, 
α6β1 was upregulated on lung fibroblasts in response to matrix stiffness, while anti-
α6β1 blocking antibody and siRNA knockdown significantly prevented invasion[75]. 
FAK is also known to regulate lung fibroblast migration, predominantly via β1 
integrins[76], and 3T3 murine fibroblast invasion by activating transcription factor 
STAT3-dependent MMP-2 expression[77].  
Again, these studies demonstrate that integrins are important for regulating TGF-β1-
induced remodelling and invasion by fibroblasts. However, although fibroblast 
differentiation and activity is necessary during wound healing, these cells are 
inappropriately activated in diseases such as cancer and organ fibrosis.  
 
1.5. The role of fibroblasts in disease  
1.5.1. Cancer progression    
In 2014, 29% of all deaths registered in England and Wales were due to cancer[78], 
while lung cancer remains the most common cause of cancer death in both males 
and females combined[79]. In addition, lung, breast, prostate and bowel cancers 
accounted for 53% of all newly diagnosed cancers in the UK in 2013[80]. Although 
the incidence of particular cancers, such as those originating in the bladder[81] and 
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stomach[82] are gradually decreasing, the incidence of cancer overall is steadily 
increasing each year[83].  
Cancer becomes lethal if it metastasizes from the primary tumour site to other 
organs, making it more difficult to treat, resulting in a poorer prognosis. This is 
exemplified by the way cancer disease stage is linked with survival rates. For 
example, 87% of lung cancer patients presenting small tumours at stage I survived 
for at least one year, compared to the survival of only 19% of patients diagnosed with 
metastatic stage IV cancer[84]. Moreover, myofibroblasts identified in the tumour 
microenvironment are known to directly influence cancer spread[85].  
The existence of a reactive stroma that actively supports angiogenesis, tumour 
growth and progression has been known for many years. Once a tumour has formed, 
it initiates a local inflammatory reaction and eventually modifies the 
microenvironment. Fibroblasts are key components of this reactive stroma and 
copious levels of TGF-β1 are released from tumour and inflammatory cells[86]. 
Eberlein and colleagues showed that integrin αvβ6 expressed by lung tumour cells 
was key in activating latent TGF-β1, which led to the TGF-β1-induced differentiation 
of normal fibroblasts into a cancer-associated fibroblast (CAF)-like phenotype. These 
effects were abrogated by an αvβ6-blocking antibody and a small molecule inhibitor 
of the TGF-β type I receptor[87].  
Tumours appear to chronically activate a wound healing signature in resident 
fibroblasts, as recently characterised by the overlapping genes expressed by breast 
CAFs and TGF-β1-stimulated mammary fibroblasts[88]. Furthermore, paracrine 
interactions between tumour cells and fibroblasts promotes a cancer-promoting 
feedback loop. This was exhibited by colorectal and breast cancer cells that activated 
TGF-β/Smad signalling in adjacent CAFs, which increased secretion of hepatocyte 
growth factor (HGF)[89] and TGF-β1 (at a higher level than TGF-β2 and TGF-β3)[90]. 
These factors reciprocally promoted cancer cell proliferation and tumour cell 
invasion via EMT[91], respectively, also signifying that hyper-activated TGF-β1 
signalling appears to be sustained by the secretion of TGF-β1 from myofibroblasts. 
Hence, it is unsurprising that the presence of α-SMA-positive myofibroblasts 
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correlates with a worse clinical outcome in many types of cancer, including 
breast[92], colorectal[93] and oral squamous cell carcinomas (SCC)[94].    
Similar to their function during wound healing, activated fibroblasts secrete a variety 
of matrix proteins, such as fibronectin and collagens, in addition to matrix cross-
linking proteins that produce a stiffened matrix; a characteristic feature of many 
tumours, which supports tumour proliferation and cell invasion[95]. A key cross-
linking protein secreted by TGF-β1-stimulated fibroblasts is lysyl oxidase (LOX)[96], 
which catalyses post-translational modifications on ECM proteins that are essential 
to the structure of newly generated or repaired connective tissue. LOX initiates 
covalent crosslinking between elastin and collagen fibres by oxidising the amino acid 
lysine within these proteins. The oxidised lysine can then covalently attach to 
neighbouring fibres, thereby stabilising the ECM and producing stiffness when LOX is 
overexpressed[97].  
Recent in vivo evidence shows LOX-mediated stiffness is associated with driving 
colorectal cancer proliferation and invasion by increasing FAK/Src phosphorylation in 
tumour cells, which may be mediated by tumour β1 integrin[95]. LOX expression also 
correlates with metastasis and a poor prognosis in various cancers, including 
squamous cell carcinomas[98]. Voloshenyuk and colleagues demonstrated that LOX 
expression is regulated by both canonical and non-canonical TGF-β1-induced 
signalling in cardiac fibroblasts, as the chemical inhibition of Smad3, PI3K, p38-MAPK, 
JNK and ERK1/2 each significantly reduced the expression of LOX in response to TGF-
β1 stimulation[96].  
Furthermore, changes in matrix tension also affects other cell types in the tumour 
microenvironment. Recent proteomic studies of endothelial cells cultured on 
matrices of increasing stiffness has shown endothelial cells upregulate matricellular 
protein CCN1. CCN1 then mediates the expression of endothelial cell adhesion 
molecule N-cadherin, and together these proteins promote the adhesion of tumour 
cells to endothelial cells, enhancing trans-endothelial migration of tumour cells into 
blood vessels. They further validated this in vivo, whereby inducible knockdown of 
vascular CCN1 reduced the number of circulating tumour cells and metastases in the 
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lungs[99], providing a defined mechanism by which exaggerated matrix stiffness 
could facilitate tumour cell invasion.    
In addition, recent results demonstrated that breast CAFs exposed to matrix stiffness 
exhibit greater expression of pro-fibrotic genes, such as collagen (COL1A1, COL1A2, 
COL4A5) and LOX, in addition to increased intracellular tension, each of which were 
mediated by transcription factor SNAI1. These results suggest that stiffness is 
sustained in the tumour microenvironment by continued myofibroblast-induced 
fibrogenesis[100]. ECM contraction also accounts for increased matrix stiffness. Erler 
and colleagues recently found that prolonged hypoxia suppressed CAF-induced 
contraction and reduced levels of phosphorylated myosin light chain, which 
accounted for decreased matrix stiffness. Moreover, using organotypic invasion 
assays they showed that hypoxia prevented the ability of CAFs to remodel the ECM, 
which resulted in significantly lower SCC cell invasion[101].   
Integrin function also contributes to the capacity of fibroblasts to promote tumour 
cell invasion. Gaggioli and colleagues showed that silencing of α3 and α5 integrin 
subunits in head and neck CAFs reduced contraction of organotypic gels, thereby 
fewer holes were created, which significantly decreased collective SCC cell 
invasion[102]. Paracrine factors secreted by activated fibroblasts also bind to local 
tumour cells. Tumour-derived TGF-β1 was found to activate fibroblasts in vitro, which 
induced SNAI1-dependent prostaglandin E2 secretion that correspondingly 
stimulated collective breast tumour cell invasion[103].  
Particular integrins also appear to have an earlier role during tumour cell growth. The 
integrin subunit α11 expressed on stromal fibroblasts markedly increased the growth 
of lung adenocarcinomas compared to tumour cells co-injected with fibroblasts 
derived from α11-knockout mice. Further tests revealed tissue from α11-knockout 
tumours expressed 250-fold less insulin growth factor-2 (IGF-2) when compared to 
wild-type. IGF-2 is a potent stimulator of epithelial cell growth and when stably 
knocked down in wild-type fibroblasts and co-implanted with lung cancer cells, 
resulted in a significantly slower tumour growth rate[104]. These studies implicate 




Inflammation is also a hallmark of cancer and aside from activating fibroblasts in the 
tumour microenvironment, myofibroblasts secrete a variety of pro-inflammatory 
mediators that influence tumour growth, immune infiltration, invasion and 
metastasis[105]. Profiling of CAFs from ovarian and breast tumours showed high 
levels of pro-inflammatory transcription factor NF-κB, cytokine IL-6, cyclooxegenase-
2 (COX-2) and CXCL1. This signature and the presence of infiltrating leukocytes was 
enhanced in invasive ductal carcinoma tissue compared to normal breast and ductal 
carcinoma tissue, demonstrating a correlation between inflammation and tumour 
progression[106]. These pro-invasive effects were also demonstrated recently, 
whereby chemokines CCL2 and CCL7 secreted by CAFs promoted the invasion of 
hepatic carcinoma cells in vitro. Further analysis to define this mechanism revealed 
that fibroblast-secreted chemokines promoted hedgehog and TGF-β1 signalling 
pathways in tumour cells, which increased the expression of EMT markers, such as 
vimentin, N-cadherin and Twist1[107].  
Despite advances in developing targeted anti-tumour treatments, CAFs can promote 
drug resistance by a variety of mechanisms[108]. For example, Sahai and colleagues 
showed that inhibition of oncogene B-RAF in melanoma cells using drug PLX4720 
actually activated CAFs. These CAFs contracted matrices, which increased β1 
integrin/FAK/ERK signalling in melanoma cells, providing tolerance to the same 
drug[109]. Another mechanism involves the secretion of hepatocyte growth factor 
(HGF) from fibroblasts, which binds to its receptor, c-Met on adjacent tumour cells, 
while activation of c-Met signalling is associated with increased drug resistance to 
inhibitors of the epidermal growth factor receptor[110] and B-RAF[111], used in lung 
cancer and melanoma treatment, respectively. Conversely, addition of the c-Met 
inhibitor cabozantinib overcame gemcitabine-resistant pancreatic cancer cells and 
induced apoptosis[112].  
Fibroblasts can also undergo senescence, which contributes to both tumorigenesis 
and tumour progression. Cellular senescence is an aging-associated process and can 
result from oncogenic-stress, oxidative stress, DNA damage and after repeated cell 
replications[113].  Although this is a tumour-suppressive mechanism to induce cell-
cycle arrest in cells at risk of malignant transformation, senescent cells can 
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accumulate in tissues over time. Senescent and activated fibroblasts differ in growth 
potential, yet they can both stimulate proliferation and invasion of epithelial cells by 
the secretion of paracrine factors[113]. Studies suggest senescent fibroblasts acquire 
a permanent senescence-associated secretory phenotype (SASP), resulting in the 
secretion of many types of proteases, including PAI-1, MMP-3, collagenase MMP-1 
and pro-inflammatory factors, such as chemokines and cytokine IL-6, which is a key 
inducer of senescence and is also secreted by senescent fibroblasts[114, 115]. 
The presence of the SASP phenotype has previously been linked to promoting the 
growth and invasion of tumour cells from different tissues, including premalignant 
and malignant breast epithelial cells (via MMP secretion)[116], and growth of 
prostate tumour cells via CTGF[117]. In addition, it was reported that senescent 
fibroblasts also promote angiogenesis via increased secretion of VEGF, as noted by 
greater blood vessel density when tumours formed alongside senescent fibroblasts 
compared with pre-senescent cells[118]. Furthermore, senescent fibroblasts also 
affect the balance of infiltrating immune cells, by promoting the recruitment of 
monocytes and regulatory T cells, which are associated with tumour 
progression[115].  
These studies demonstrate the detrimental consequences of fibroblast activation 
and activity within the tumour microenvironment, as summarised in Figure 1.6, and 
supports the hypothesis that targeting fibroblasts/myofibroblasts may reduce the 
progression and lethality of cancer.  
Figure 1. 6. Key contributions of myofibroblasts to cancer progression. 
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1.5.2. Organ fibrosis 
Fibrosis occurs in organs such as the lungs, liver and heart and is often fatal as the 
condition worsens over time. Approximately 5000 new cases of pulmonary fibrosis 
are diagnosed every year in the UK, with the average survival only 3 years after 
diagnosis and lung transplant the only option if patients fail to respond to drug 
treatment[119]. Fibrosis results from an over-production of collagen, which 
surrounds organs reducing their functional efficiency and culminates in organ failure. 
In cases of idiopathic pulmonary fibrosis (IPF) the effectiveness of existing treatment 
options is disappointing and drug options are limited, as no particular cause of lung 
fibrosis is currently known, therefore current drugs only slow disease 
progression[120]. Though, fibrotic tissue is typically characterised by an 
overabundance of differentiated fibroblasts and these cells are thought to be crucial 
in its pathophysiology, particularly as they are the largest producers matrix 
proteins[121] and promote tissue stiffness via contraction and matrix 
crosslinking[122]. 
In fibrotic tissues, aberrant TGF-β1 signalling is present. Initially, damaged epithelia 
upregulate αvβ6 integrin, which culminates in excess levels of active TGF-β1 and 
subsequently promotes the differentiation of resident fibroblasts into α-SMA-
positive myofibroblasts[123]. This critical step was demonstrated using β6 knockout 
mice and αvβ6 antibody blockade, which protected mice from lung fibrosis[124]. 
Tissue remodelling by myofibroblasts is also evident in cases of cardiac fibrosis. 
Sarrazy and colleagues found that integrins αvβ3 and αvβ5, as well as phospho-
Smad3 were upregulated in porcine models of ventricular fibrosis, indicating the 
presence of enhanced TGF-β signalling. This increased integrin expression was also 
replicated with TGF-β1 treatment of human cardiac fibroblasts in vitro. Furthermore, 
by co-culturing cardiac fibroblasts with mink lung epithelial cells containing a PAI-1 
promoter fused with a luciferase reporter gene, they found αvβ3 and αvβ5 mediated 
latent TGF-β1 activation, while this effect was abolished using small-molecule 
peptide inhibitors to αvβ3 (EMD 66203) and αvβ5 (cilengitide)[125]. 
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Increased fibroblast proliferation also characterises organ fibrosis. Analysis of tissues 
from IPF patients identified an accumulation of myofibroblasts in the alveolar wall of 
the airways, which generate a rich collagen type I matrix that permanently damages 
the alveoli. In addition, in healthy lung fibroblasts, interaction of β1 integrins with 
polymerised collagen suppresses fibroblast proliferation by inhibiting the PI3K 
pathway via activation of its negative regulator PTEN. In contrast, IPF fibroblasts 
displayed pathological α2β1 integrin signalling in response to collagen, leading to 
chronic activation of the PI3K pathway promoting proliferation. Furthermore, the 
authors suggested that IPF fibroblasts attain a stable pathological phenotype that 
does not depend on continuous exposure to pro-fibrotic cytokines, supporting the 
hypothesis that alternative strategies outside direct TGF-β antagonism may be more 
beneficial for development of future therapies for IPF[126].  
Liver fibrosis also is an increasingly common condition, which occurs as a 
consequence of chronic liver injury and inflammation, e.g. excess alcohol 
consumption, chronic hepatitis. Activated hepatic stellate cells (HSC) are a common 
source of hepatic myofibroblasts, which are localised to the lining of blood vessels in 
the liver. They display enhanced secretion of collagen, TGF-β1, PDGF and CTGF, which 
all contribute to fibrogenesis, resulting in liver failure[127]. Moreover, integrins 
expressed by these myofibroblasts play a prominent role in this process, as activated 
HSCs exhibit increased α5β1 integrin, active ERK signalling and enhanced collagen 
expression[128]. In addition, de-novo expression and upregulation of α8β1 integrin 
has been noted in myofibroblast-like HSCs and pulmonary interstitial fibroblasts, 
respectively, where this integrin has increased interaction with fibronectin, resulting 
in contraction-induced tissue stiffness[129]. 
In 2013, Henderson, Sheppard and colleagues highlighted the value of targeting 
integrins expressed by myofibroblasts in the treatment of organ fibrosis. Deletion of 
the integrin αv subunit in murine HSCs protected mice from liver fibrosis, most likely 
due to the declined TGF-β1 activity that was measured. This method of indirectly 
reducing TGF-β1 activity claims benefits over direct global TGF-β inhibition, which is 
expected to increase adverse side effects. The same results were also found using 
mouse models of lung and renal fibrosis[130]. Furthermore, recent work from the 
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Sheppard laboratory using a small-molecule inhibitor suggested these effects in lung 
and liver fibrosis models were mediated by integrin αvβ1, which they showed binds 
to the latency-associated peptide and activates TGF-β1[38].  
These studies strongly suggest that myofibroblasts are important therapeutic targets 
due to their overwhelming contribution during cancer and organ fibrosis. 
Furthermore, transmembrane integrins expressed by myofibroblasts are potential 
therapeutic targets due to their ability to activate latent TGF-β1 and mediate TGF-β1 
signalling intracellularly. However, targeting fibroblasts is complex, as fibroblasts 
from different organs are known to exhibit heterogeneity.   
 
1.6. The heterogeneity of fibroblasts 
Fibroblasts are not a uniform cell type, as those derived from different tissues display 
varied characteristics in features including proliferation, transmembrane protein 
expression and matrix production[131]. The presence of these subpopulations is 
highlighted by studies of the human dermis where three fibroblast subtypes have 
been identified, namely papillary, reticular and hair follicle-associated fibroblasts. 
Schafer and colleagues found that human papillary fibroblasts divide more rapidly 
than their reticular counterparts, while reticular fibroblasts are capable of 
contracting collagen matrices faster than those derived from the papillary 
dermis[132, 133].  
More recently, analysis of fibroblasts from different organs demonstrated that 
cardiac fibroblasts had lower proliferation rates when compared with human dermal 
and lung fibroblasts. Production of matrix metalloproteinases was also variable, as 
the expression of MMP-1 was 24- and 17-fold higher in dermal and pulmonary 
fibroblasts when compared to cardiac fibroblasts, respectively. These tissue-specific 
differences were further highlighted in response to cytokine TNF-α stimulation, as 
each fibroblast displayed different levels of sensitivity[134].  
Fibroblasts from distinct locations also appear to respond differently to TGF-β1 
stimulation. In response to TGF-β1, lung myofibroblasts increased α-SMA and pro-
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collagen type I expression, whereas TGF-β1-treated nasal fibroblasts showed no 
change in either factor[135]. While the addition of TGF-β1 to fibroblasts from the oral 
mucosa, dermis and kidneys also induced different levels of α-SMA expression, with 
renal fibroblasts exhibiting 2-4 times less α-SMA protein than oral mucosa and 
dermal fibroblasts. Moreover, these results correlated to differential levels of gel 
contraction in response to TGF-β1, as renal fibroblasts contracted collagen to the 
lowest degree. In addition, the investigators in the same study examined integrin-
mediated regulation in each of the three fibroblast types. They found that both anti-
αvβ3 and anti-αvβ5 blocking antibodies prevented TGF-β1-induced α-SMA 
expression in oral mucosa and dermal fibroblasts. However, blockade of only αvβ5 in 
renal fibroblasts prohibited differentiation, suggesting that fibroblasts from different 
organs rely on distinct integrins to regulate differentiation[64].   
Although TGF-β1 is a key promoter of fibroblast-myofibroblast differentiation, very 
few studies have compared the responses of fibroblasts derived from separate 
organs to this cytokine. Furthermore, integrins appear to regulate TGF-β1-induced 
differentiation, in addition to myofibroblast functions, such as secretion, contraction 
and invasion. However, the complete integrin expression profile of different TGF-β1-
treated fibroblasts has not been previously compared, therefore whether integrin 
function also produces heterogeneity and different integrins regulate myofibroblasts 
from separate organs, has not been examined extensively. These integrin 
characterisation studies in TGF-β1-exposed fibroblasts are required to further 
understand and manipulate myofibroblast biology, which my research aims to 
address.  
Fibroblast phenotypes are also important to characterise, as their tissue of origin may 
dictate the mechanisms by which they enhance tumour progression. Sorell and 
colleagues demonstrated that co-culturing papillary dermal fibroblasts with human 
vascular endothelial cells in vitro supported the formation of highly branched, tube-
like structures, whereas the same experiments using reticular dermal fibroblasts 
instead were unable to reproduce this result. HGF was identified as the key factor 
supporting blood vessel growth, which was secreted significantly more by papillary 
fibroblasts than reticular fibroblasts, indicating fibroblasts from separate sites have 
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specialised functions[136]. A similar phenomenon was also found in the context of 
cancer tissue, whereby breast tumour cell growth was only supported by IL-6-
secreting breast, lung and bone fibroblasts, in contrast to skin fibroblasts that 
expressed little or no IL-6. Moreover, senescent skin fibroblasts that exhibited 
increased IL-6 production were able to promote breast tumour growth and invasion 
in vivo, which was inhibited with anti-IL-6 antibody treatment[137]. These studies 
indicate that fibroblasts from distinct sites may differentially support tumour 
progression by particular paracrine factors they express, thereby highlighting the 
need to characterise fibroblasts from different tissues, which could guide future drug 
treatments.  
 
1.7. Potential therapeutic treatments in cancer and lung fibrosis 
1.7.1. Targeting myofibroblasts 
Due to their capacity to promote tumour growth, invasion, immune suppression, 
drug resistance and fibrosis, myofibroblasts comprise a key approach to 
therapeutically target the stroma.  
In preclinical models of pancreatic cancer, hedgehog signalling was implicated as a 
key regulator of paracrine signalling, as tumour cells secreted hedgehog ligands that 
activated the pathway in stromal cells. Olive and colleagues found that hedgehog 
inhibitor IPI-926 depleted stromal fibroblasts in mouse models of pancreatic ductal 
adenocarcinoma and enhanced intra-tumoural vessel density, facilitating the 
delivery of cytotoxic drug gemcitabine[138]. However, clinical trials using hedgehog 
inhibitors in pancreatic cancer patients showed no clinical benefits, perhaps 
demonstrating limitations of mouse models and off-target effects. Moreover, it was 
noted that there was an absence of predictive stromal biomarkers, which could help 
assess therapeutic efficacy[139].  
Matrix metalloproteinases secreted by stromal fibroblasts also represent potential 
therapeutic targets. Several pieces of promising pre-clinical data led to clinical testing 
of pan-protease inhibitors, such as tanomastat and marimastat (Table 1.2). However, 
these drugs showed no significant benefits over standard treatments in patients with 
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non-small cell lung cancers. Suggested reasons for this outcome were that early-
stage tumours were more dependent on MMP function than later-stage tumours and 
that further research was needed to identify which specific MMP isoforms contribute 
to a poor prognosis[140].  
 
Table 1. 2. Examples of small-molecule inhibitors that target the extracellular 
matrix (ECM)/fibroblasts for cancer treatment. 
Molecule Target Status (reference) 
Marimastat MMP – broad 
spectrum 
Phase III negative for NSCLC, SCLC and 
breast cancer (NCT00002911, 
NCT00003010, NCT00003011) 
Prinomastat MMP-2, 3, 9, 13, 14 Phase III negative for NSCLC and prostate 
cancer (NCT00004199, NCT00003343) 
Tanomastat MMP-2, 3, 9 Phase III terminated (NCIC-CTG trial 
OV12) 
Neovastat VEGFR2, MMP-2, 9, 
12 
Phase III negative for NSCLC 
(NCT00005838) 
Rebimastat MMP-1, 2, 8, 9, 14 Phase III negative NSCLC (NCT00006229) 
Vismodegib Smoothened receptor Phase II negative for CRC and ovarian 
cancer and phase II for PDAC 
(NCT00636610, NCT00739661, 
NCT01064622) 
Saridegib Smoothened receptor Phase II terminated for PDAC 
(NCT01130142, NCT01310816) 




Tyrosine kinase receptors also reflect key therapeutic targets on both tumour cells 
and fibroblasts, which are paracrinally activated by excess ligands secreted by both 
cell types. Therefore, growth factor receptor signalling by mediators such as PDGF, 
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) is 
chronically activated in many tumour types. Lucitanib is an inhibitor of receptors 
FGFR1-3, VEGFR1-3 and PDGFRα and β, which inhibited tumour growth in vivo[141]. 
It is currently under investigation in phase II trials for the treatment of metastatic 
breast cancer (NCT02202746, NCT02053636) and lung cancer (NCT02109016), while 
NSCLC; non-small cell lung cancer, SCLC; small-cell lung cancer, CRC; colorectal 
cancer, PDAC; pancreatic ductal adenocarcinoma. Adapted from Junttila and 
Sauvage, 2013.  
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dovitinib is a non-specific receptor tyrosine kinase inhibitor in phase II trials for 
pancreatic (NCT01497392), urothelial (NCT01732107) and prostate cancers 
(NCT01741116). In addition, the multiple tyrosine kinase receptor inhibitor 
nintedanib improved progression-free survival and is currently being tested at phases 
I-III for several cancers, including monotherapy and combination treatment for 
ovarian cancer (NCT01610869, NCT01669798) and various solid tumours 
(NCT02835833)[142]. Furthermore, as the same pathways were known to be pro-
fibrotic, nintedanib was investigated for the treatment of IPF. In preclinical tests, 
nintedanib counteracted the effects of TGF-β1 on myofibroblasts from IPF patients, 
as measured by reduced MMP expression, collagen secretion and cell proliferation, 
demonstrating the benefits of directly targeting myofibroblasts, even when already 
differentiation[143]. Encouragingly, in 2014 nintedanib was approved for use in the 
United States and Europe after it demonstrated the ability to slow the decline in lung 
function, though due to the limited number of current treatment options available 
for IPF, there is still a requirement for drugs that reverse fibrotic effects in lung 
tissues[144].  
1.7.2. Targeting integrins 
Due to their exposed extracellular ligand-binding sites, cell-type restricted expression 
and their association with certain diseases, integrins have long been attractive 
therapeutic targets in the pharmaceutical industry. Currently, there are only three 
heterodimers, αIIbβ3, α4β1 and α4β7, which are therapeutically targeted using 
monoclonal antibodies, peptides or small-molecule inhibitors in cases of thrombosis, 
Crohn’s disease, multiple sclerosis and ulcerative colitis. In addition, at present, there 
are 80 clinical trials investigating integrins as therapeutic drugs, imaging agents and 
biomarkers[145].  
Integrins are upregulated in many cancers and are known to facilitate metastasis. 
Overall, several compounds targeting integrins in cancers have been previously 
investigated for clinical development, while the majority of these drugs target 
integrins that recognise the RGD sequence (i.e. αv-, α5- or α8- containing 
integrins)[146]. One predominant example is cilengitide, a cyclic peptide that blocks 
αvβ3 and αvβ5 integrins. However, in contrast to preclinical data, cilengitide 
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detrimentally enhanced angiogenesis[147], though recently Wong and colleagues 
took advantage of this by administering low doses of cilengitide to mice, which aided 
the delivery of anti-cancer drugs inside perfused tumours, thereby reducing tumour 
growth[148]. Furthermore, this peptide was investigated for combination treatment 
of glioblastoma in phase II trials, where improved progression-free survival 
correlated with tumour αvβ3 expression, though there was no correlation with 
phospho-Smad2 levels, suggesting cilengitide was not regulating TGF-β 
activation[149].  
Regulating TGF-β1 activation by indirectly targeting integrins, such as αvβ6 has 
shown positive results during in vivo treatment of breast cancer models[150]. 
Moreover, post-analysis of tissue from the recent phase I/II POSEIDON trial 
investigating the pan-αv blocking antibody abituzumab, demonstrated that 
colorectal tumours that exhibited high αvβ6 expression were predicative of overall 
survival, as survival was only higher in these patients, suggesting inhibiting αvβ6 
provided therapeutic benefit[151]. In addition, αvβ6-blocking antibody STX-100 is 
currently under examination in phase II trials for IPF (NCT01371305). This approach 
of regulating TGF-β activity by targeting integrins may be beneficial as TGF-β1 
activation would be locally controlled. This contrasts to direct global inhibition, which 
could be detrimental where TGF-β1 displays tumour-suppressive functions early in 
cancer pathogenesis.  
In summary, although targeting fibroblasts is, perhaps, an obvious therapeutic 
strategy, a better understanding of mechanisms that regulate myofibroblast biology 
is required to identify new therapeutic targets to modulate the phenotype. This is 
particularly evident in the treatment of cancer and organ fibrosis, as many fibroblast-
targeted agents have failed. Moreover, the identification of targets restricted to TGF-
β1-activated fibroblasts would greatly enhance drug development. Furthermore, the 
use of anti-integrin therapies in various diseases and ongoing clinical trials suggests 





TGF-β1 activated fibroblasts are key contributors to cancer progression and organ 
fibrosis, but these cells display heterogeneity depending on their tissue origin. 
Therefore, the first aim of this study was to compare fibroblast responses to TGF-β1 
stimulation (Results Part I) and determine whether different integrins regulate 
myofibroblast biology (Results Part II). TGF-β1-treated lung fibroblasts were further 
examined to detect global gene expression changes (Results Part III) and identify 
integrin-independent mechanisms involved in regulating differentiation (Results Part 
IV).  
This was investigated by the following: 
1. To compare skin, lung and breast fibroblast responses to TGF-β1, the gene 
‘activation signature’, integrin expression and collagen gel contraction was 
measured.   
2. To examine whether different integrins regulate myofibroblast biology, 
integrins were targeted using small-molecule inhibitors and siRNA-mediated 
knockdown. The activation status of TGF-β1-treated fibroblasts was then re-
examined by measuring invasion, collagen contraction and gene expression. 
3. To examine which biological networks TGF-β1-stimulated fibroblasts 
contribute to, RNA sequencing of TGF-β1-treated lung fibroblasts was 
performed.  
4. To identify additional mechanisms that regulate TGF-β1-induced lung 
fibroblast differentiation, a high throughput screen using a FDA-approved 








CHAPTER II. MATERIALS AND METHODS 
2.1. Cell culture 
2.1.1. Human primary fibroblasts  
All nine strains received were human primary fibroblasts derived from normal tissue 
(Table 2.1). For cell isolation, skin tissue was de-epidermised using dispase (Sigma, 
D4693-1G) and mechanical separation and fibroblasts were released from the dermis 
using collagenase D (Roche, 11088866001). Cells were then filtered through cell 
strainers (Fisherbrand, 22363548) and seeded in 75cm2 dishes. Lung fibroblasts were 
originally sourced from National Disease Research Interchange (NDRI) resource and 
derived by explant culture, as described in [152]. Breast fibroblasts were isolated 
using an adapted method published by Gomm and colleagues[153]. Primary cells 
were isolated from segmented tissue using collagenase (1mg/ml, Sigma, C2674) and 
hyaluronidase (1mg/ml, Sigma, H3506) treatment. The resulting organoids and 
stromal fibroblast fractions underwent three sedimentation steps that separated 
fibroblasts into the supernatant, which was propagated in culture.  
A light microscope (Olympus, IMT-2) was used to observe fibroblast morphology, 
which was expected as elongated cells with bipolar or multipolar processes when 
observed at sub-confluence and arranged in parallel patterns at confluence. 
Fibroblasts were also regularly examined for the presence of Mycoplasma using the 
polymerase chain reaction (PCR) method (see below).  
Table 2. 1. Details of primary fibroblasts used. 
Cell strain Donor details Tissue type Provided by 
Skin strain 1 Male, 28 days Foreskin Dr Su Marsh, 
(Blizard Institute, 
QMUL) 
Skin strain 2 Male, 19 days Foreskin 
Skin strain 3 Adult, unknown Dermal 
Lung strain 1 Male, 60 years Post-mortem Dr Rob Slack 
(GlaxoSmithKline), 
cells from NDRI 
resource 
Lung strain 2 Female, 22 years 
Lung strain 3 Male, 22 years 
Breast strain 1 Female, 27 years Reduction 
mammoplasty 
Dr Jenny Gomm 
(Breast Tissue 
Bank in Barts 
Breast strain 2 Female, 58 years 
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Breast strain 3 Female, 49 years Cancer Institute, 
QMUL) 
 
2.1.2. Human cancer cell lines  
Cancer cell lines (Table 2.2) were solely used during mini-organotypic invasion 
assays. 
Table 2. 2. Details of key cancer cell lines used. 
Cell line Donor 
details 




- Well differentiated, retroviral 







Non-small cell lung cancer, lymph 







Pleural effusion metastases, 




2.1.3. Culture conditions and routine cell culture 
All cells were cultured as adherent monolayers in sterile tissue culture flasks of 
various sizes (Corning 25cm2, 75cm2, 175cm2) in a humidified atmosphere at 37oC 
with 8% CO2. Skin and lung fibroblasts and MDA-MB-468 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, D6429) and breast fibroblasts 
were cultured in a 1:1 mixture of DMEM and Ham’s F12 (Sigma, N6658). VB6 OSCC 
cells were cultured in α-Minimum Essential Medium (α-MEM, Invitrogen, 22571-020) 
supplemented with 18mM adenine (Sigma, A2786-2SG), 0.5μg/ml hydrocortisone 
(Sigma, H4001), 10μg/ml insulin (Sigma, I1882), 10ng/ml epidermal growth factor 
(Sigma, E9644) and 1 x 10-10M cholera toxin (Calbiochem 227035) and H1299 lung 
cancer cells were cultured in Roswell Park Memorial Institute (RPMI-1640, Sigma, 
R8758) medium. All media was supplemented with 10% (volume/volume) foetal 
bovine serum (FBS, Gibco, 10500-064) during routine culture. 
To passage cells after reaching 80% confluence, medium was removed and trypsin-
EDTA (Sigma, 59418C) was added for 2-5 minutes at 37oC to detach adherent cells. 
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Once cells were in suspension, trypsin was inactivated by combining with medium 
containing 10% FBS and centrifuging the cell suspension at 1200rpm for 3 minutes. 
Cell pellets were resuspended in the appropriate medium and counted with a 
haemocytometer using a light microscope, before adding portions of the cell 
suspension to new tissue culture flasks. All fibroblasts used in experiments were 
between passages 2-7.  
For cell preservation, cell pellets were resuspended in mixtures of 90% FBS and 10% 
dimethyl sulphoxide (DMSO) and placed in a cryovial freezing container at -80oC. 
After 48 hours, cryovials were transferred to liquid nitrogen for long-term storage. 
To culture cells from storage, frozen cryovials were held in a 37oC water bath until 
thawed (approximately 1.5 minutes) and diluted with 10ml cell culture medium and 
centrifuged (1200rpm for 3 minutes). Pellets were re-suspended with fresh medium 
and added in appropriate volumes to tissue culture flasks.    
 
2.2. Reagents 
2.2.1. TGF-β1 stimulation of fibroblasts 
During experiments, cultured fibroblasts were either exposed to vehicle alone 
(control sample) composed of 10mM citric acid diluted in 0.1% bovine serum albumin 
(BSA, Sigma A8022) or 5ng/ml TGF-β1 (PeproTech, 100-21). During experiments, 
‘vehicle’ and TGF-β1 was further diluted in 1% FBS in DMEM for specific time-points. 
Further details for each experiment are listed in relevant sections.  
2.2.2. Antibodies 
All antibodies and the final concentrations used are summarised in Table 2.3. 
Table 2. 3. Details of antibodies used. 
Target (Clone) Species Supplier (Cat No) Dilution/Concentration 
α-SMA (1A4) Mouse Dako (M0851) WB: 1/1000, IF-P: 1/50, 
IF-CS: 1/200 
CTGF Rabbit Abcam (AB6992) WB: 1/500 
PAI-1 Goat Abcam (AB31280) WB: 1/1000 
HSC70 Mouse Santa Cruz (sc-137211) WB: 1/1000 
Integrin αv Rabbit CST (4711) WB: 1/1000 
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α-SMA: α-smooth muscle actin, CTGF: connective tissue growth factor, PAI-1: 
plasminogen activator inhibitor-1, HSC70: heat shock 70kDa protein 8, DAPI: 4’,6-
diamidino-2-phenylindole, FC: flow cytometry, WB: western blotting, IF-P/CS: 
immunofluorescent staining (-P: paraffin, -CS: coverslip), CST: Cell signalling 
Technology, HRP: Horseradish peroxidase.  
 
2.2.3. Integrin inhibitors 
Three small-molecule integrin inhibitors were applied to various fibroblast strains 
(Figure 2.1). Compound 1 was SC-68448, compound 2 was cilengitide and compound 
Integrin β3 Rabbit CST (4702) WB: 1/1000 
Integrin β5 Rabbit CST (4708) WB: 1/1000 
Anti-mouse HRP Goat Dako (P0447) WB: 1/1000 
Anti-rabbit HRP Donkey GE Healthcare 
(NA9340) 
WB: 1/1000 
Anti-goat HRP Rabbit Dako (P0160) WB: 1/1000 
Integrin α1 Mouse Millipore (MAB1973Z) FC: 10μg/ml 
Integrin α2 Mouse Millipore (MAB1950Z) FC: 10μg/ml 
Integrin α3 Mouse Millipore (MAB1952Z) FC: 10μg/ml 
Integrin α4 Mouse Millipore (MAB16983Z) FC: 10μg/ml 
Integrin α5 
(P1D6) 
Mouse Millipore (MAB1956Z) FC: 10μg/ml 
Integrin αv (L230) Mouse Hybridoma, in house FC: 10μg/ml 
Integrin β1 
(P4C10) 
Mouse Hybridoma, in house FC: 10μg/ml 
Integrin αvβ3 
(LM609) 
Mouse Millipore (MAB1976Z) FC: 10μg/ml 
Integrin αvβ5 
(P1F6) 
Mouse Millipore (MAB1961) FC: 10μg/ml 
IgG1 isotype Mouse Millipore (MABC002) FC: 10μg/ml, 
IF-CS: 1/1000 
IgG isotype Rabbit Santa Cruz (sc-2027) FC: 10μg/ml, IF-CS: 
1/1000  
Cytokeratin Rabbit Dako (Z0622) IF-P: 1/200 




- ThermoFisher (R415) IF-CS: 1/1000 
Anti-mouse 
Alexa Fluor-488 








3 was an αvβ1-selective inhibitor, which were provided by the Fibrosis and Lung 
Injury Discovery Performance Unit (DPU) Medicinal Chemistry group at 
GlaxoSmithKline (GSK) Medicines Research Centre (Stevenage, UK)[158]. SC-68448 
(Figure 2.1A) is described as an αvβ3 RGD-mimetic antagonist in the literature[159], 
but was shown to target multiple αv-containing integrins by the GSK Fibrosis and 
Lung Injury DPU and is therefore described in this study as a pan-αv inhibitor. 
Cilengitide (Figure 2.1B) is a cyclic RGD peptide that selectively inhibits αvβ3/αvβ5 
integrins by binding to a space between the integrin β-propeller and βA domain in 
the integrin head[160] and the integrin αvβ1-selective compound (Figure 2.1C) is 
‘compound 8’, published by Reed and colleagues[38], which binds to the ligand 
binding α-I region[161]. Each inhibitor was dissolved in 100% (v/v) DMSO at stock 
concentrations of 10mM, aliquoted and stored at -20oC. During experiments, each 
compound was freshly diluted to the required concentration in tissue culture 
medium, as further detailed in relevant sections. Equal volumes of DMSO served as 


















αvβ1 integrin inhibitor 
Integrin inhibitors A) SC-68448 (pan-αv inhibitor), B) Cilengitide (targets 
αvβ3/αvβ5) and C) αvβ1-selective. This compound was designed by combining 
the positively charged guanidine moiety in an αvβ3 inhibitor (blue region) and 
a sulphonamidoproline moiety in an α2β1 inhibitor (green region). Images 








2.2.4. Small interfering RNA (siRNA) oligonucleotides 
Fibroblasts were transfected with a pool of four siRNAs using the human SMARTpool 
siGENOME siRNA (Dharmacon CO). 
 
2.3. Primer design and optimisation 
All primers were manually designed using the NCBI primer design tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and specificity was validated 
using the online Basic Local Alignment Search Tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). When designing primers, criteria included 
that primers should span exon-exon junctions to avoid amplification of genomic DNA 
and that the primer pair should be separated by at least one intron on corresponding 
genomic DNA. In addition, guanine-cytosine content in each primer was 
approximately 50% to regulate primer melting temperature and PCR product size was 
measured between 90-150 base pairs to ensure an efficient reaction.  
Table 2. 4. siRNA product codes and target sequences. 
Target (Cat. No) Target sequences  





















All primers (Sigma-Aldrich, UK) used are detailed in Tables 2.5-2.7. Before 
experimentation, primers were tested to ensure they annealed at 60oC. Therefore, 
standard PCR using MegaMix-Blue (Microzone, 2MMB-5) was conducted using each 
primer (0.5μM) and positive control cDNA (see Section 2.4 for RNA/cDNA synthesis 
method). cDNA was derived from TGF-β1-treated (5ng/ml, 24 hours) fibroblasts to 
optimise myofibroblast activation marker primers and housekeeping genes, while 
cancer cells known to be positive for particular integrins were used to validate 
integrin subunit primers, as listed in Table 2.7. The PCR cycling conditions consisted 
of: one cycle of 30 seconds at 95oC, 35 cycles of 30 seconds at 95oC (denaturation), 
30 seconds of a temperature gradient 55-65oC (annealing), 1 minute of 72oC 
(extension) and lastly one cycle of 1 minute at 72oC (final extension). PCR products 
were run on 1.5% agarose gels with ethidium bromide (Sigma, E1510) and visualised 
using ultraviolet light to confirm products were generated using an annealing 
temperature of 60oC. Subsequently, to determine the efficiency of primer binding to 
template DNA, qPCR (see Section 2.5.2 for qPCR method) was performed with 10-
fold serial dilutions of positive control cDNA. The percentage of primer efficiency for 
each primer is listed beside primer sequences in Tables 2.5-2.7. 
Table 2. 5. Primer details for myofibroblast activation markers. 
 
Primers Primer sequences Primer 
efficiency 
α-Smooth muscle actin: 
ACTA2 – Forward (F) 





Collagen Type I: 
COL1A2 - F 






MMP-1 - F 





Tissue inhibitor of MMP(TIMP3): 
TIMP3 - F 






FN1 - F 





Myosin heavy chain 9: 






MYH9 - R TTTTGGGCAGCTGTGTTGT 







Plasminogen activator inhibitor: 
PAI-1 - F 







Table 2. 6. Primer details for housekeeping genes. 











































Table 2. 7. Primer details for integrin subunits. 
























































































































































































2.4. RNA extraction and cDNA synthesis 
To extract RNA from positive control cells listed in Table 2.7 and fibroblasts at the 
end of each treatment period, cells were first trypsinised, centrifuged, washed with 
PBS and lysed at 4oC using lysis buffer (RLT buffer) provided in the RNeasy Mini kit 
(Qiagen, 74104). Total RNA was then extracted according to the manufacturer’s 
protocol and quantified using a NanoDrop 1000 spectrophotometer (ThermoFisher 
Scientific). Skin fibroblast RNA quality was assessed using the RNA 6000 Nano Chip 
(Agilent Technologies, 5067-1511) on the Agilent 2100 Bioanalyzer (all samples 
exhibited high RNA integrity) and RNA was stored at -80oC. Total RNA (0.5-1μg) was 
reverse transcribed according to the manufacturer’s protocol in a 20μl reaction 
volume using the QuantiTech Reverse Transcription kit containing random primers 
(Qiagen, 205311). The resulting cDNA was then diluted 1:40 in RNAase-free water 
(Sigma, W4502) and stored at –20oC, ready for qPCR. 
 
2.5. Quantitative real-time polymerase chain reaction (qPCR)  
2.5.1. 384-well plate format 
qPCR was conducted to allow housekeeping gene selection, TGF-β1 time-course 
analysis (4-, 8-, 16- and 24-hour treatments) and to assess integrin subunit expression 
in each vehicle and TGF-β1-treated skin, lung and breast fibroblasts. Initially, these 
qPCR experiments were performed manually over 6 months using a 96-well plate 
format. However, as there were hundreds of samples to be assessed, progress was 
improved by moving to a high throughput qPCR method using the 384-well format. 
Dr Steve Ludbrook and Dr Emma Koppe (GlaxoSmithKline, Stevenage) kindly 
permitted the use of their automated pipetting machine, the mosquito HV (TTP 
Labtech) to automatically pipette 4μl mastermix consisting of QuantiTech SYBR green 
(Qiagen, 204145), primers (0.5μM) and RNAase-free water into each well of a 384-
well plate (Applied Biosystems, 4309849), followed by 1μl fibroblast cDNA (1.25ng/µl 
RNA). qPCR was performed at GlaxoSmithKline using the 7900HT Fast Real-Time PCR 
system (Applied Biosystems, 4329001). The cycling conditions involved one cycle of 
2 minutes at 50oC, 10 minutes at 95oC to activate HotStarTaq DNA polymerase, 40 
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cycles of 15 seconds at 95oC, 1 minute at 60oC and 1 minute at 72oC. At the end of 
each qPCR run, an additional step for melt curve analysis was added comprising 15 
minutes at 95oC and 15 minutes at 60oC, to denature all the PCR products in each 
well, whereby the same PCR products have the same melting temperature, which is 
used to determine whether any non-specific amplification has occurred.  
At the end of each qPCR run, a cycle threshold (Ct) value was generated, which is the 
number of cycles that was required for the fluorescence signal to cross the 
threshold/exceed background levels. These values were used for data analysis.  
Housekeeping genes were required to act as internal controls to ensure the quality 
and quantity of cDNA was similar in each untreated/treated fibroblast sample. To 
select housekeeping genes per fibroblast strain, ten housekeeping genes were first 
investigated using qPCR. The 2-ΔCt equation was used to determine which 
housekeeping genes produced similar Ct values between vehicle and TGF-β1-treated 
samples in each of the three independent repeats conducted per fibroblast strain. 
Only housekeeping genes that produced fold-changes between 0.5-1.5 in the TGF-
β1-treated samples relative to vehicle were considered appropriate. The three 
housekeeping genes selected per strain are listed in Table 2.8. Data was analysed by 
normalising the TGF-β1-induced Ct value and vehicle-induced Ct value to the 
housekeeping gene Ct, as detailed here: Fold-change = 2-[(TGF-β1 Ct - Housekeeping 
Ct)-(Vehicle Ct – Housekeeping Ct)].  This is summarised by the equation 2-ΔΔCt, as 
















Table 2. 8. Housekeeping genes used for each strain of skin, lung and breast 
fibroblast during qPCR. 
 
Fibroblast strain Housekeeping genes selected 
Skin strain 1 B2M, GAPDH, PPIA 
Skin strain 2 B2M, GAPDH, TRIM27 
Skin strain 3 B2M, GAPDH, HPRT-1 
Lung strain 1 GAPDH, HPRT-1, PPIA 
Lung strain 2 B2M, HPRT-1, PPIA 
Lung strain 3 GAPDH, HPRT-1, PPIA 
Breast strain 1 B2M, HPRT-1, PPIA 
Breast strain 2 B2M, HPRT-1, TRIM27 
Breast strain 3 B2M, HPRT-1, PPIA 
 
2.5.2. 96-well plate format  
qPCR was conducted in the 96-well plate format (Applied Biosystems, 4346906) for 
all the additional qPCR experiments. This included initial primer efficiency testing, 
integrin siRNA-mediated knockdown and assessing the expression of myofibroblast 
activation markers after integrin knockdown. These qPCRs were performed in 
triplicate wells using 20μl total reaction volumes with SYBR green and 0.5μΜ primers, 
and run on the StepOne Plus system (Applied Biosystems, 4376598) at Barts Cancer 
Institute, using the same method of analysis described in Section 2.5.1, although only 
one housekeeping gene (HPRT-1) was used due to lack of space per plate. The cycling 
conditions were one cycle for 10 minutes at 95oC, 40 cycles for 15 seconds at 95oC, 1 
minute for 60oC, 30 seconds at 72oC and one cycle for 15 seconds at 95oC. An 
additional melt curve analysis step was included which ran for one minute at 60oC 





2.6. Western blotting 
2.6.1. Protein Isolation and quantification 
To collect proteins from fibroblasts, adhered cells were washed with ice cold 
phosphate-buffered saline (PBS, Severn Biotech Ltd, 20-7461-01) and lysed in a fresh 
mixture of protease inhibitor (Calbiochem, 539131) and phosphatase inhibitor 
(Calbiochem, 524625) diluted 1/100 in NP40 cell lysis buffer (Invitrogen, FNN0021). 
Fibroblasts were collected in microcentrifuge tubes by scraping cells in lysis buffer 
using a plastic scraper, which were placed on ice and vortexed every 5 minutes, 4 
times. Lysates were spun in a microcentrifuge at 13,000rpm for 10 minutes at 4oC to 
remove cell debris and supernatants were each transferred into new 1.5ml tubes for 
storage at -20oC. 
Protein concentration was quantified in 96-well plates (Corning, 3599) using Bio-rad 
Protein Assay reagents according to the manufacturer’s instructions (Bio-Rad 
Laboratories, Reagent A, 500-0113, Reagent B, 500-0114, Reagent S, 500-0115), 
alongside a series of known concentrations prepared using BSA (0-5mg/ml). The 
absorbance of each sample was measured at 550nm using a microplate reader 
(Tecan, Infinite F50) and compared between samples of known BSA concentrations 
and cell lysates to determine the micrograms/ml of protein collected.  
2.6.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
To perform SDS-PAGE, lysates containing 15-25µg total protein were diluted in an 
appropriate volume of 2x laemmli sample buffer (Sigma, S3401) and heated to 95oC 
for 10 minutes. Samples were then run on freshly made 8% polyacrylamide gels in 
gel cassettes (ThermoFisher Scientific, NC2010), where resolving gel for a 15ml gel 
consisted of 7ml distilled water, 4ml acrylamide (National Diagnostics, EC-890), 3.8ml 
Tris-HCl (1.5M, pH 8.8), 10% SDS (Fisher Scientific, BP1311-1), 10% ammonium 
persulphate (APS, Sigma, A3678) and 9μl TEMED (National Diagnostics, EC-503). 
Stacking gel (3ml) was composed of 2.1ml distilled water, 0.5ml acrylamide, 0.38ml 
Tris-HCl (1M, H 6.8), 10% SDS, 10% APS and 3μl TEMED and added above polymerised 
resolving gel with a 10-well comb until set. Cassettes were inserted into SDS-PAGE 
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chambers (ThermoFisher Scientific, EI0001) with 10x Tris-glycine SDS-PAGE buffer 
(Severn Biotech, 20-6300-100) diluted in distilled water and lysates were loaded into 
each well alongside a pre-stained protein ladder (ThermoFisher Scientific, 26616) and 
run at 120 volts for 95 minutes.  
2.6.3. Immunoblotting 
Proteins were transferred to nitrocellulose membranes (GE Healthcare, 10600003) 
for up to 3 hours at 35 volts and the resulting membranes were stained with Ponceau 
S (Sigma, P7170) to confirm protein transfer. Membranes were washed in distilled 
water briefly and blocked in 5% BSA and 0.1% tris-buffered saline (TBS)-Tween20 
(TBS; Severn Biotech, 20-7301-10, Tween20; Sigma, P9416) for 30 minutes on a 
rotator. Primary antibodies were diluted in the blocking buffer and incubated with 
the membrane, rotating overnight at 4oC. Subsequently, membranes were washed 
several times in 0.1% TBS-Tween20 and incubated with species-specific horseradish 
peroxidase (HRP) conjugated-secondary antibody for 30 minutes at room 
temperature. Protein bands were visualised by chemiluminescence using HRP 
substrate (Millipore, WBLUR0100) and the ChemiDoc Imager 600 (GE Healthcare). 
2.6.4. Densitometry  
Densitometric analysis was performed using Image J software (National Institute of 
Health, USA) to quantify band densities, which were normalised to the loading 
control (HSC70) for each sample.  
 
2.7. Flow cytometry  
Fibroblasts were trypsinised, counted and resuspended at 4 x 106 cells/ml in FACS 
buffer (0.1% BSA and 0.1% sodium azide diluted in DMEM). 50μl cell suspension was 
aliquoted per tube and incubated with anti-integrin antibodies for 45 minutes on ice. 
A species-matched IgG was also applied to cells as a negative control. Cells were 
washed twice with FACS buffer by centrifuging in between washes (1200rpm, 3 
minutes) and then cells were incubated with species-specific secondary antibody 
AlexaFluor-488 for 30 minutes on ice in the dark. Cells were washed in FACS buffer, 
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resuspended in 400µl and fluorescence was determined with a flow cytometer (BD 
FACS Calibur, BD Biosciences) using Cell Quest Pro software, collecting 10,000 events. 
Data were plotted as geometric mean fluorescence intensity (MFI). 
 
2.8. Collagen gel contraction 
Collagen type I (Corning, 354236) was added at an 8x ratio to 1x concentrated DMEM 
10x (Sigma, D2429) and 1x FBS and neutralised with 0.1M sodium hydroxide on ice 
until the mixture became magenta-coloured. The cell suspension (40,000 cells per 
gel) was resuspended in 100µl DMEM and mixed into the gel mixture. Subsequently, 
400µl gel mix was added to each well of a 24-well plate and initially kept at 37oC for 
2 hours to set, and then incubated overnight to allow cells to adhere, with culture 
media on top. The next day, vehicle or TGF-β1 diluted in 1% FBS in DMEM was added 
on top of gels, which were released from the edge of the well using a sterile needle 
and imaged at selected time-points using a light microscope (Stemi SV11, Zeiss, 
Germany). Gel images were analysed using ImageJ software.  
 
2.9. Mini-organotypic gel invasion assay 
Transwells (0.4μM pore size, Corning, 3470) were placed in 24-well plates and were 
coated with type I collagen diluted in PBS (1/100) and incubated at 37oC for 1 hour. 
Excess collagen in PBS was removed from each Transwell and replaced with a 120μl 
gel mixture. To produce 1ml organotypic gel mixture, the following volumes were 
used: 525µl collagen type I, 175µl Matrigel (Corning, 354234), supplemented with 
100µl 10x DMEM, 100µl tissue culture media, 100µl filtered FBS and neutralised 
using 0.1M sodium hydroxide. Gels were left to polymerise at 37oC for 1.5 hours and 
a 2:1 ratio of fibroblasts (67,000 cells) and tumour cells (33,000 cells) were pre-mixed 
and plated in a total number of 100,000 cells in 200μl culture media on top of each 
gel. Next, 600μl tissue culture media containing 10% FBS was pipetted below each 
Transwell and the plate was incubated at 37oC for 24 hours. The next day, the media 
above each gel was carefully removed as most cells would have adhered to the gel, 
while media below each Transwell was replaced with 350μl cell culture media, which 
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was replaced with fresh media every 2 days. After 7 days, Transwells were fixed in 
10% neutral buffered formalin (Cellstor, BAF-0010-25A) for 24 hours and then placed 
in 70% ethanol for at least 15 minutes. Gels were bisected and embedded in paraffin 
wax and 4μM thick sections were stained with haematoxylin and eosin by Mr George 
Elia (Pathology Centre, Barts Cancer Institute) and imaged using the Zeiss Axiophot 
Microscope (Zeiss, Germany). 
 
2.10. Immunofluorescence 
2.10.1. Cells cultured on coverslips 
Fibroblasts (1 x 104) were plated on to 13mm diameter glass coverslips in 24-well 
plates. After the treatment period, cells were washed thrice in PBS and a cytoskeletal 
fixative (10mM 2-(N-morpholino)ethanesulphonic acid (MES) pH6.1, 125mM KCl, 
3mM MgCl, 2mM EGTA, 10% sucrose, 4% formaldehyde) was applied for 10 minutes 
and cells were washed again in PBS. Fibroblasts were permeabilised using 0.1% 
Triton-x for 5 minutes and blocked with 0.1% sodium azide/0.1% BSA in DMEM for 
30 minutes. Primary antibodies were also diluted in blocking buffer and applied for 
45 minutes. Species-matched immunoglobulin (IgG) isotype controls were applied as 
negative controls. Cells were washed thrice with blocking buffer and Alexa Fluor-
conjugated secondary antibodies diluted in blocking buffer were applied for 30 
minutes while covered with foil. Nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI) diluted in PBS for 10 minutes. Coverslips were gently dipped in 
distilled water, inverted and mounted on glass slides using Mowiol (Calbiochem, 
475904). Stained slides were imaged using a confocal laser-scanning microscope 
(LSM 710, Carl Zeiss, Germany). 
2.10.2. Paraffin-embedded sections 
Paraffin-embedded sections were de-waxed in xylene and rehydrated with 
decreasing concentrations of ethanol. Antigen retrieval constituted heating slides for 
8 minutes in 0.01M citrate buffer. Slides were washed in PBS for 10 minutes, 
permeabilised with 0.2% Triton-x for 5 minutes and blocked in PBSABC (2% BSA, 10% 
FBS diluted in PBS) for 1 hour at room temperature. Primary antibodies were diluted 
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in PBSABC and incubated at 4oC overnight. Slides were washed twice for 5 minutes 
in PBSABC and incubated with Alexa Fluor-conjugated secondary antibodies for 1 
hour at room temperature. Slides were washed in PBSABC and PBS alone and 
incubated with DAPI for 15 minutes. Once re-washed, slides were mounted with glass 
coverslips and Mowoil. 
 
2.11. Integrin manipulation in fibroblasts 
2.11.1. Integrin small-molecule inhibitors 
Fibroblasts were cultured in tissue culture flasks and at 50% confluency were treated 
with either vehicle or TGF-β1 (5ng/ml) in 1% FBS-DMEM for 48 hours. Cells were 
trypsinised and cell pellets were combined with either DMSO control or each of the 
three integrin small-molecule inhibitors in an appropriate volume, ready for plating 
in Transwell invasion assays (Section 2.12) or collagen gel contraction assays (section 
2.8).  
2.11.2. Integrin siRNA transfection 
Fibroblasts were plated in 10cm diameter petri dishes and treated with either vehicle 
or TGF-β1 (5ng/ml) diluted in 1% FBS-DMEM for 48 hours, reaching approximately 
40% confluency. Commercially pooled siRNA (final concentration 15nM, sequences 
detailed in Table 2.4) was mixed with 24µl transfection reagent INTERFERin (PolyPlus, 
409-10) in serum-free DMEM, vortexed and incubated for 15 minutes at room 
temperature. This mixture (1.224ml) was administered to cells covered with a final 
volume of 8ml fresh 1% FBS-DMEM for 72 hours (in the absence of vehicle and TGF-
β1). Non-targeting luciferase siRNA was used as a control for off-target effects. Cells 
were then trypsinised, counted and 40,000 cells were added to collagen gel 
contraction assays or after 72 hours’ siRNA exposure, dishes were placed on ice and 
rinsed in ice cold PBS and cells were scraped using a plastic scrapper in RLT lysis buffer 




2.12. Transwell invasion assay using integrin inhibitors 
To measure cell invasion, Matrigel was diluted in serum-free DMEM and 70µl was 
pipetted to the centre of each Transwell (8µM pore size, Corning, 3422) inserted in a 
24-well plate, which was left to polymerise at 37oC for 90 minutes. 50,000 cells were 
then plated on top of the Matrigel and 500µl of 10% FBS-DMEM was added 
underneath each Transwell and plates were incubated at 37oC for 48 hours. Invaded 
cells that had adhered to the bottom well in the 24-well plate were collected with 
500µl trypsin-EDTA, which was exposed to cells for 45 minutes and then diluted 1/20 
in isotonic buffer (OMNI Life Science, 5651808) for counting using a CASY® counter 
(Shärfe System GmbH, Germany). 
 
2.13. RNA sequencing 
RNA sequencing (RNA-seq) was conducted using total RNA extracted from three 
strains of primary lung fibroblasts that were treated with vehicle and TGF-β1 
(5ng/ml) for 24 hours (RNA extraction: section 2.4). Two biological repeats were 
performed with lung fibroblast strain 1 and strain 3, and one repeat with strain 2. 
These RNA samples were the same as those used for time-course stimulation studies. 
RNA-seq was conducted by the Oxford Genomics Centre, Welcome Trust Centre for 
Human Genetics (UK) using the Illumina HiSeq 4000 platform with 2μg total RNA. 
PolyA selection was performed to detect messenger RNA (mRNA) and 75 base paired-
end reads per sample were generated using the TruSeq Stranded mRNA library 
preparation kit (Illumina, RS-122-2101), with 18 million reads in total. 
2.13.1. Data analysis  
Bioinformatic analysis was completed by Dr Ai Nagano (Barts Cancer Institute). 
Sequencing reads were aligned to the human genome build hg38/GRCh38.p5 with 
the HISAT2 aligner program[163]. Transcript quantification was performed with 
htseq-count, part of the HTSeq package version 0.6.1p1, using GENCODE vh25 
human gene annotation. The read count data was filtered to keep genes that 
achieved at least one read count per million (cpm) in at least 25% of total number of 
samples. Reads per kilobase per million mapped reads (RPKM) values were calculated 
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with the conditional quantile normalization (cqn) counting for gene length and GC 
content, in the R statistical environment via Bioconductor packages. Differential 
expression analysis was performed using LIMMA to fit a linear model to the 
expression data for each gene to detect differentially expressed genes between two 
groups. Differential expressed genes were gauged using LIMMA empirical Bayes 
statistics module and the adjusted p-values (false discovery rate) were estimated by 
the Benjamini and Hochberg procedure[164]. The differentially expressed genes 
were selected when the raw p-value was less than 0.05 and when the relative fold 
change was equal to or above 2-fold. Unsupervised hierarchical clustering (method: 
Ward, distance: Pearson correlation) was performed on the heatmap to assess the 
reproducibility of the groupings. To generate expression heatmaps, RPKM values 
were scaled relative to the mean expression of each gene across all samples. 
Differentially expressed genes were input into Database for Annotation, Visualisation 
and Integrated Discovery (DAVID) and Ingenuity Pathway Analysis (IPA) software to 
detect enriched biological pathways involved in the experimental results. 
 
2.14. FDA-approved drug library screening 
2.14.1. Treatment of lung fibroblasts 
Primary lung fibroblasts were plated at a density of 1000 cells per well in a volume of 
95µl of 1% FBS-DMEM in 96-well plates (Corning, 3599). Dr Sarah Martin (Barts 
Cancer Institute) kindly provided the FDA-approved drug library (in 2µl aliquots), 
which was contained in a 96-well plate format (SelleckChem, L1300) and dissolved in 
98µl DMEM containing 1% FBS just prior to use. A multi-channel pipette was used to 
add 5µl compound or DMSO alone to duplicate wells (final concentration 10µM), 
which was incubated for 48 hours at 37oC. Remaining drug aliquots were stored at 
4oC. All media was then removed from the wells by rapidly inverting the plate into a 
plastic container and 95µl of either vehicle or TGF-β1 (5ng/ml) was added to one of 
the duplicate wells. 5µl of the same drug (final concentration 10µM) was also added 
to each well in duplicate, so that wells contained either drug and vehicle or drug and 
TGF-β1, in addition to DMSO controls. The plate was further incubated for 48 hours 
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at 37oC. At the end of the treatment period, plates were checked using a light 
microscope to examine any cell death that may have occurred as a result of drug 
treatment.  
2.14.2. Immunofluorescent staining of 96-well plates 
At the end of the treatment period, using a multi-channel pipette plates were twice 
washed in PBS, fixed using cytoskeletal fixative buffer (see 2.10.1) for 10 minutes and 
again washed in PBS. Fibroblasts were then permeabilised using 0.1% Triton-x in PBS 
for 10 minutes and PBS-washed twice. A buffer containing DMEM supplemented with 
0.1% BSA and 0.1% sodium azide was applied for 30 minutes and then removed. 
Primary antibodies for α-SMA (DAKO, anti-mouse, 1/200) and fibronectin (Abcam, 
ab23750 anti-rabbit, 1/500) were diluted in DMEM (BSA/sodium azide) buffer and 
added to each well for 1 hour and cells were washed thrice with fresh buffer solution. 
Species-specific secondary antibodies (Invitrogen, AlexaFluor-488 anti-mouse and 
AlexaFluor-546 anti-rabbit, 1/125) were diluted in DMEM buffer and applied to every 
well for 30 minutes. On each plate, duplicate wells containing fibroblasts were 
treated with secondary antibody only, as a control for background staining. Nuclei 
was stained using DAPI and whole cells were stained simultaneously in PBS using 
CellMask (ThermoFisher Scientific, H32721, 1/50,000) for 1 hour. Cells were washed 
and kept in 100ul PBS at 4oC until imaging. 
2.14.3. IN Cell microscope imaging  
With the kind help of Mr Luke Gammon (Blizard Institute, QMUL), the IN Cell analyzer 
1000 microscope was used automatically image each 96-well plate (10x 
magnification) with 20 fields collected from each well. Before each batch of 3-4 plates 
was imaged, one well on each plate was imaged to ensure microscope settings, such 
as focus and contrast were suitable. Each channel was imaged individually to capture 
α-SMA, fibronectin, DAPI and CellMask staining. Images were analysed using the 
Developer Toolbox 2.1 software to ensure α-SMA and fibronectin strands were 
correctly identified and were associated with whole cells using CellMask/DAPI 
staining to prevent inclusion of extraneous background staining during data analysis. 
Various measurements were also selected on the software, including cell counts of 
65 
 
DAPI/CellMask-positive cells, pixel intensity and fibre length. Data was exported as 
Microsoft Excel files. 
2.14.4. Data analysis 
Drug screen analysis was conducted using coding programming software RStudio to 
automate statistical and graphical analysis (with the kind help of Mr William Cross, 
Barts Cancer Institute). The script used is presented in Appendix Figure 20. α-SMA 
and fibronectin staining was examined in drug + TGF-β1-treated wells compared to 
DMSO + TGF-β1, while cumulative frequency was used to assess the distribution of 
staining intensity. Cumulative frequency also used to normalise cell numbers in drug 
and control wells, as each well may have contained different numbers of cells by the 
end of the treatment/staining period. The Kolmogorov-Smirnov test was used to 
analyse the data, which is a statistical test typically used to compare cumulative 
distribution of a sample (drug) with a control (DMSO) distribution and is non-
parametric. A second statistical test (Wilcoxon signed rank test) was used to compare 
the median staining intensity in drug and DMSO-treated wells. Furthermore, wells 
that ultimately contained less than 200 cells were excluded from analysis due to 
potential toxicity from drug treatment.  
2.14.5. Validation experiments 
To validate the results of the drug screen, 3 compounds from the library were 
purchased; axitinib (Sigma, PZ0193), anastrozole (Sigma, A2736) and dasatinib 
(Sigma, 90525). For immunofluorescent staining on coverslips and western blotting, 
plated fibroblasts were treated with drug or DMSO diluted in 1% FBS-DMEM for 48 
hours, this media was removed and replaced with vehicle or TGF-β1 (5ng/ml) diluted 
in the same media with the same drug or DMSO as a control, for a further 48 hours. 
Cell lysates were collected according to the method described in Section 2.6 and cells 





2.15. Statistical analysis 
All numerical data are presented as mean or median ± standard deviation (s.d), with 
respective statistical tests chosen depending on the normality of distribution, the 
number of groups compared and the chance to avoid type I statistical errors. 
Standard deviation was selected for representation to demonstrate the variation of 
the data points and indicate why some differences were considered non-significant.  
Significance was defined as p<0.05 and software GraphPad Prism 5 (Graphpad, La 
Jolla, USA) was used for statistical analysis and graphical presentation, unless 
otherwise stated. The number of independent repeats performed per experiment 







CHAPTER III. RESULTS PART I 
Exploring the genetic and functional responses of fibroblasts derived from different 
tissues to activation with TGF-β1 
 
3.1. Background 
In published studies, fibroblast heterogeneity was reported in fibroblasts derived from 
the same organ, such as skin[165], in addition to fibroblasts from separate organs[64, 
134]. TGF-β1 is a key regulator of fibroblast activity, yet the response of different 
fibroblasts to TGF-β1 has not been extensively studied and compared previously.  
The first aim of this study was to characterise the genetic and functional responses of 
fibroblasts derived from skin, lung and breast tissue, as it was hypothesised that these 
fibroblasts would display heterogeneity with each other. TGF-β1 is a potent stimulator 
of fibroblast-to-myofibroblast differentiation and therefore was chosen to stimulate the 
skin, lung and breast fibroblasts in these experiments. In addition, the term fibroblast 
‘activation’ is used interchangeably with ‘differentiation’ in this study, as TGF-β1-
induced activity of myofibroblasts is synonymous with a differentiated phenotype, while 
no definitive marker of fibroblast-to-myofibroblast differentiation currently exists.  
 
3.2. Expression of TGF-β1-responsive genes in TGF-β1-stimulated skin, lung and 
breast fibroblasts  
The expression of eight genes that are commonly altered during fibroblast 
differentiation were investigated to ensure a myofibroblast phenotype was induced 
and were named ‘activation markers’ in this study. The eight markers of activation 
chosen were α-smooth muscle actin (ACTA2/α-SMA)[166], collagen type I 
(COL1A2)[167, 168], matrix metalloproteinase-1 (MMP-1), tissue inhibitor of 
metalloproteinase-3 (TIMP-3)[169], fibronectin (FN1)[166], myosin heavy chain-9 
(MYH9)[170], connective tissue growth factor (CTGF)[166, 169] and plasminogen 
activator inhibitor-1 (SERPINE1/PAI-1)[166, 168]. Previously published papers were 
used as a guide to determine a suitable TGF-β1 concentration, where a range of 1 - 
10ng/ml was commonly used to produce a myofibroblast phenotype[166, 171, 172]. 
Therefore, a preliminary experiment was conducted to test a mid-concentration of 
5ng/ml TGF-β1, which was used to stimulate strain 1 and strain 2 skin fibroblasts for 
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24-hours to assess the expression of the eight activation markers by qPCR. These 
results revealed genes TIMP3, FN1, CTGF and SERPINE1 were induced by TGF-β1 
(Appendix Figure 1). However, as genes such as COL1A2 and MMP-1 did not change 
at the 24-hour time-point in response to TGF-β1, all eight genes were examined at 
earlier time-points during 24-hours of TGF-β1 stimulation (4-, 8-, 16- and 24-hours) 
in the next experiment. This was to ensure earlier peaks in gene expression were not 
missed in skin, lung and breast fibroblasts. To note, qPCR was conducted on all nine 
fibroblast strains (3 strains per organ), however to facilitate easier comparison for 
the reader, only one representative strain is shown in the following figures, while 
the results from the additional strains are displayed in the Appendix. 
The qPCR results shown in Figure 3.1 and 3.2 represent fold-changes of TGF-β1- 
relative to vehicle-treated fibroblasts and the results of the three tissues are shown 
on one graph to allow direct comparisons. Please see Appendix Figures 2-15 for the 
gene expression by each strain of fibroblast.  
The results in Figure 3.1A suggests the expression of myofibroblast marker ACTA2 
was significantly different between the three tissues, which is particularly evident at 
the 24-hour time-point, as lung fibroblasts expressed 2.7-fold more ACTA2 than skin 
(p<0.001) and 5.9-fold more than breast (p<0.001) respectively, in response to TGF-
β1. In contrast, TGF-β1-induced MMP-1 (Figure 3.1B) and COL1A2 (Figure 3.1C) were 
not significantly different in fibroblasts from these three tissues. Unfortunately, the 
MMP-1 data for all three breast fibroblast strains was unusable due to primer 
contamination in those samples and is therefore not present. Figure 3.1D shows FN1 
expression patterns were significantly different and appear similar to ACTA2, as TGF-
β1-treated lung fibroblasts exhibited approximately 3.7-fold more FN1 than TGF-β1-
treated skin or breast fibroblasts at the 24-hour time-point, perhaps indicating a 
biologically relevant difference in the role of fibronectin in lung tissue. To note, 
Appendix Figure 2 and 3 show intra-tissue differences in each of these four genes, 





qPCR used to assess the fold-change of ACTA2 (A), MMP-1 (B), COL1A2 (C) and 
FN1 (D) mRNA of TGF-β1 (5ng/ml)-treated fibroblasts relative to vehicle-treated 
cells. One representative fibroblast strain shown out of three per tissue, cell 
strains shown: skin strain 2, lung strain 2 and breast strain 3. Vehicle-treated cells 
are represented by dotted line. Data were normalised to 3 housekeeping genes 
per tissue listed in the Materials and Methods section. ***p<0.001, two-way 
ANOVA with Bonferroni post-hoc. Data shown represents mean ± s.d of three 
independent experiments. See Appendix Figure 2-15 for results of 3 fibroblast 








Figure 3. 1. Comparison of 4 myofibroblast-associated genes in TGF-β1-treated 
skin, lung and breast fibroblasts during 4 - 24-hour exposure. 
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Figure 3.2 demonstrates TIMP3, CTGF and PAI-1 also exhibited striking tissue-
specific differences in response to TGF-β1. However, this time TIMP3 expression was 
lowest in skin fibroblasts (Figure 3.2A), where TGF-β1 did not significantly affect 
expression relative to untreated skin fibroblasts. Of note, this was also verified in the 
three strains of skin fibroblasts derived from separate subjects (Appendix Figure 4). 
TIMP3 was expressed approximately 7-fold and 5-fold more by stimulated lung and 
breast fibroblasts respectively, than skin fibroblasts at 24-hours. Moreover, lung 
fibroblasts also displayed higher TIMP3 expression earlier than either skin or breast 
fibroblasts within eight hours of TGF-β1 addition.  
The next gene studied was MYH9, which is a non-muscle, actin-binding protein 
associated with regulating cell adhesion and contractility[173]. MYH9 results showed 
high variation in technical repeats and was not differentially expressed by TGF-β1-
exposed skin, lung or breast fibroblasts (Figure 3.2B). However, MYH9 was 
significantly upregulated by TGF-β1 only in skin fibroblasts, at the 24-hour time-point 
(p<0.05) relative to vehicle treatment.  
As previously mentioned, CTGF was differentially expressed in fibroblasts derived 
from three different tissues (Figure 3.2C), as skin fibroblasts expressed more CTGF 
mRNA, particularly at the 16-hour time-point compared to lung and breast (p<0.01). 
However, increasing the time of TGF-β1 exposure did not significantly affect CTGF 
expression in lung and breast fibroblasts, as CTGF largely remained at consistent 
levels between 4-24 hours. Finally, SERPINE1 mRNA was also differentially expressed, 
as breast fibroblasts exhibited significantly lower levels compared to skin or lung 
fibroblasts (Figure 3.2D), which was evident within eight hours of TGF-β1 exposure.  
Overall, these results demonstrated five out of the eight genes examined displayed 
differential expression in TGF-β1-treated skin, lung and breast fibroblasts and in cells 
derived from different donors. Considering all these results, the top four genes 
chosen to measure myofibroblast activity in later experiments were ACTA2, FN1, 









qPCR used to assess the fold-change of TIMP3 (A), MYH9 (B), CTGF (C) and 
SERPINE1 (D) mRNA of TGF-β1 (5ng/ml)-treated fibroblasts relative to vehicle-
treated cells. One representative fibroblast strain shown out of three per tissue, 
cell strains shown: skin strain 2, lung strain 2 and breast strain 3. Vehicle-treated 
cells are represented by dotted line. Data were normalised to 3 housekeeping 
genes per tissue listed in the Materials and Methods section. ***p<0.001, 
**p<0.01 two-way ANOVA with Bonferroni post-hoc. Data shown represents 
mean ± s.d of three independent experiments. See Appendix Figure 2-15 for 








Figure 3. 2. Comparison of 4 myofibroblast-associated genes in TGF-β1-treated 
skin, lung and breast fibroblasts during 4 - 24-hour exposure. 
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To examine the pattern of expression within each tissue, activation markers were 
compared at one time-point of peak gene expression. Figure 3.3A shows ACTA2 
(p<0.05), MYH9 (p<0.05) and CTGF (p<0.05) mRNA were significantly increased in skin 
fibroblasts in response to 24-hour TGF-β1 treatment, while SERPINE1 was also highly 
upregulated but was found non-significant, possibly due to technical variations. In 
contrast, genes COL1A2, MMP-1, TIMP3, FN1 and MYH9 displayed no significant 
changes in response to TGF-β1. 
In 24-hour TGF-β1-treated lung fibroblasts (Figure 3.3B), significantly higher ACTA2 
(p<0.05), TIMP3 (p<0.01), FN1 (p<0.01), CTGF (p<0.01) and SERPINE1 (p<0.05) were 
expressed relative to untreated lung fibroblasts, while COL1A2, MMP-1 and MYH9 
showed no change in expression. Surprisingly, this breast fibroblast strain (Figure 
3.3C) only significantly raised TIMP3 (p<0.01) above basal levels, while the residual 
genes remained unchanged after TGF-β1. Moreover, intra-tissue variation was 
evident between the three breast fibroblast strains, (Appendix Figure 16), while the 
three skin and three lung strains demonstrated more homogeneity within each 
tissue, even though each strain was derived from a different donor.  
These results demonstrated genes were upregulated to different extents in skin, lung 
and breast fibroblasts in response to TGF-β1, further highlighting the heterogeneity 


















































The following representative fibroblast strains from skin (A), lung (B) and breast 
(C) tissue are shown; skin strain 2, lung strain 2 and breast strain 3, which were 
exposed to TGF-β1 (5ng/ml) for 24 hours. The qPCR data shows fold-change of 
TGF-β1 relative to vehicle-treated cells and data were normalised to 
housekeeping genes documented in Materials and Methods. *p<0.05, **p<0.01, 
Paired Students t-test. Data shown represents the mean ± s.d of three 




Figure 3. 3. Gene expression of 8 markers of myofibroblast activation after TGF-





































































































































































































3.3. Protein expression of key myofibroblast-associated factors in TGF-β1 
stimulated skin, lung and breast fibroblasts  
Western blotting was conducted to determine the protein expression level of TGF-
β1-upregulated genes that were identified using qPCR and to directly compare 
fibroblasts derived from the three different tissues. This time, all fibroblasts were 
treated with TGF-β1 for 48-hours to allow time for protein expression to occur. 
Furthermore, only a subset of differentially expressed genes was examined and were 
selected according to the previous qPCR results. 
Figure 3.4A reveals skin fibroblasts expressed larger quantities of myofibroblast 
marker α-SMA at the basal level, and as a result, there was no significant change in 
α-SMA expression after TGF-β1 addition in these cells (Figure 3.4B). In contrast, 
Figure 3.4B shows stimulated lung and breast strains upregulated α-SMA up to 2-
fold, although the Students t-test could not be conducted as only two independent 
repeats were completed. In addition, TGF-β1-induced CTGF could not be quantified 
accurately as there were no visible bands in some vehicle samples (lower CTGF band 
in Figure 3.4A), but was clearly upregulated by TGF-β1 in each fibroblast. 
Plasminogen activator inhibitor-1 (PAI-1) was increased the highest in skin fibroblasts 
after TGF-β1 (Figure 3.4B), though there was approximately a 2-fold increase in PAI-
1 expressed by lung and breast fibroblasts.  
Figure 3.4C directly compares protein expression between the three tissues. As 
noted previously, basal α-SMA in skin fibroblasts was significantly higher than basal 
α-SMA in lung (p<0.01) or breast fibroblasts (p<0.01), while basal PAI-1 was 
significantly higher in unstimulated breast fibroblasts (p<0.01) compared to skin, 
though TGF-β1-treated skin fibroblasts expressed more PAI-1 than lung or breast. 
Conversely, there were no significant differences between skin, lung and breast 
fibroblasts in the levels of α-SMA and CTGF after TGF-β1 (Figure 3.4C), suggesting 
these proteins were ultimately expressed at similar levels in differentiated 








Fibroblast skin strain 2, lung strain 2 and breast strain 3 were stimulated with 
either vehicle (-) or TGF-β1 (+) (5ng/ml) for 48-hours. α-SMA, CTGF and PAI-1 
protein expression analysed using densitometry to test vehicle vs TGF-β1 (B) and 
compare the 3 tissues under basal and TGF-β1 conditions (C). Hsc70 serves as 
loading control. Data shown represents the mean ± s.d of two independent 
experiments. **p<0.01, one-way ANOVA with Tukey’s post-hoc. 
  Skin       Lung       Breast  
B) 
Figure 3. 4. Western blot analysis of myofibroblast-associated proteins in TGF-

































































































































































































3.4. Gene expression of integrin subunits in TGF-β1 stimulated skin, lung and breast 
fibroblasts  
We considered that differential expression or activity of integrins may underlie key 
differences between skin, lung and breast myofibroblasts. Therefore, to identify 
which integrins are transcriptionally regulated by TGF-β1 in these fibroblasts, the 
expression of relevant integrin α- and β-subunits was investigated during 24-hours of 
TGF-β1 exposure. As expected, integrin subunits α9, β2, β4, β6 and β7, which are not 
typically expressed by fibroblasts did not produce Ct values for any strain and are 
therefore excluded in Figure 3.5. 
The integrin gene expression was examined in all nine strains of fibroblasts, though 
again, the results of only one representative strain per tissue is displayed. To note, 
the three strains of lung fibroblasts produced the most consistent patterns in 
response to stimulation across the three tissue types (see Appendix Figure 17 for all 
9 strains). Figure 3.5A shows TGF-β1-treated skin fibroblasts notably increased α1 (5 
± 2.8-fold) and α11 (4 ± 0.7-fold) integrin subunit mRNA, while TGF-β1-exposed lung 
fibroblasts significantly elevated α11 (19.5 ± 6.2-fold) and β3 (2.4 ± 0.6-fold) (Figure 
3.5B). To note, α1 was also significantly upregulated in lung strain 1 (2.6 ± 0.5-fold) 
and strain 2 (2.4 ± 0.2-fold) in response to TGF-β1 treatment (Appendix Figure 17). 
In contrast, TGF-β1-treated breast fibroblasts exhibited more α4 relative to vehicle-
treated cells (Figure 3.5C), which was consistent between the three breast fibroblast 
strains. Interestingly, all fibroblasts strains from skin, lung and breast significantly 
downregulated the β8 subunit in response to TGF-β1. 
When comparing the responses to TGF-β1 stimulation, it appears skin fibroblast α1 
expression was higher than lung or breast, however more independent repeats are 
required to confirm this due to large deviations in the replicates. In addition, lung α11 
and β3 expression was greater compared to most skin and breast fibroblast strains. 
Interestingly, only HLF strain 2 significantly upregulated integrin subunit α8, which 
needs to be repeated at least once more to be statistically relevant (4.0 ± 0.002-fold 
change, n = 2). This contrasts to breast fibroblasts where no α8 and very little α11 
mRNA was detected (Figure 3.5C).  
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These results again demonstrated heterogeneity exists between TGF-β1-treated skin, 
lung and breast fibroblasts and identified integrin targets of interest within each 









   
   
  
The following representative fibroblast strains from skin (A), lung (B) and breast 
(C) tissue are shown; skin strain 2, lung strain 2 and breast strain 3, which were 
exposed to TGF-β1 (5ng/ml) for 24 hours. The qPCR data shows fold-change of 
TGF-β1 relative to vehicle-treated cells and data were normalised to 
housekeeping genes documented in Materials and Methods. *p<0.05, **p<0.01, 
***p<0.001, Paired Students t-test. Data shown represents mean ± s.d of three 
independent experiments, except α8 where only two independent experiments 




Figure 3. 5. Gene expression of integrin subunits in TGF-β1-treated fibroblasts 
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3.5. Protein expression of selected integrins expressed by skin, lung and breast 
fibroblasts 
To determine transmembrane integrin expression and total protein levels, flow 
cytometry and western blotting were performed, respectively, though, α8 and α11 
expression could not be assessed due to poor quality of commercial antibodies.  
During flow cytometry experiments, TGF-β1 (5ng/ml) was used to stimulate 
fibroblasts for 24 hours due to the changes observed in the previous integrin gene 
expression analysis. However, due to the differential growth rates of fibroblasts it 
was not possible to examine the three tissues in the same flow cytometry 
experiment, therefore post-comparisons would be inaccurate.  
The flow cytometry results (Figure 3.6) suggest TGF-β1 did not induce significant 
changes in surface integrin expression in either skin or lung fibroblasts. Low cell 
counts of all three strains breast fibroblasts due to their slow proliferation meant 
only vehicle-stimulated cells were analysed. Noticeably, most integrins produced 
mean fluorescence intensities higher than the species-matched isotype control 
antibody in all fibroblasts (isotype control mean fluorescence intensity was typically 
between 2.5 - 4), which verified positive surface expression during both basal and 























As surface integrin expression appeared to remain constant in stimulated fibroblasts, 
total protein levels were investigated using western blotting, although this time, 
fibroblasts were treated for 48-hours with TGF-β1, as it was assumed fibroblasts 
needed longer to generate integrin proteins. Due to the lack of effective integrin 
antibodies only a few subunits could be examined, as attempted optimisation of 
various α1 and α11 commercial antibodies suitable for western blotting failed and 
therefore could not be characterised.  
The following representative fibroblast strains from skin (A), lung (B) and breast 
(C) tissue are shown; skin strain 2, lung strain 2 and breast strain 3, which were 
exposed to TGF-β1 (5ng/ml) for 24 hours. Note, due to slow growth/low cell 
number only vehicle treatment was applied to breast fibroblasts. Data shown 
represents the mean ± s.d of least two-three independent experiments.  
A) B) 
C) 
Figure 3. 6. Flow cytometry analysis of integrin expression in TGF-β1-treated 
skin, lung and breast fibroblasts. 


























































































Figure 3.7 shows, in skin fibroblasts total αv (Figure 3.7B), β3 (Figure 3.7E) and β5 
protein (Figure 3.7H) were increased 1.5-2-fold after 48-hour TGF-β1 exposure, while 
lung fibroblasts only upregulated β3 protein (Figure 3.7E) after stimulation (3.4 ± 1.2-
fold). In contrast, TGF-β1 only slightly raised αv expression in breast fibroblasts, but 
had no effect on β3 and β5 expression. Although the non-significant changes in total 
integrin protein after TGF-β1 appear to support the flow cytometry results, I believe 
more biological repeats are needed for western blotting to confirm this. 
Subsequently, to compare between tissues, total protein was examined at either 
basal levels or after TGF-β1 exposure, where interestingly breast fibroblasts 
expressed significantly more αv (Figure 3.7C), β3 (Figure 3.7F) and β5 (Figure 3.7I) 
protein than skin or lung fibroblasts during basal conditions. Whether these results 
are tissue-specific or not could be established during future studies by examining 





































































































































D)  Skin       Lung      Breast 
   Skin     Lung      Breast 
The following representative fibroblast strains from skin strain 2, lung strain 2 and 
breast strain 3 were stimulated with either vehicle (-) or TGF-β1 (+) (5ng/ml) for 
48-hours. Vehicle vs TGF-β1 (B, E, H) and TGF-β1-stimulated skin vs lung/breast 
myofibroblasts (C, F, I). HSC70 serves as loading control. Note, the Students t-test 
could not be used to compare vehicle and TGF-β1 in B, E and H as n=2. Data shown 
represents the mean ± s.d. of two independent experiments. *p<0.05, **p<0.01 
one-way ANOVA with Tukey’s post-hoc. 
Figure 3. 7. Western blot analysis of αv, β3 and β5 integrin expression in TGF-







































































































































































3.6. The response of skin, lung and breast fibroblasts in functional assays 
The contraction of the surrounding ECM by myofibroblasts is a fundamental feature 
of wound healing[4], while matrix remodelling also facilitates cancer cell 
invasion[102] and promotes the activation of matrix-bound latent-TGF-β1[39]. 
Furthermore, in vitro co-culture studies demonstrate fibroblasts are necessary to 
promote tumour cell invasion, as tumour cells plated alone on top of three-
dimensional (3D) gels did not invade the underlying matrix[102]. Therefore, to ensure 
these fibroblasts had differentiated towards the expected functional phenotype, cells 
were examined in collagen gel contraction and mini-organotypic invasion assays. 
3.6.1. Contraction of collagen type I gels by skin, lung and breast fibroblasts 
Skin, lung and breast fibroblasts were plated inside collagen type I gels in the absence 
or presence of TGF-β1 (5ng/ml). The constitution of the gel mixture was adapted 
from Nystrom and colleagues[174], although Matrigel was left out of the gel 
contraction mixture due to accelerated fibroblast-mediated contraction in 
preliminary tests, which became problematic to measure within a 24-hour period. 
Therefore, the gels used to measure contraction consisted of collagen type I.       
When comparing the three fibroblasts during vehicle control treatment (Figure 
3.8A), the analysis revealed lung fibroblasts contracted collagen gels at the slowest 
rate compared to skin and breast. Furthermore, the post-hoc test demonstrated that 
skin and breast fibroblasts contracted gels 30% more than lung fibroblasts by day 9 
(skin p<0.01, breast p<0.01), while skin and breast fibroblasts contracted gels at 
similar rates.  
Furthermore, Figure 3.8B shows the addition of TGF-β1 significantly increased skin, 
lung and breast fibroblast-mediated contraction relative to vehicle-treated cells from 
day 5 onwards, though there was no significant difference between the three 
fibroblasts in their response to TGF-β1. Figure 3.8C illustrates these results in 
representative images from selected days during the gel contraction assay.  




Fibroblasts plated within collagen type I gels stimulated with either vehicle or 
TGF-β1 (5ng/ml). One representative fibroblast strain from each tissue shown: 
skin strain 2, lung strain 2 and breast strain 3. A) The percentage surface area of 
collagen type I gels relative to a whole well and significance is relative to lung 
fibroblasts. B) Significance measured by contraction of TGF-β1-treated gels 
relative to vehicle. C) Representative images of collagen gels on selected days 
after stimulation. Data shown represents the mean ± s.d from two-three 
independent experiments. *p<0.05, **p<0.01, ***p<0.001 two-way ANOVA with 
Bonferroni post-hoc test.  
 
Skin fibroblasts 
Lung fibroblasts Breast fibroblasts 
A) B) 
C) 
Figure 3. 8. Vehicle and TGF-β1-induced collagen gel contraction by skin, lung 
and breast fibroblasts. 



























































































3.6.2. Mini-organotypic invasion assays of tissue-matched cancer cells and 
corresponding fibroblasts 
To investigate whether these non-cancer-associated fibroblasts could promote 
cancer cell invasion in a 3D setting, a collagen-Matrigel mixture was pipetted into 
Transwell inserts in a 24-well plate, where tissue-matched cancer cells were cultured 
with fibroblasts in a 1:2 ratio on top of gels for seven days.  
In Figure 3.9, cancer cells in the H & E images are distinguished as larger, multi-
nucleated cells (red arrow) and fibroblasts are much smaller, appearing as dots with 
a single nucleus (green arrow). Immunofluorescent staining of organotypic sections 
was conducted to identify each cell type using cell-specific markers, specifically 
cytokeratin staining for cancer cells and α-SMA for fibroblasts. Unfortunately, there 
was only weak α-SMA staining in most sections in Figure 3.9. Nevertheless, the 
images demonstrate cancer cell lines derived from skin (Figure 3.9A), lung (Figure 
3.9C) and breast (Figure 3.9E) tissue did not invade into these 3-D gels when plated 
alone. However, the H and E and immunofluorescent images suggest invasion of both 
cell types was apparent after seven days when skin (Figure 3.9B), lung (Figure 3.9D) 
and breast (Figure 3.9F) cancer cells and fibroblasts were admixed and cultured on 
top of gels. In addition, the immunofluorescent staining of lung tumour cells and 
fibroblasts (Figure 3.9D) shows the majority of cells were positive for α-SMA, perhaps 
suggesting epithelial-to-mesenchymal (EMT) transition occurred.   
In the graphs shown in Figure 3.9G and 3.9H, two fibroblast strains from skin and 
breast tissue are presented to demonstrate tissue-specific responses, as these same 
strains were also used in the next set of experiments, presented throughout the 
forthcoming chapter; Results Part II. Unfortunately, weak cytokeratin staining of lung 
mini-organotypic gels prevented reliable analysis and is therefore absent from the 
graphs. In Figure 3.9G, the results indicate more oral squamous cell carcinoma cells 
(OSCC) invaded when plated with skin fibroblasts compared to the number of 
invading breast cancer cells. Furthermore, co-culture with strain 3 dermal fibroblasts 
resulted in significantly higher numbers of invading tumour cells than any other 
combination analysed. Surprisingly, Figure 3.9H shows the number of invaded 
fibroblasts followed an inverse trend to invaded tumour cells, as high numbers of 
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OSCC cells were associated with low numbers of invaded skin fibroblast strain 3 and 
lower numbers of breast cancer cells were associated with higher numbers of 
invading breast fibroblasts (strain 2 and 3). Although whether this was an effect of 
the fibroblasts themselves or the different cancer cells used is uncertain. In addition, 
the co-culture of breast cancer cells with breast strain 3 fibroblasts resulted in a 
thicker layer of cytokeratin-positive tumour cells at the top of the gel (Figure 3.9F) 
compared to skin and lung sections.  
Overall, these functional assays demonstrated that these skin, lung and breast 
fibroblasts exhibited the expected functional responses, as each significantly 
contracted collagen gels in response to TGF-β1, while fibroblasts markedly promoted 







































































































H & E and immunofluorescent staining of cancer cells alone (A, C, E) or admixed 
with fibroblasts (B, D, F) in a 1:2 ratio plated above mini-organotypic gels and 
cultured for 7 days. Cytokeratin staining (red) identifies tumour cells (red arrow) 
and cytokeratin-negative/α-SMA-positive cells are fibroblasts (green arrow). 
Graphs show the average number of invading cancer cells (G) and fibroblasts (I) 
per field (20x magnification), quantified by counting cytokeratin-positive/negative 
cells below the epithelial layer, per field in each gel (2-3 fields/gel and 3 gels per 
condition). Strains: oral squamous cell carcinoma (OSCC), skin fibroblast strain 2 
and 3 (skin S2 and S3) and breast fibroblast strain 2 and 3 (BF2 and BF3). Data 
shown represents mean ± s.d. *P<0.05, **P<0.01, ***P<0.001, one-way ANOVA 
with Tukey’s post-hoc. Representative images from one independent experiment 














MDA-MB-468 breast cancer cells alone 
















Figure 3. 9. Skin, lung and breast cancer cells co-cultured with fibroblasts in 3

































































































































































3.7.1. Expression of myofibroblast-associated markers in TGF-β1-treated 
fibroblasts 
This study set out to determine whether the activated form of fibroblasts from 
separate tissues exhibit different activation markers and biological activities. We 
used TGF-β1 as an exogenous inducer of the activated phenotype, known as a 
myofibroblast. Thus we compared normal fibroblasts from skin, lung and breast 
tissue exposed to TGF-β1 stimulation. After analysis, I can confirm that fibroblasts 
derived from these tissues exhibit heterogeneity in response to TGF-β1 in context of 
the various parameters measured. These differences exist in expression patterns of 
selected ‘markers of activation’ and integrin expression.  
Previous studies investigating fibroblast heterogeneity are limited and involve cells 
from distinct layers of skin, different organs or compare responses to cytokines, such 
as TNF-α[134, 165]. Therefore, considering the relevance of TGF-β1 in stimulating 
fibroblast-to-myofibroblast differentiation during tumour progression and fibrosis, it 
was surprising that the analysis of fibroblasts’ response to TGF-β1 across different 
tissues had not been studied. However, in 2004, Lygoe and colleagues investigated 
the response of single strains of fibroblasts from dermal, oral and renal tissues to 
TGF-β1. Although, these experiments only assessed expression of α-SMA and 
integrins αv and β1[64]. In contrast, this current study here in has significantly 
extended those results by comparing three strains of skin, lung and breast fibroblasts 
and conducting a complete characterisation of the integrin gene expression profile of 
TGF-β-treated cells. These results now spur further research to test the various 
integrins identified that were modified by TGF-β1, but were not examined in the later 
experiments of this study.     
The results generated here support other published studies that recognise 
heterogeneity in different fibroblasts, although the combination of skin, lung and 
breast fibroblasts has not been directly compared previously. Lindner and colleagues 
found that fibroblasts from cardiac, dermal and pulmonary tissue produce different 
levels of MMP-1 and MMP-3 in response to cytokine TNF-α stimulation, parallel to 
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findings here where skin, lung and breast fibroblasts generate different mRNA levels 
of ACTA2, FN1, TIMP-3, CTGF and SERPINE1 after TGF-β1 treatment[134]. Therefore, 
these data support the concept that stimulation of fibroblasts with pro-inflammatory 
cytokines, such as TNF-α or TGF-β1 affects gene expression differentially according 
to the tissue origin, but also donor, of the fibroblast.  
 
The role of α-SMA as a consistent marker of fibroblast-myofibroblast differentiation 
is controversial, as myofibroblasts that display phenotypic characteristics such as 
stress fibre formation and contraction during wound healing do not necessarily 
require α-SMA expression[175]. Nevertheless, in this study all fibroblast strains 
increased α-SMA at either gene or protein levels in response to TGF-β1, indicating 
differentiation was induced. Notably, α-SMA protein displayed higher basal levels in 
skin fibroblasts (Figure 3.4), possibly suggesting these cells are more sensitive to 
substrate stiffness than lung or breast fibroblasts and may have already undergone 
partial differentiation by culture on plastic. Huang and colleagues found that 
fibroblasts expressed 4-fold more α-SMA when plated on stiff vs soft gel 
substrates[176], though here, the addition of TGF-β1 to these susceptible skin 
fibroblasts still produced an active myofibroblast phenotype, as evidenced by 
increased expression of activation marker and integrin genes and gel contraction in 
the presence of TGF-β1.  
The tissue-specific expression of α-SMA is also supported by other studies. The 
variances shown in α-SMA time-course data from skin, lung and breast fibroblasts 
(Figure 3.1A) mimics divergences observed in fibroblasts derived from skin, oral 
mucosa and kidneys, where dermal and oral fibroblasts expressed 3-4-fold more α-
SMA after 72-hour TGF-β1 stimulation compared to renal fibroblasts that only 
increased α-SMA approximately 1.5-fold[64]. However, after TGF-β1 stimulation, α-
SMA protein levels (Figure 3.4) did not demonstrate significant differences between 
tissues. It should be acknowledged that this may change if additional repetitions on 
more strains were performed.  
In contrast, MMP-1 and collagen type I gene expression did not significantly change 
in any fibroblast after TGF-β1 stimulation, although COL1A2 was increased to 2.5 ± 
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1.2-fold in lung fibroblasts, pointing towards the pro-fibrotic effects of TGF-β by 
shifting towards collagen deposition and away from proteolysis. These results are 
supported by studies in which dermal or primary lung fibroblasts were stimulated 
with TGF-β1 for up to 24 hours, where no change in MMP-1 or decreased expression 
was evident, respectively [177, 178]. Moreover, Goffin and colleagues suggest MMP-
1 and COL1A2 are differentially regulated factors, as TGF-β1 induces transcription 
factor SP-1 binding to COL1A2 promoter regions, whereas MMP-1 depends on 
transcription factors, such as c-Jun, independent of TGF-β stimulation[177].  
In contrast, TIMP3 revealed tissue-specific expression that was highly induced by 
TGF-β1 in lung and breast fibroblasts, but not in skin, indicating different mechanisms 
of regulation of the same gene. Investigation of fibroblast TIMP3 expression in ductal 
breast tumours showed positive correlation with the presence of distant 
metastases[179], while TIMP-3 expression was upregulated in the fibroblastic foci of 
IPF tissues when compared to normal lung sections[180]. These results validate the 
value of characterising fibroblasts from different sites, which may lead to a better 
understanding of disease pathophysiology and potentially generate clinical 
biomarkers.  
Overall, the differences noted in myofibroblast genes may result from distinct 
quantities of TGF-β-receptors expressed by each fibroblast, which should be 
quantified in future experiments. Chipev and Simon show dermal fibroblasts derived 
from keloids, normal heel/palm tissue and non-palmar sites exhibit differing levels of 
TGF-β type II transmembrane receptors. Moreover, in fibroblasts derived from 
palmar vs non-palmar skin of healthy subjects the levels of TGF-β type II receptor 
positively correlated with α-SMA and ED-A fibronectin expression[181].  In addition, 
the secretion of TGF-β1 from fibroblasts may also influence the heterogeneity 
observed of myofibroblast-associated factors. Therefore, the differences between 




3.7.2. Expression of integrins in TGF-β1-treated skin, lung and breast fibroblasts 
Although it seemed TGF-β1 enhanced the expression of some integrin subunits at the 
gene level (α1, α11, β3), the results at the protein level via western blotting (αv, β3, 
β5) were non-significant, yet perhaps more biological repeats or longer TGF-β1 
exposure may resolve this. In comparison, Lygoe and colleagues assessed αv and β1 
subunits using western blotting and flow cytometry by exposing fibroblasts to TGF-
β1 for 72 hours. Their results found TGF-β1 significantly increases expression of each 
subunit by 1.5-fold, with similar changes in dermal, oral and renal fibroblasts[64]. In 
addition, Heino and colleagues demonstrated that lung fibroblast cell line WI-38 
upregulated α1, α2, α3, α5 and β1 subunits to varying degrees in response to TGF-
β1, as I also observed, suggesting expression is regulated by independent 
mechanisms[60]. 
Flow cytometry data in this study also suggests integrin surface expression is not 
augmented by TGF-β1 stimulation, although it should be noted fibroblasts were only 
stimulated for 24 hours. Nevertheless, this suggests that these fibroblasts may not 
upregulate the number of integrins upon their cell surface to potentially regulate 
myofibroblast activity. Instead, as integrins can initiate intracellular signalling 
pathways by clustering on the plasma membrane, perhaps redistribution of 
transmembrane integrins was sufficient to enhance integrin activation in response to 
TGF-β1[182]. Preliminary tests (Figure 3.10, next page) using an anti-αv integrin to 
stain vehicle and TGF-β1-treated strain 2 skin fibroblasts showed clustered integrins 
are present in TGF-β1-exposed cells (Figure 3.10D-F), although talin or kindlin co-
staining is required to confirm integrin activation. Furthermore, intracellular 
signalling that begins at the cytosolic portion of the β-integrin tail may have also been 
amplified to promote myofibroblast functions[28]. However, this will require further 
characterisation of specific signalling kinases, e.g. FAK, in future studies. In addition, 
while all fibroblasts were cultured on tissue culture plastic, recent studies 
demonstrate cardiac fibroblasts differentially express a variety of integrins according 
to whether cells are grown on collagen, fibronectin or organ-specific decellularised 
ECM[183]. Therefore, in the future perhaps studying the integrin expression profile 
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of fibroblasts grown on organ-derived matrices would be more biologically 
representative.  
 
When comparing integrin expression between the 3 tissues, breast fibroblasts appear 
to express more αv and β5 than skin or lung fibroblasts, evidenced at the protein 
level. Additional studies are required to determine whether breast fibroblasts have 
enhanced capacity to activate latent-TGF-β1, as do cardiac fibroblasts in vitro via 
αvβ5-mediated contraction[125]. Moreover, integrin expression should be examined 
in further strains of breast fibroblasts to establish whether these effects are tissue- 
or strain-specific.  
The expression of integrin α11 by myofibroblasts is also of particular interest as 
published literature contains large gaps in understanding of its contribution to 
tumour progression and fibrosis. Data here showed TGF-β1 significantly increased 
α11 in skin and lung fibroblasts, though α11 mRNA in breast fibroblasts displayed no 
change in response to stimulation. However, investigating the protein levels in each 
A   Vehicle 
 
B C 
E F D   TGF-β1 
Representative images of vehicle (A - C) or TGF-β1 (5ng/ml) (D – F) stimulated strain 
2 skin fibroblasts (24 hours), which was fixed with paraformaldehyde and 
permeabilised. Examples of potentially clustered integrins highlighted inset. 




of these fibroblasts would validate these results. Previous published studies have 
focused on the role of α11 in skin and lung myofibroblasts and show knockdown of 
integrin α11 in mouse embryonic fibroblasts co-implanted with lung adenocarcinoma 
cells significantly delayed tumour growth compared with wild-type fibroblasts. In 
addition, knockdown of α11 was linked to markedly lower insulin-like growth factor-
2 expression in fibroblasts, impacting tumour growth[104], demonstrating the 
potential impact of myofibroblast integrin expression in cancer tissues.   
Integrin subunit β8 also revealed striking results, as this gene was downregulated in 
all skin, lung and breast fibroblasts in response to TGF-β1 stimulation. Moreover, this 
effect was also similar in each strain of fibroblast from each tissue. Published findings 
demonstrate this integrin is expressed in cerebral astrocytes, where αvβ8 appears to 
regulate MMP-14-dependent activation of latent TGF-β1[22] and hence, its 
expression was associated with the invasiveness of glioblastoma cells[184]. In 
addition, though there are few studies investigating the role of β8 in fibroblasts, 
Kitamura and colleagues found this integrin is upregulated on human chronic 
obstructive pulmonary disease fibroblasts by IL-1β, where it activated latent TGF-β1, 
which in turn increased the expression of TGF-β1-responsive ECM genes in 
fibroblasts, such as COL1A2 and SERPINE1[185]. However, my results indicate β8 
downregulation may constitute a negative feedback loop to perhaps prevent further 
activation of latent TGF-β1 by skin, lung and breast fibroblasts. 
3.7.3. Functional activity of skin, lung and breast fibroblasts: collagen gel 
contraction and invasion 
According to the results, vehicle-treated lung fibroblasts contracted collagen type I 
gels significantly less than skin or breast-derived cells (Figure 3.8). However, these 
observations cannot be explained by differences in α-SMA or integrin expression, as 
skin and breast fibroblasts contracted gels at similar rates, even though breast 
fibroblasts expressed less basal α-SMA than skin. Moreover, recent investigations 
into the role of α-SMA expression in fibroblasts revealed α-SMA correlates with 
contractile activity, but is not essential for contraction to occur. Hinz and colleagues 
showed lung fibroblasts with higher α-SMA levels contracted collagen gels more than 
rat subcutaneous fibroblasts that expressed less α-SMA[186], though Tomasek and 
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colleagues demonstrated there was no notable difference in dermal fibroblasts from 
α-SMA-null and wild-type mice, as both contracted collagen gels to a similar extent 
in response to TGF-β1. They found this was possible as other actin isoforms had 
replaced α-SMA function in null fibroblasts[175]. Furthermore, in ACTA2-/- and 
heterozygous mice, wound healing is significantly slower than controls, yet 
contraction still occurs indicating α-SMA enhances contraction but is not 
essential[187]. The data in this current study provides support to the notion that α-
SMA expression does not directly correlate with the contractile activity of fibroblasts. 
However, after skin, lung or breast fibroblasts were plated inside collagen gels the 
expression of α-SMA was not examined, which may help to clarify this conclusion. In 
addition, previous studies suggest fibroblast exhibit a more proliferative phenotype 
when plated on collagen[188], therefore perhaps differences in proliferation rates 
would also contribute to the differential rates of gel contraction observed.   
Myofibroblasts are also known to invade into the surrounding ECM and promote 
tumour cell invasion. Therefore, mini-organotypic invasion assays provided a 
translational model to examine tumour-stroma interactions. The importance of close 
proximity of fibroblasts to cancer cells to promote invasion has been demonstrated 
previously by this laboratory. Nystrom and colleagues reported that tumour cell 
invasion through collagen-Matrigel gels required the presence of fibroblasts[174]. 
Gaggioli and colleagues also demonstrated fibroblasts created physical tracks within 
the ECM that squamous cell carcinoma cells (SCCs) exploited to follow behind the 
leading fibroblast. In addition, these authors reported that SCC cells did not invade 
underlying gels in the absence of matrix remodelling by fibroblasts, in agreement 
with my results here (Figure 3.9). Furthermore, Gaggioli et al. reported that integrin 
α3β1 and α5β1 expression was linked to this force-mediated remodelling by 
fibroblasts, as knockdown of these integrins resulted in a lack of holes in the 
organotypic gel, ultimately reducing the level of collective SCC cell invasion[102].  
Tumour-fibroblast interactions are dynamic; thus tumour cells release factors such as 
TGF-β1 that stimulate fibroblasts to secrete ECM-degrading proteases and TGF-β1 
secreted from CAFs, in turn can promote EMT of local tumour cells, enhancing the 
ability of tumour cells to invade through a 3D matrix, demonstrating the symbiotic 
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relationship of tumour cells and fibroblasts[91, 189]. Quantifying the levels of TGF-
β1 secreted by both tumour cells and fibroblasts would shed further light on the 
results obtained from these invasion assays. 
My data suggests some breast fibroblasts appear to promote more cancer cell 
proliferation, owing to the thicker cytokeratin-positive layer observed during mini-
organotypic assays. This effect was specific to this breast fibroblast strain (strain 3), 
as when an alternative breast fibroblast strain (strain 2) was combined with the same 
MDA-MB-468 breast cancer cells, the epithelial layer was noticeably thinner in 
comparison (Appendix Figure 18A). Incidentally, breast fibroblast strain 3 expressed 
more basal αv and β5 integrin protein than breast strain 2 (Appendix Figure 18B), 
therefore perhaps breast strain 3 had a higher capacity to activate latent-TGF-β than 
other fibroblasts. This would result in the presence of additional active TGF-β1, 
thereby potentially establishing autocrine TGF-β signalling in breast 
myofibroblasts[190], which may have continuously secreted factors that promoted 
tumour growth.      
 
Overall, my findings demonstrate skin, lung and breast fibroblasts exhibited 
heterogeneity in response to TGF-β1, predominantly by their activation marker gene 
expression and integrin expression, though strain-specific responses were also 
evident. In addition, lung fibroblasts contracted collagen gels at the slowest rate, but 
the levels of contraction by skin, lung and breast fibroblasts in response to TGF-β1 
were similar. Furthermore, each strain of fibroblast, which were derived from 
healthy tissues promoted the invasion and growth of tumour cells in a 3D 
environment. These results also identified which integrins were to be further 




CHAPTER IV. RESULTS PART II 
The role of specific integrins in the functional behaviour of activated skin, lung 
and breast fibroblasts. 
 
4.1. Background 
Having examined which integrins were expressed by skin, lung and breast fibroblasts 
and which were regulated by TGF-β1, I next used a combination of pharmalogical 
(small-molecule integrin inhibitors from my sponsor, GlaxoSmithKline) and genetic 
(siRNA) tools to investigate the role of key integrins in both the activation state of 
myofibroblasts and their functional activity. Previous experiments by Lygoe and 
colleagues using pan-αv, αvβ3 and αvβ5 blocking antibodies on dermal, oral mucosa 
and renal fibroblasts in the presence of TGF-β1, suggested different integrins 
regulated fibroblast activation and activity depending on which tissue the fibroblast 
was derived from[64]. Therefore, it was hypothesised that different integrins in skin, 
lung and breast fibroblasts would be responsible for regulating myofibroblast 
invasion, contraction and gene expression.  
  
4.2. The inhibition of integrins in TGF-β1-treated skin, lung and breast fibroblasts 
4.2.1. Cell viability of fibroblasts treated with small-molecule inhibitors  
The three integrin inhibitors provided by GSK were a pan-αv integrin inhibitor, 
cilengitide (targeting αvβ3/αvβ5) and an αvβ1-selective compound. As detailed in 
the Materials and Methods section, the pan-αv inhibitor[159] and cilengitide[160] 
are RGD-mimetics, while each of the three inhibitors bind to the ligand-binding 
regions of integrins. To determine a suitable concentration to use with fibroblasts, a 
MTT assay was performed to examine cell viability during exposure to each drug at 
10-fold dilutions (0.1-10μM) for 72 hours. The same 2 fibroblast strains per tissue 
tested in the previous mini-organotypic invasion assays are also presented here, 





Overall, Figure 4.1 shows pan-αv inhibition significantly reduced the viability of skin 
strain 2 fibroblasts by 15-35% (Figure 4.1A), although there was no clear correlation 
between cell viability and inhibitor concentration, and no significant effect on the 
viability of skin strain 3 (Figure 4.1B). In addition, in lung (Figure 4.1C-D) and breast 
fibroblast strains (Figure 4.1E-F), the highest concentration of 10μM pan-αv reduced 
the viability of each strain by approximately 25-50%.  
In contrast, whereas cilengitide had no significant effect on skin or lung fibroblast 
viability, the viability of both strains of breast fibroblasts was significantly affected by 
cilengitide at each of the concentrations tested, particularly using the highest 10μΜ 
dose (Figure 4.1E-F).  
The αvβ1-selective compound only slightly reduced the viability of skin and breast 
fibroblasts at lower concentrations between 0.1-1μΜ, while 5μM doubled the 
viability of breast strain 3 fibroblasts (Figure 4.1F). In addition, it appears lung 
fibroblast viability was unaffected by αvβ1 blockade. Overall, as most fibroblasts 
exhibited at least 60% viability using 1μM of each drug, this concentration was 



















The cell viability of two strains of skin (A, B), lung (C, D) and breast (E, F) fibroblasts 
was assessed using a MTT assay after 72 hours culture in 10-fold dilutions of DMSO 
control or integrin small-molecule inhibitors; pan-αv, cilengitide (targeting β3/β5) 
and αvβ1-selective. *p<0.05, **p<0.01, ***p<0.001, one-way ANOVA with 
Dunnet’s post-hoc to compare each concentration to DMSO control. Data 




Figure 4. 1. The effect of integrin inhibitors on fibroblast cell viability. 
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4.2.2. The effect of small-molecule integrin inhibitors on skin, lung and breast 
myofibroblast invasion 
An in vitro Transwell invasion assay was conducted to test the effect of integrin 
blockade on the ability of skin, lung and breast fibroblasts to invade Matrigel. In 
preliminary tests, I used three different concentrations of compounds with non-TGF-
β1 stimulated skin and lung fibroblasts. Figure 4.2A shows the pan-αv inhibitor at 
10μM (p<0.01) and 1μm cilengitide (p<0.05) both significantly inhibited invasion of 
skin fibroblasts after 48 hours, although it appears 0.1μM of the αvβ1-selective 
inhibitor promoted invasion relative to the DMSO control. In addition, each of these 
integrin inhibitors also significantly promoted the invasion of lung fibroblasts at 
either 0.1μM or 1μM concentrations (Figure 4.2B). Furthermore, in general the data 
for each drug followed a dose-response pattern. For practical and cost reasons, only 
one concentration could be selected for additional functional studies; 1μM was 























Skin (A) and lung (B) fibroblasts were exposed to either matched DMSO volumes 
(control) or 0.1μM, 1μM or 10μM integrin inhibitors; pan-αv, cilengitide (targeting 
β3/β5) and αvβ1-selective before addition to Matrigel-coated Transwells for a 48-
hour invasion assay. *p<0.05, **p<0.01 one-way ANOVA with Dunnet’s post hoc 
to compare each column to DMSO. Data represented by mean ± s.d (skin n=1, lung 
n=2) with at least 4 technical replicates per concentration.  
A) B) 
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To examine the effect of each compound on skin, lung and breast myofibroblast 
invasive propensity, cells were pre-treated with TGF-β1 for 48-hours and then 
combined with inhibitors (1μM) shortly before plating on top of Matrigel-coated 
Transwells and left to invade for 48 hours. The rationale behind pre-treating 
fibroblasts with TGF-β1 was to test how integrin inhibitors would affect the 
phenotype of activated fibroblasts. This result would also be more clinically relevant 
as fibroblasts in the tumour microenvironment are likely to already be exposed to 
TGF-β1 before a possible integrin-targeting therapeutic would be administered.  
Figure 4.3 shows the invasion of only skin strain 2 and lung strain 3 fibroblasts were 
significantly increased by TGF-β1 pre-treatment. The invasion of other skin, lung and 
breast strains were unaffected by TGF-β1. 
Figure 4.4 demonstrates that myofibroblasts displayed a highly variable response to 
small molecule integrin inhibitors, which appeared in a tissue-specific pattern. Firstly, 
targeting αv-containing integrins using the pan-αv compound inhibited invasion by 
skin strain 2 fibroblasts by 63% (p<0.001), but did not affect skin strain 3. Cilengitide 
significantly reduced the invasion of skin fibroblast strain 2 by 60 ± 16% (Figure 4.4A) 
and skin strain 3 by 46 ± 22% (Figure 4.4B), while the administration of the αvβ1-
selective inhibitor also significantly decreased invasion of skin strain 2 by 41 ± 14% 
and skin strain 3 by 38 ± 16%.  
In contrast, pan-αv and αvβ1 inhibition had no significant effect in lung (Figure 4.4C-
D) and breast (Figure 4.4E-F) fibroblast invasion. Strikingly, cilengitide had the 
opposite effect on lung and breast fibroblasts as it significantly promoted at least 
50% more invasion in lung strain 2 (Figure 4.4C) and breast strain 3 fibroblasts (both 

























Skin, lung and breast fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) 
in tissue culture flasks for 48 hours and then trypsinised and plated on top of 
Matrigel-coated Transwells. Cells were incubated for a further 48 hours and only 
cells underneath Transwells were counted. *p<0.05, one-way ANOVA with 
Dunnet’s post hoc to compare each column to DMSO. Data represented by mean 
± s.d of three independent experiments with at least 3 technical replicates per 
cell strain.  
























































































Skin (A, B), lung (C, D) and breast (E, F) fibroblasts were pre-treated with TGF-β1 
(48-hours), trypsinised and then combined with a matched volume of DMSO 
(control) or 1μM integrin inhibitors; pan-αv, cilengitide (targeting β3/β5) and 
αvβ1-selective and plated on Matrigel-coated Transwells for a 48-hour invasion 
assay. Only cells underneath the Transwell were counted. *p<0.05, **p<0.01 
***p<0.001 one-way ANOVA with Dunnet’s post hoc to compare each column to 
DMSO. Data shown represents mean ± s.d of three independent experiments 




Figure 4. 4. Invasion assay using integrin inhibitors with TGF-β1 treated skin, 





























































































































































































































































































































4.2.3. The effect of small-molecule integrin inhibitors on skin, lung and breast 
myofibroblast-mediated collagen gel contraction  
All fibroblasts were again pre-treated with TGF-β1 (5ng/ml) for 48-hours before being 
plated inside collagen type I gels. TGF-β1-treated fibroblasts were trypsinised and 
resuspended in collagen gels containing 1μM concentrations of each integrin 
inhibitor. The next day, media containing TGF-β1 (5ng/ml) was added on top of gels, 
which were imaged on every 2-3 days.  
Figure 4.5 shows gel contraction on selected days, where none of the three integrin 
inhibitors significantly affected gel contraction by 2 strains of skin (Figure 4.5A-B), 
lung (Figure 4.5C-D) or breast (Figure 4.5E-F) fibroblasts compared to control gels 
(TGF-β1 + DMSO). However, in strain 2 breast fibroblasts pan-αv blockade 
significantly increased gel contraction by an average of 36% (p<0.01). In addition, 
breast fibroblasts took longer to contract gels overall, with or without inhibitors, 
therefore their images and graphs in Figure 4.5 are from later time-points (Day 14 
and Day 25) compared to skin or lung (Day 4-7). To ensure efficacy of the inhibitors 
was maintained during the assay, gels were re-drugged with inhibitors at 1μM 
concentrations in TGF-β1-containing media every 3 days, although this also had no 
































































































































































































































 Skin (A, B), lung (C, D) and breast (E, F) fibroblasts were pre-treated with TGF-
β1 (5ng/ml) for 48 hours and then combined with matched volumes of DMSO 
(control) or 1μM integrin inhibitors; pan-αv, cilengitide (targeting β3/β5) and 
αvβ1-selective and plated inside collagen type I gels. TGF-β1 (5ng/ml) was 
added to gels the following day, which were released from the edge of each 
well. Graphs show selected days of gel contraction as listed in the images below 
each graph. **p<0.01 one-way ANOVA with Dunnet’s post-hoc. Data shown 
represents mean ± s.d of three independent experiment with triplicate gels.  
E) F) 
Figure 4. 5. Effect of integrin inhibitors on skin, lung or breast myofibroblast-






















































































4.2.4. Collagen gel contraction after integrin silencing in skin, lung and breast 
myofibroblasts  
As the integrin inhibitors used bind only transiently to the extracellular ligand-binding 
regions of heterodimers, it’s possible not all integrin functional activity was inhibited. 
Therefore, siRNA was utilised to silence the expression of selected subunits and 
further understand the role of integrins. Ideally, every integrin subunit should be 
knocked down and investigated, but to make the range of experiments more feasible 
only α1, α11, β3 and β5 were targeted in this study. Integrin subunits αv or β1 could 
not be targeted, as this would affect multiple heterodimers. Collagen-binding subunit 
α1 was chosen due to evident TGF-β1-induced transcription in skin fibroblasts and 
high mean fluorescence intensity values during flow cytometry. Although much less 
is known about α11, published studies suggest it has a role in regulating dermal 
fibroblast α-SMA expression and contraction [61, 74], therefore α11 exists as a 
potential therapeutic target. Lastly, TGF-β1-induced β3 and β5 expression was 
validated at both the gene and protein level, while previous studies have also 
demonstrated their role in myofibroblast regulation and latent-TGF-β activation in 
vitro [64, 191, 192], though this combination of fibroblasts (skin, lung and breast) has 
not been examined previously.  
Figure 4.6 and 4.7 show α11 and β5 integrin knockdown significantly inhibited skin 
fibroblast-induced collagen contraction, which was a consistent observation 
between the two different skin fibroblast strains tested. In strain 2 skin fibroblasts 
(Figure 4.6), α11 silencing produced gels 180% larger than control gels (non-targeting 
siRNA-treated fibroblasts), even in the presence of TGF-β1 (p<0.001). While in skin 
strain 3 (Figure 4.7), β5 integrin subunit knockdown was most effective in reducing 
gel contraction as gels were on average 130% larger than controls. Note that, qPCR 
results in Figure 4.6C and 4.7C confirmed the expression of each integrin subunit was 


























Fibroblasts were pre-treated with TGF-β1 (5ng/ml) for 48 hours and then integrin 
siRNA (15nM) for 72 hours. Fibroblasts were then plated inside collagen gels with RNA 
collected from the remaining cells. Vehicle or TGF-β1 was added to each gel. A) Graph 
and images (B) show representative results on day 6. **p<0.01, ***p<0.001 one-way 
ANOVA with Dunnet’s post-hoc to compare each column to NT (non-target siRNA). C) 
Effective integrin knockdown confirmed using qPCR. **p<0.01, ***p<0.001, paired 
Student’s t-test. Data shown represents mean ± s.d of two independent experiments 
with triplicate gels.  
A) Fibroblast-mediated gel contraction after integrin knockdown  
B) Images of fibroblast-mediated gel contraction after integrin knockdown 
C) Confirmation of integrin knockdown  
Figure 4. 6. Effect of integrin-targeted siRNA on skin strain 2 myofibroblast-























































































































































































































A) Fibroblast-mediated gel contraction after integrin knockdown 
B) Images of fibroblast-mediated gel contraction after integrin knockdown 
C) Confirmation of integrin knockdown  
Fibroblasts were pre-treated with TGF-β1 (5ng/ml) for 48 hours and then integrin 
siRNA (15nM) for 72 hours. Fibroblasts were then plated inside collagen gels with RNA 
collected from the remaining cells. Vehicle or TGF-β1 was added to each gel.  A) Graph 
and images (B) show representative results on day 6. ***p<0.001 one-way ANOVA 
with Dunnet’s post-hoc to compare each column to NT (non-target siRNA). C) Effective 
integrin knockdown confirmed using qPCR, **p<0.01, ***p<0.001 Students paired t-
test. Data shown represents mean ± s.d of two independent experiments with 
triplicate gels.  
Figure 4. 7. Effect of integrin-targeted siRNA on skin strain 3 myofibroblast-






































































































































































































Figure 4.8 and 4.9 display the results of lung strain 2 and breast strain 3-mediated 
contraction, respectively. Unfortunately, an additional second strain from lung and 
breast tissue was not completed. Nevertheless, collagen gels containing lung 
fibroblasts where α11 or β5 expression was abolished were 50% larger than control 
gels (non-targeting siRNA) and did not display any contraction by day 8 (Figure 4.8B). 
Although striking, it should be noted this is only a result from one independent 
experiment and again, integrin knockdown was confirmed using qPCR (Figure 4.8C).  
Lastly, Figure 4.9A demonstrates α1 knockdown had striking effects on breast 
fibroblasts, as gel contraction was significantly prevented in the presence of TGF-β1, 
although only 20% ITGA1 gene knockdown was achieved (Figure 4.9C). In addition, 
α11 and β3 knockdown produced similar results as both sets of gels were 
approximately 33% larger than control gels, while silencing of β5 in breast fibroblasts 
also significantly reduced contraction and resulted in collagen gels 58% larger than 
controls on average. Figure 4.9C demonstrates at least 50% gene silencing was 
induced for α11, β3 and β5 subunits, although this needs to be improved in future 
replicate assays. 
Overall, these results suggest different integrins are responsible for mediating 

























Fibroblasts were pre-treated with TGF-β1 (5ng/ml) for 48 hours and then integrin 
siRNA (15nM) for 72 hours. Fibroblasts were then plated inside collagen gels with RNA 
collected from the remaining cells. Vehicle or TGF-β1 was added to each gel. A) Graph 
and images (B) show representative results on day 8 gel contraction. Dashed lines 
outline non-contracted gels. C) Effective integrin knockdown confirmed using qPCR 
(NT=non-target siRNA). Data shown represents mean ± s.d of one independent 
experiment with triplicate gels.  
A) Fibroblast-mediated gel contraction after integrin knockdown 
B) Images of fibroblast-mediated gel contraction after integrin knockdown 
C) Confirmation of integrin knockdown  
Figure 4. 8. Effect of integrin-targeted siRNA on lung strain 2 myofibroblast-




















































































































































































































A) Fibroblast-mediated gel contraction after integrin knockdown 
B) Images of fibroblast-mediated gel contraction after integrin knockdown 
C) Confirmation of integrin knockdown  
Fibroblasts were pre-treated with TGF-β1 (5ng/ml) for 48 hours and then integrin 
siRNA (15nM) for 72 hours. Fibroblasts were then plated inside collagen gels with RNA 
collected from the remaining cells. Vehicle or TGF-β1 was added to each gel. A) Graph 
and images (B) show representative results on day 8. ***p<0.001 one-way ANOVA 
with Dunnet’s post-hoc. Dashed line outlines non-contracted gel. C) Integrin 
knockdown examined using qPCR (NT = non-target siRNA); *p<0.05, ***p<0.001 
Students paired t-test. Data shown represents mean ± s.d of three independent 
experiments with triplicate gels, although α1: n=2.  
Figure 4. 9. Effect of integrin-targeted siRNA on breast strain 3 myofibroblast-




































































































































































































4.2.5. Expression of myofibroblast-associated genes after integrin silencing in skin, 
lung and breast myofibroblasts  
As the previous results demonstrated integrin blockade affects fibroblast invasion 
and integrin knockdown prevents gel contraction, the expression of ACTA2, FN1, 
CTGF and SERPINE1 was re-examined after α1, α11, β3 or β5 gene ablation to 
determine whether integrins also regulate the gene expression of ‘markers of 
fibroblast activation’. 
Again, fibroblasts were pre-treated with TGF-β1 (5ng/ml) for 48 hours, washed and 
then exposed to either non-targeting or integrin-targeted siRNA (15nM) for 72 hours 
in media without supplemented TGF-β1 and RNA was collected at this point to 
examine gene expression. Figure 4.10A demonstrates that TGF-β1-treated skin strain 
2 fibroblasts maintained ACTA2, FN1, CTGF and SERPINE1 expression up to 72 hours 
after the removal of TGF-β1 and therefore, remained activated. Figure 4.10B shows 
the effects of integrin-targeted siRNA on skin strain 2 genes. Overall, α1, α11, β3 and 
β5 knockdown significantly decreased the expression of ACTA2, FN1, CTGF and 
SERPINE1, although to slightly different extents, i.e. α1 knockdown was the most 
potent, as knockdown reduced the expression of each gene by at least 50%. 
Surprisingly, silencing of the β3 subunit significantly increased ACTA2 by 1.2-fold. 
Figure 4.11 demonstrates similar experiments using strain 3 skin fibroblasts to 
determine whether the effects are strain- or organ-specific. Again, Figure 4.11A 
confirms the expression of each myofibroblast-associated gene is upheld when TGF-
β1 is removed from culture media. However, Figure 4.11B indicates integrin 
regulation is strain-specific as integrin silencing significantly increased myofibroblast-
associated genes, particularly CTGF. Although it appears SERPINE1 was significantly 
lowered after α1, α11, β3 and β5 siRNA is applied to cells, suggesting this gene is 





































Fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) for 48 hours and then 
non-target (NT) or integrin siRNA (15nM) for 72 hours. Integrin knockdown was 
confirmed, as shown in Figure 4.6C. A) TGF-β1-induced expression of selected genes 
relative to vehicle-treated fibroblasts, exposed to NT siRNA. B) The expression of 
selected genes in integrin siRNA-treated cells relative to non-targeting-siRNA. 
*p<0.05, **p<0.01, ***p<0.001, paired Student’s t-test. Data shown represents 
mean ± s.d of two independent experiments with triplicate samples.  
A) 
B) 



















































































































































































































































































Fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) for 48 hours and then 
non-target (NT) or integrin siRNA (15nM) for 72 hours without TGF-β1. Integrin 
knockdown was confirmed, as shown in Figure 4.7C. A) TGF-β1-induced expression 
of selected genes relative to vehicle-treated fibroblasts, exposed to NT siRNA. B) The 
expression of selected genes in integrin siRNA-treated cells relative to non-targeting-
siRNA. *p<0.05, **p<0.01, ***p<0.001, paired Student’s t-test. Data shown 






































































































































































































































































Figure 4.12A and 4.13A shows both lung fibroblast strains continued to express 
significantly high mRNA levels of ACTA2, FN1, CTGF and SERPINE1 after pre-
treatment with TGF-β1. Figure 4.12B displays differential effects of integrin 
knockdown on lung strain 2 fibroblasts, as α1 significantly downregulated the 
expression of each of the four genes, conversely α11, β3 and β5 knockdown 
significantly increased fibronectin expression. Furthermore, as previously noted in 
skin fibroblasts, knockdown of α1, α11 and β3 in lung fibroblasts also significantly 
reduced SERPINE1 expression.  
Figure 4.13B exhibits the effects of integrin silencing on lung strain 3 fibroblasts. 
Again results appear as strain-specific, as each marker decreased in response to 
integrin knockdown, contrary to lung strain 2 fibroblasts. In addition, β3 and β5 
targeting was particularly effective, as ACTA2, FN1, CTGF and SERPINE1 were all 
reduced more than 50% relative to genes expressed by non-targeting siRNA-treated 









Figure 4. 12. Effect of integrin siRNA on lung strain 2 myofibroblast genes. 
A) 
B) 
Fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) for 48 hours and then 
non-target (NT) or integrin siRNA (15nM) for 72 hours without TGF-β1. Integrin 
knockdown was confirmed, as shown in Figure 4.8C. A) TGF-β1-induced expression 
of selected genes relative to vehicle-treated fibroblasts, exposed to NT siRNA. B) 
The expression of selected genes in integrin siRNA-treated cells relative to non-
targeting-siRNA. *p<0.05, **p<0.01, ***p<0.001, paired Student’s t-test. Data 






































































































































































































































































Fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) for 48 hours and then 
non-target (NT) or integrin siRNA (15nM) for 72 hours without TGF-β1. Integrin 
knockdown was confirmed, as shown in Appendix Figure 19. A) TGF-β1-induced 
expression of selected genes relative to vehicle-treated fibroblasts, exposed to NT 
siRNA. B) The expression of selected genes in integrin siRNA-treated cells relative 
to non-targeting-siRNA.  Data shown represents mean ± s.d of one experiment 
with triplicate samples.  
A) 
B) 






























































































































































































Next, the effect of integrin knockdown was examined using 2 strains of breast 
fibroblasts.  
Figure 4.14 displays breast fibroblasts strain 2, where unfortunately silencing of only β3 
and β5 was sufficient (Figure 4.14B), though this should be improved in future repeats 
as integrin expression was only reduced by 30-40%. Regardless, this was enough to 
impact the expression of myofibroblast genes, all four of which were evidently lowered 
in response to β3 or β5 knockdown (Figure 4.14C), with ACTA2 and SERPINE1 decreased 
the most relative to non-target treated fibroblasts.  
Lastly, in Figure 4.15 similar results were achieved using breast strain 3 fibroblasts, 
whereby α1, α11, β3 and β5 silencing markedly downregulated the expression of these 
myofibroblast-associated genes. Moreover, these results support the findings from 
breast strain 2, as ACTA2 and SERPINE1 are notably lower when comparing all four 
genes. Again, it should be noted both these strains each represent one independent 
experiment. 
Overall, these experiments demonstrate that integrins modulate TGF-β1-induced 
fibroblast activation and activity, as measured by invasion, collagen contraction and 
‘activation marker’ gene expression. In addition, integrin-regulated functions such as 
invasion and contraction appear to be tissue-specific, although there is variation 
between strains derived from different people. Furthermore, it is evident that α1, α11, 
β3 and β5 integrins regulate the TGF-β1-induced expression of SERPINE1 regardless of 






Fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) for 48 hours and then 
non-target (NT) or integrin siRNA (15nM) for 72 hours without TGF-β1. A) TGF-β1-
induced expression of selected genes relative to vehicle-treated fibroblasts, exposed 
to NT siRNA. B) Partial β3 and β5 integrin knockdown was confirmed. C) The 
expression of selected genes in integrin siRNA-treated cells relative to non-targeting-











































































































































































































































































Fibroblasts were pre-treated with vehicle or TGF-β1 (5ng/ml) for 48 hours and then 
non-target (NT) or integrin siRNA (15nM) for 72 hours without TGF-β1. Integrin 
knockdown was confirmed, as shown in Figure 4.9C. A) TGF-β1-induced expression of 
selected genes relative to vehicle-treated fibroblasts, exposed to NT siRNA. B) The 
expression of selected genes in integrin siRNA-treated cells relative to non-targeting-
siRNA. Data shown represents mean ± s.d of one experiment with triplicate samples.  











































































































































































































































4.3. Discussion  
Previous studies have demonstrated that there is increased integrin expression 
during fibroblast-myofibroblast differentiation[191] and have identified various roles 
that particular integrins play during typical fibroblast functions, such as adhesion, 
contraction and migration. In addition, the presence of α-SMA-positive 
myofibroblasts correlates with a poor prognosis in various cancers, such as breast[92] 
and oral squamous cell carcinomas[94], while in vitro studies also suggest that αvβ3 
and αvβ5 integrins expressed by fibroblasts regulate α-SMA expression and 
contraction[64]. More recently, in vivo studies demonstrate the targeting of αv-
containing integrins expressed by lung and liver fibroblastic cells reduces organ 
fibrosis in mice[130]. Therefore, this study here in hypothesised that integrins are 
capable of regulating myofibroblast functions, such as contraction and invasion, in 
tissues which have not been compared previously. Furthermore, the integrins 
examined in this study were chosen by monitoring fibroblast activation and have also 
not been previously investigated simultaneously. Using small-molecule integrin 
inhibitors and integrin-targeted siRNA, I have shown that αv-containing integrins 
regulate myofibroblast invasion and α1, α11, β3 and β5 modulate TGF-β1 induced 
collagen gel contraction, as well as the expression of ‘markers’ of fibroblast 
activation. Moreover, the targeting of integrins in this study also identified organ- 
and strain-specific responses. 
4.3.1. The effect of integrin small-molecule inhibitors on regulating the invasion of 
skin, lung and breast myofibroblasts    
Firstly, fibroblasts pre-treated with TGF-β1 demonstrated strain-specific responses 
when plated in Matrigel-coated Transwells, as only the invasion of skin myofibroblast 
strain 2 and lung strain 3 was significantly enhanced when compared to fibroblasts 
pre-treated with vehicle, while the invasion of additional skin, lung and breast 
myofibroblast strains were unaffected by TGF-β1 (Figure 4.3). Previous studies have 
reported TGF-β1 did not affect the migration of renal fibroblasts on collagen, but 
increased adhesion[193]. In addition, Denys and colleagues found that TGF-β1 
increased stress fibre formation in immortalised dermal fibroblasts, but significantly 
reduced invasion, which was associated with low Rac1 expression, known to 
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positively regulate cell invasion[68]. Overall, these findings suggest TGF-β1 does not 
support fibroblast invasion.  
Organ-specific functions were apparent using integrin small-molecule inhibitors, 
whereby skin fibroblast invasion was significantly impaired by cilengitide and an 
αvβ1-selective compound. Encouragingly, these effects were validated in two strains 
of skin fibroblasts, which were derived from separate donors. The specificity and 
efficacy of this αvβ1 compound was first published in 2015 by Reed and colleagues, 
who demonstrated that αvβ1 blockade reduced liver and lung fibrosis in vivo, as αvβ1 
has a key role in activating TGF-β by binding to its latency-associated peptide[38]. 
However, the study of αvβ1 biology had been previously hampered due to the lack 
of specific suitable reagents to identify this heterodimer; thus no heterodimer-
specific antibodies exist, and as both αv and β1 partner with many other subunits, 
antibodies to either subunit cannot be used to specifically identify αvβ1. Therefore, 
the authors acknowledged that unidentified functions of αvβ1 may still exist[38].  
αvβ1 expression has previously been linked to tumour cell migration and invasion. 
Before use of this small-molecule inhibitor, αvβ1 expression was manipulated by 
intracellular antibody blockade of the αv subunit, as it was hypothesised that αvβ1 is 
formed in the presence of an excess of both αv and β1 subunits. After confirming 
knockdown of αvβ1 by immunoprecipitating αv and then blotting for subunits 
including β1, Koistinen and Heino found that αvβ1 mediates the migration of 
melanoma cells on fibronectin coated wells[194]. More recently, fibroblast-specific 
deletion of β1 integrin in conditional-knockout mice displayed delayed wound closure 
and less α-SMA-positive myofibroblasts. Furthermore, explant growth of dermal 
fibroblasts from knockout mice showed reduced adhesion to fibronectin, migration 
and activation of latent-TGF-β1, although it was not confirmed whether the 
heterodimer mediating these effects was αvβ1[195]. In addition, Hu and colleagues 
showed that αvβ1 regulates glioma cell invasion in vitro by enhancing MMP-2 
expression after activating the FAK-ERK1/2 pathway[196]. Aside from this, it is clear 
that further research into the role of αvβ1 in fibroblasts is much needed and this new 
αvβ1-selective inhibitor, makes this now possible.  
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It is possible that skin fibroblasts express distinct amounts of αvβ1 and aside from 
TGF-β activation, utilise this integrin to regulate unknown mechanisms relevant 
during fibroblast invasion, such as protease expression. In contrast, lung and breast 
fibroblast invasion was unaffected by αvβ1 blockade, suggesting redundancy of this 
integrin in these cells. However, only one concentration was tested in these assays 
(1μM), therefore perhaps multiple lower concentrations should be tested to examine 
dose-response effects, as Reed and colleagues reported, as little as 1nM was 
sufficient to prevent αvβ1 binding to LAP in vitro [38].    
The use of cilengitide also produced differential effects during invasion through 
Matrigel-coated Transwells, as skin fibroblast invasion was significantly prevented 
while lung and breast fibroblast invasion was enhanced, again a phenomenon 
observed in two strains per tissue derived from different donors. The effect on skin 
fibroblasts is supported by Fu and colleagues, who also discovered that cilengitide 
inhibited the migration of dermal fibroblasts on fibrinogen matrices. After addition 
of cilengitide they also found that fibroblasts exhibited significantly lower α-SMA and 
phospho-Smad3 protein, suggesting integrin inhibition directly interfered with TGF-β 
signalling, although the mechanism of interaction was not investigated. The authors 
proposed that binding of fibrinogen to αvβ3 integrin may have triggered clustering 
with TGF-β receptors on the cell surface, enhancing the activation of TGF-β1-induced 
Smad signalling. Therefore, binding of cilengitide may have obstructed αvβ3-ligand 
binding, reducing clustering and signal transduction[188]. Moreover, previous 
reports suggested the expression of protease MMP-9 is partially Smad3-
dependent[189], which is important for fibroblast invasion[197]. Alternatively, 
cilengitide may prevent latent-TGF-β activation. Sarrazy and colleagues discovered 
the use of cilengitide (1µM) on cardiac fibroblasts prevented contraction-mediated 
activation of latent-TGF-β1 and subsequent α-SMA expression in vitro[125], with 
similar findings using cilengitide on intestinal smooth muscle cells[198]. As a 
reminder, TGF-β1 was not supplemented during my own invasion assays. Skin, lung 
and breast fibroblasts were pre-treated with TGF-β1 and then plated on top of 
Transwells in media without TGF-β1, although the cytokine was present in its latent 
form in the Matrigel coating of the Transwells and perhaps in the serum below. It is 
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also possible that latent TGF-β1 was secreted by skin fibroblasts, which required 
activation via β3 or β5 integrins. 
The tissue-specific responses and increased invasion by lung and breast fibroblasts in 
response to cilengitide cannot be explained by differing levels of integrins, as breast 
strain 3 fibroblasts exhibited higher amounts of αv and β5 subunits than skin or lung, 
although β1 levels were not characterised and cilengitide also inhibits αvβ1, albeit 
weakly[199]. Lung and breast fibroblasts may over-compensate for integrin blockade 
by raising the expression of other integrins and integrin-associated proteases. Sarrazy 
and colleagues found the overexpression of β3 integrins in cardiac fibroblasts in vitro 
significantly reduced the expression of β5 and vice versa. Conversely, short hairpin 
RNA-mediated silencing of either subunit also increased expression of the other 
subunit[125]. It would be interesting to determine whether cilengitide has similar 
effects on other integrin subunits, particularly in lung and breast fibroblasts. 
Furthermore, Caswell and colleagues reported that administration of 1μΜ cilengitide 
promoted migration of ovarian tumour cells into Matrigel by promoting α5β1 
recycling and the formation of pseudopod extensions[200], while a similar 
mechanism of α5β1 internalisation was also necessary to promote the migration of a 
human foreskin fibroblast cell line on fibronectin[201]. These studies provide a 
potential mechanism by which cilengitide could promote fibroblast invasion. 
It appears my data adds to the previously reported differential effects of cilengitide 
and further experiments using cilengitide on skin, lung and breast fibroblasts would 
likely reveal more on the diverse mechanisms of αvβ3 and αvβ5 integrins utilised 
during invasion. In the wider context, cilengitide previously reached phase III clinical 
trials for glioblastoma and randomized controlled Phase II studies for non-small-cell 
lung cancer and squamous cell carcinoma of the head and neck, although proved 
unsuccessful[202]. Consequently, determining the mechanism of action of cilengitide 
on stromal cells growing in the tumour microenvironment would also guide the 
therapeutic efficacy of this compound.   
Lastly, due to lack of time, the effect of integrin silencing during fibroblast invasion 
was not investigated. Future completion of these experiments may validate the 
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findings from using integrin inhibitors and the use of 3D organotypic invasion assays 
would assess repercussions on tumour cell growth and invasion when the expression 
of particular integrins in fibroblasts are abolished using siRNA.  
4.3.2. The role of integrins in regulating TGF-β1-induced skin, lung and breast 
fibroblast gel contraction  
The ability of adult fibroblasts to contract the ECM is a central role during wound 
healing to induce closure of injured tissues. However, in more pathogenic settings 
such as the tumour microenvironment, activated fibroblasts secrete collagens, 
collagen cross-linking proteins and contract the matrix, stiffening the area 
immediately surrounding tumours, resulting in the promotion of tumour growth via 
stiffness-induced signalling[203]. Furthermore, fibrosis itself is enough to 
compromise the normal function of organs[204]. Therefore, reducing the capacity of 
fibroblasts to contract and stiffen tissue is an important therapeutic goal.  
In this study, siRNA-mediated knockdown of α11 and β5 subunits impaired collagen 
contraction by the skin and lung fibroblast strains tested, suggesting these integrins 
are key regulators of contractile activity in these fibroblasts. These results are 
supported by Barczyk and colleagues, who demonstrated α11 knockdown in 
periodontal ligament fibroblasts reduced gel contraction by 20-30% after 8 days[74]. 
Moreover, in 2015, Navab and colleagues used α11-knockout mice to show stromal 
α11β1 integrin mediated the reorganisation of collagen fibres in tumour xenografts, 
where measurements of tissue stiffness were lower in α11-knockout mice compared 
to wild-type. Furthermore, knockout of stromal-localised α11 in these mouse models 
also significantly reduced tumour growth and the metastatic potential of lung cancer 
cells, suggesting α11β1-mediated tissue stiffness may contribute to tumorigenicity 
and metastasis[205]. In support of the findings generated by β5 knockdown, 
administration of integrin-neutralising antibody, P1F6 (αvβ5) to dermal and oral 
mucosal fibroblasts inhibited contraction, as gels were 100% larger than  TGF-β-
treated control gels[64]. It may be worth noting that siRNA to α11 was particularly 
effective in regulating strain 2 foreskin fibroblasts derived from a young donor, 
whereas siRNA to β5 displayed a more prominent role during gel contraction 
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mediated by adult dermal fibroblasts. It would be interesting to determine whether 
these effects are dependent on the age of donors.  
As a reminder, integrin inhibitors (pan-αv, cilengitide and αvβ1-selective compounds) 
did not affect gel contraction overall. In this study, active TGF-β1 was supplemented 
at the beginning of gel contraction assays, therefore if the mechanism of integrin 
inhibitors is to prevent latent TGF-β1 activation, this function becomes redundant in 
the presence of active TGF-β1. Furthermore, it is likely that small-molecule inhibitors 
that bind to the extracellular ligand-binding region of integrins may not interfere with 
the ability of integrins to activate intracellular signalling pathways and proteins 
involved in contraction. In contrast, although integrin knockdown was not validated 
at the protein level, qPCR results confirmed silencing at least at the mRNA level, 
suggesting that siRNA may have also impacted integrin expression at the plasma 
membrane, preventing activation of integrin signalling pathways. This is supported 
by findings here that siRNA-mediated knockdown of integrins also modified the 
expression of TGF-β-responsive genes, such as ACTA2, which is partially responsible 
for the level of contractile activity exhibited by myofibroblasts[175]. Of course, the 
effect of integrin inhibitors on ACTA2 expression should also be investigated to 
validate this. If time permitted, the effect of antibody-mediated blockade of integrins 
during collagen contraction would have also been investigated, as previous studies 
have demonstrated this prevented fibroblast-induced contraction[64]. In addition, 
perhaps proteomic analysis of fibroblasts after integrin silencing would identify the 
regulation of other proteins that may contribute to contraction.  
Furthermore, integrins are also known to form complexes with growth factor 
receptors on the cell surface, which couples their intracellular signalling pathways. 
For example, proximity ligation assays identified β1 integrin interaction with VEGF 
receptor-2 on the surface of endothelial cells, which was necessary for downstream 
VEGF signalling[206]. In addition, β1 integrin is known to associate with EGFR in 
breast cancer cells, which together activates FAK and the MAPK pathway and when 
either of these transmembrane components were neutralised with specific 
antibodies, the expression of both proteins decreased[207]. More importantly, Asano 
and colleagues found that β5 subunits are associated with TGF-β receptor I and 
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receptor II proteins in clathrin-coated membranes in dermal fibroblasts, potentially 
establishing an autocrine signalling network[191]. Therefore, perhaps the addition of 
siRNA in this study removed integrins from potential complexes involving growth 
factor receptors, which small-molecule integrin inhibitors did not affect, thereby 
permitting lateral integrin interactions and allowing fibroblasts to contract gels as 
usual.   
My results support the concept that integrins expressed by myofibroblasts regulate 
collagen contraction; one potential mechanism is by perhaps mediating TGF-β1-
activated non-canonical signalling pathways. Though some previous studies suggest 
canonical Smad3[208] and Smad7[209] signalling regulate fibroblast-mediated 
contraction, recent studies show non-canonical proteins, such as Jun N-terminal 
kinase mediate α11 integrin-induced collagen remodelling[210]. In future studies, the 
expression and activity of proteins involved in typical signalling pathways, such as 
Smads, FAK, integrin-linked kinase, ERK1/2 and p38 MAPK should be characterised 
after integrin knockdown in the presence of TGF-β1 to investigate this hypothesis.  
Tissue-specific effects were also observed during gel contraction experiments, 
particularly with the effect of silencing α1. α1β1 integrin is a collagen receptor and 
significantly prevented gel contraction in breast fibroblasts alone. Furthermore, as 
noted in Results Part I, the expression of an alternative collagen receptor subunit, 
α11 integrin, is significantly increased in skin and lung after TGF-β1 treatment but not 
in breast fibroblasts, perhaps indicating skin and lung fibroblasts rely on α11β1 for 
collagen remodelling, while breast fibroblasts principally utilise α1β1. The key role of 
α11 in dermal fibroblasts has been reported by Schulz and colleagues, who compared 
the effects of collagen receptor subunits α2 and α11 by silencing either subunit or 
both in knockout mice during wound healing, and found only α11 was responsible for 
impairing wound closure, suggesting this is the predominant collagen receptor 
regulating the function of dermal fibroblasts, although they did not compare α1 
integrin function[210].  
The impact of integrin knockdown on the expression of other integrins in the same 
cell is unknown. Other studies identify compensatory increases in integrins, such as 
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silencing of β1 integrin in dermal fibroblasts upregulated β3 protein[195], therefore 
the expression of other integrins, such as α2β1, which is also known to contribute to 
collagen gel contraction should be characterised in each fibroblast after knockdown 
as this may explain the observed phenotypes[211]. In addition, while I did not notice 
significant changes in cell morphology in response to siRNA treatment when 
fibroblasts were adhered to collagen, measurement of fibroblast cell viability, 
adhesion, proliferation and apoptosis after integrin siRNA treatment would rule out 
these factors as influencing gel contraction.  
4.3.3. The role of integrins in regulating TGF-β1-induced skin, lung and breast 
myofibroblast gene expression 
My study also confirmed integrins can modulate the expression of myofibroblast 
gene markers during TGF-β1 treatment of fibroblasts. However, intra-strain variation 
meant the two skin and lung fibroblast strains examined displayed differential 
responses, though these experiments need to be repeated to reach three 
independent experiments per strain. Nevertheless, the qPCR results clearly indicate 
that integrins potently regulated SERPINE1 regardless of tissue type, as its expression 
was reduced by at least 80% in some fibroblasts. PAI-1 is an indirect protease inhibitor 
by preventing function of the enzyme ‘plasminogen activator’, which converts 
plasminogen to protease plasmin, hence the expression of PAI-1 results in reduced 
breakdown of ECM proteins, enhancing fibrosis. PAI-1 expression is also a common 
measure in TGF-β1 signalling assays[35] and previous studies have linked PAI-1 
activity to regulating the expression of αvβ3 in corneal[212] and cardiac 
fibroblasts[213]. Previously, Pedroja and colleagues had shown that PAI-1 binding to 
its receptor promoted the internalisation of αvβ3[214] and this study has shown β3 
regulates PAI-1 expression, suggesting the presence of a regulatory feedback loop. 
Furthermore, this study provides evidence that αvβ3 is not the only integrin to 
regulate PAI-1 expression, but α1, α11 and β5 each contribute to regulating disease-
promoting genes, including PAI-1. Again, mini-organotypic assays and fibroblast-
tumour cell co-culture experiments would demonstrate the knock-on effects on 
tumour cells, when expression of these and other potentially tumour-promoting 
genes are minimised.  
129 
 
In summary, my findings indicate integrins modulate myofibroblast invasion in a 
tissue-specific manner. In addition, integrins α1, α11, β3 and β5 regulated TGF-β1-
induced collagen contraction and gene expression, particularly in a strain-specific 
manner. Integrin α1 appeared to only regulate TGF-β1-induced contraction by breast 
fibroblasts, however additional repeats and strains need to be tested. Overall, these 
results indicate particular integrins are potential therapeutic targets to dampen the 






CHAPTER V. RESULTS PART III  
RNA sequencing of TGF-β1-stimulated human lung fibroblasts 
5.1. Background 
Previous microarray studies using TGF-β1-treated lung fibroblasts have 
demonstrated that TGF-β1 can induce the expression of a variety of genes, including 
those involved in cytoskeletal reorganisation, signalling, matrix formation, cell 
proliferation and metabolism[168, 169], which facilitated the characterisation of 
genes that were commonly upregulated in myofibroblasts. The profiling of CAFs has 
also provided invaluable information that has shown to predict clinical outcomes in 
breast cancers[215], therefore characterising gene expression in TGF-β1-activated 
fibroblasts and CAFs has immense prognostic value[85].   
In Chapter III (Results Part I), one primary task was to select a manageable subset of 
eight TGF-β1-induced genes to characterise in skin, lung and breast fibroblasts using 
qPCR. However, to obtain a broader picture of the genetic response of fibroblasts to 
TGF-β1 and a better understanding of lung fibroblast biology, RNA sequencing (RNA-
seq) was conducted on three normal strains of primary lung fibroblasts (named HLF1, 
HLF2 and HLF3). To note, the same RNA samples from 24-hour vehicle and TGF-β1-
treated lung fibroblasts that were used during the qPCR experiments presented in 
Results Part I were sent for RNA sequencing. Ideally, RNA-seq would have been 
performed on TGF-β1-treated skin, lung and breast fibroblasts to compare 
differentially expressed genes and further identify heterogeneity, however, due to 
cost, only one tissue type could be selected. Lung fibroblasts were utilised due to the 
availability of remaining RNA from previous qPCR experiments and to provide 
contextual information on any successful drug hits identified during the upcoming 
drug library screen, which was also performed on lung fibroblasts derived from the 
same donors (Chapter VI, Results Part IV). In addition, my sponsor, GSK Fibrosis and 
Lung Injury unit, have a specific interest in lung biology.  
RNA-seq was conducted on HLF1, HLF2 and HLF3 to identify which genes are up- or 
downregulated after 24 hours of TGF-β1 (5ng/ml) stimulation relative to vehicle 
treatment. The subsequent data was input into knowledgebase software ‘Database 
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for annotation, visualisation and integrated discovery’ (DAVID) and ‘Ingenuity 
pathway analysis’ (IPA) that independently accrues published data to identify 
biological networks that these differentially expressed genes are likely to map to.  
 
5.2. RNA sequencing of TGF-β1-stimulated human lung fibroblasts 
The raw data generated from RNA sequencing was analysed by Bioinformatician Dr 
Ai Nagano (Barts Cancer Institute), whereby gene expression in vehicle-treated lung 
fibroblasts was compared with TGF-β1-treated cells. Only genes that were 
significantly differentially expressed and up- or downregulated by at least 2-fold were 
included for further analysis.  
Figure 5.1 shows the global expression changes of 1,643 genes that were 
differentially expressed in the three strains of vehicle and TGF-β1-treated lung 
fibroblasts. The results indicate numerous genes were both up- (762 genes) and 
downregulated (881 genes) by TGF-β1, while each of the three strains of lung 
fibroblasts derived from different donors displayed similar responses to treatment 
overall, although some variability was visible between biological repeats and strains.    
The datasets of differentially expressed genes were first investigated using software 
DAVID to identify possible biological networks that these genes are involved in; the 
top networks and their associated genes are listed in Table 5.1. The top networks 
identified were ‘TGF-β signalling’, ‘pathways in cancer’, ‘cytokine-cytokine receptor 
interaction’, ‘ECM-receptor interaction’ and ‘focal adhesion’. The genes associated 
to the network ‘TGF-beta signalling pathway’ includes TGF-β1 (TGFB1) and TGF-β2 
(TGFB2), which were significantly upregulated by an average of 2.5-fold and 2.1-fold 
in all three TGF-β1-treated strains, respectively. Furthermore, key components that 
typically enhance TGF-β1 signalling, including SMAD3 and type II receptor TGFBR2 
were both significantly downregulated after 24-hour exposure to TGF-β1, whereas 
the expression of pathway inhibitor SMAD7 was significantly raised 4.3-fold in TGF-
β1-activated HLFs.  
In addition, the same genes were also linked to the ‘pathways in cancer’ network, 
which included several genes, such as fibroblast growth factors (FGFs), e.g. FGF2, 
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which was upregulated by an average of 3.9-fold in all three HLFs in response to TGF-
β1, and vascular endothelial growth factor-A (VEGFA), which was raised 2.8-fold, 
while each molecule is known to promote fibrosis[86] and angiogenesis[216], 
respectively. In addition, RNA-seq revealed the hedgehog signalling pathway was 
activated in lung myofibroblasts, as indicated by upregulated ligands HHIP and 
WNT5A, transmembrane receptor FZD8 and transcription factors GLI1 and GLI2. 
Table 5.1 also shows the network ‘cytokine-cytokine receptor interaction’ was 
enriched, which encompasses various pro-inflammatory molecules produced by 
myofibroblasts; an area that was not investigated in my own previous qPCR 
experiments. Many genes in this network were downregulated, though cytokines 
such as interleukin-6 (IL6), which is implicated in cancer progression, was significantly 
elevated 2.9-fold in TGF-β1-treated HLFs, in addition to the interleukin-21 receptor 
(IL21R), which was increased 5-fold. Most notably, several receptor subtypes 
constituting the tumour necrosis factor (TNF) superfamily, a major inflammatory 
cytokine, were downregulated by TGF-β1 exposure (TNFRSF1B, TNFRSF11B, 
TNFRSF14, TNFRSF19, TNFRSF21).  
Reassuringly, a variety of integrin subunits were also upregulated by TGF-β1 
stimulated lung fibroblasts, including α1 (ITGA1), α11 (ITGA11) and β3 (ITGB3), 
validating the integrin qPCR results using lung fibroblasts in Results Part I. The 
individual fold-changes for each integrin are listed in Table 5.2, showing α11 
exhibited the highest significant increase of 17.5-fold in TGF-β1-treated HLFs relative 
to vehicle and β8 was significantly downregulated after 24-hour TGF-β1 exposure by 
an average of 8.3-fold in the three strains of HLFs. The integrin genes comprised the 
networks ‘ECM-receptor interaction’ and ‘focal adhesion’ (Table 5.1), encompassing 
the fundamental feature of fibroblasts to transmit extracellular signals internally via 
ECM-integrin interaction. Furthermore, genes identified by RNA-seq could spur 
future studies, such as actin-binding protein filamin B (FLNB), which is associated with 
mouse embryonic fibroblast invasion[217] and was increased approximately 4-fold 
in HLFs and yet, the function of filamin B in lung fibroblasts has not been previously 
established. Furthermore, it is also clear that the expression of several types of 
collagens were enhanced by TGF-β1, including COL4A1, COL4A2 and COL5A1, as well 
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as COL7A1 (not listed in Table 5.1). Of note, collagen cross-linking genes lysyl oxidase 
(LOX) and lysyl oxidase-like 2 (LOXL2) were also significantly upregulated 3.8-fold and 
2.3-fold by TGF-β1, respectively. 
 

































































































Figure shows fold-changes in gene expression in 3 strains of 24-hour TGF-β1-
treated human lung fibroblasts (HLF1, 2, 3) compared to vehicle-treatment. Each 
row displays expression data for a single gene (1643 genes in total) and each 
column represents pairwise comparisons of TGF-β1 or vehicle treatment in each 
biological repeat. HLF1 (n = 2), HLF2 (n = 1), HLF3 (n = 3). Changes in gene 
expression are based on log-transformed values of fold ratios, where brighter 
shades of red and green represent greater gene upregulation and 





















Figure 5. 1. Global profile of lung fibroblasts genes regulated by TGF-β1. 
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Table 5. 1. Top biological networks linked to differentially expressed genes regulated by TGF-β1 in human lung fibroblasts. 
Networks were generated in software Database for annotation, visualisation and integrated discovery (‘DAVID’) using RNA sequencing data 
from 3 strains of 24-hour vehicle and TGF-β1-treated (5ng/ml) lung fibroblasts. All genes listed were up- (red) or downregulated (green) at least 
2-fold relative to vehicle-treated fibroblasts. Genes mentioned in the text are underlined in the table.  
 







BMP4, BMP2, SMAD9, ACVRL1, SMAD7, SMAD6, GDF6, TGFBR2, RBL1, GDF5, 
SMAD3, DCN, TGFB1, TGFB2, INHBA, CDKN2B, INHBE, COMP, ID3, THBS2, 
BMP6, PITX2 
2.730068087 0.004937307 
Pathways in cancer 
E2F1, E2F2, FGF5, FGF7, PTGS2, PDGFA, STAT5A, PPARG, MITF, FGF10, GLI2, 
TGFB1, GLI1, TGFB2, CCNE2, CDKN2B, SLC2A1, RARA, RARB, HHIP, FGF2, AR, 
DAPK1, VEGFC, VEGFA, PDGFRA, LAMC2, WNT5A, WNT16, APC2, KITLG, KIT, 
RAC2, LAMB1, EGF, FIGF, TRAF5, BMP4, FZD8, COL4A2, IL6, BMP2, COL4A1, 




TNFRSF21, IL1R1, CCL2, ACVRL1, PDGFA, CSF1, IL21R, GDF5, KITLG, KIT, 
TNFSF12, IL7R, TGFB1, IL11, TGFB2, LIF, TNFRSF1B, TNFRSF11B, TNFRSF19, 
IL15RA, EGF, FIGF, GHR, IL18R1, BMP2, IL6, TNFSF4, IL7, TGFBR2, LIFR, 
TNFRSF14, HGF, IL6R, INHBA, VEGFC, TNFSF13B, RELT, INHBE, CXCL16, 




COL4A2, COL4A1, TNXB, ITGA1, ITGA11, ITGB3, SDC4, COL5A1, SDC2, CD47, 




CAV1, PDGFA, ITGA11, ITGB3, RAC2, PAK3, ITGB8, COMP, PDGFD, LAMB1, 
EGF, FIGF, THBS2, COL4A2, COL4A1, TNXB, ITGA1, ACTN1, IGF1, HGF, BIRC3, 
FLNB, COL5A1, VASP, ITGA9, VWF, VEGFC, LAMA4, LAMA3, CCND2, ITGA5, 












The RNA-seq dataset was also input into IPA software for further analysis to 
determine which TGF-β1-induced genes corresponded to proteins that would be 
localised to the plasma membrane. This was to identify transmembrane proteins that 
may be highly upregulated only on activated fibroblasts and that could potentially 
regulate the lung myofibroblast phenotype if targeted therapeutically in future 
studies. Table 5.3 shows the top TGF-β1-induced genes, which are known to be 
expressed as proteins localised to the plasma membrane. The most highly increased 
genes included potassium voltage-gated channel subfamily H (KCNH1), which was 
upregulated by an average of 60-fold by TGF-β1 across the three strains of HLFs and 
gene frizzled class receptor 8 (FZD8), which was elevated 47.5-fold after stimulation. 
In addition, integrin subunits α9, α11 and β3 were also among this dataset, while 
though not shown, many genes corresponding to cell surface proteins were also 





Gene Description Fold-change p-value 
ITGA1 integrin subunit alpha 1 2.76 0.007973475 
ITGA5 integrin subunit alpha 5 2.22 0.000580488 
ITGA11 integrin subunit alpha 11 17.49 4.82E-05 
ITGB3 integrin subunit beta 3 6.25 0.000165655 
ITGB8 integrin subunit beta 8 0.12 3.33E-05 
RNA sequencing was conducted on three strains of vehicle- and TGF-β1-treated 
(5ng/ml) human lung fibroblasts. The average fold-change between the 3 strains of 
TGF-β1 relative to vehicle treatment is presented.   
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Table 5. 3. Top plasma membrane-associated genes upregulated by TGF-β1 in 
lung fibroblasts relative to vehicle. 
  




KCNH1 potassium voltage-gated channel 
subfamily H member 1 
60.09 ion channel 
FZD8 frizzled class receptor 8 47.50 G-protein coupled 
receptor 
PMEPA1 prostate transmembrane protein, 
androgen induced 1 
31.43 Other 
AMIGO2 adhesion molecule with Ig like 
domain 2 
24.17 Other 
ITGA11 integrin subunit alpha 11 17.50 Other 
CNTN1 contactin 1 13.23 Enzyme 
SGCG sarcoglycan gamma 12.94 Other 
ADAM12 ADAM metallopeptidase domain 12 12.08 Peptidase 
NALCN sodium leak channel, non-selective 11.62 ion channel 
LRRC15 leucine rich repeat containing 15 11.59 Other 
ITGA9 integrin subunit alpha 9 11.46 Other 
DSP Desmoplakin 9.34 Other 
HHIP hedgehog interacting protein 8.81 Other 
PCDH1 protocadherin 1 8.37 Other 
KCNG1 potassium voltage-gated channel 
modifier  
7.62 ion channel 
ADAM19 ADAM metallopeptidase domain 19 7.56 Peptidase 
KIAA1324 KIAA1324 6.97 Other 
NPR3 natriuretic peptide receptor 3 6.71 G-protein coupled 
receptor 




CLTCL1 clathrin heavy chain like 1 6.52 other 
RTKN2 rhotekin 2 6.46 other 
ITGB3 integrin subunit beta 3 6.25 transmembrane 
receptor 
CDH2 cadherin 2 6.17 other 
AOC3 amine oxidase, copper containing 3 6.13 enzyme 
KCNMB1 potassium calcium-activated 
channel subfamily  
6.12 ion channel 
CELSR1 cadherin EGF LAG seven-pass G-type 
receptor 1 
6.09 G-protein coupled 
receptor 
TSPAN13 tetraspanin 13 5.91 other 
SCUBE3 signal peptide, CUB domain and EGF 
like domain 
5.90 other 
PCDH9 protocadherin 9 5.72 other 
SLC19A2 solute carrier family 19 member 2 5.54 transporter 
DYSF Dysferlin 5.49 other 
AKAP5 A-kinase anchoring protein 5 5.37 other 
PKP1 plakophilin 1 5.19 other 
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IPA software is also able to relate datasets with biological networks by tracking the 
fold-changes of each gene and comparing this with published data, generating an 
‘overlap p-value’. Using this method of analysis, IPA independently recognised that 
TGF-β1 was a principal upstream regulator in this dataset and several of its target 
genes, as established by IPA, are listed in Figure 5.2A. To note, this list included genes 
that were verified previously using qPCR in Results Part I, such as ACTA2, CTGF and 
SERPINE1.  
In addition, IPA suggested the top cellular processes induced by TGF-β1 stimulation 
of HLFs were ‘mitogenesis of fibroblasts’, ‘cell cycle progression’ and ‘adhesion of 
connective tissue cells’. Each of these networks and the genes associated are 
displayed in Figure 5.2B and 5.2C.   
In addition, as various inflammatory factors were up- and down-regulated by TGF-β1 
in HLFs, IPA software was used to determine potential signalling pathways involved 
in regulating these genes. Figure 5.3 shows many cytokine cell surface receptors, 
such as IL-6R, IL-1R, TNFR and ET-BR (endothelin receptor type B) were 
downregulated in activated HLFs, though ligands, IL-6 and ET-1 were significantly 
increased. In addition, transcription factor NF-κB (nuclear factor-κB) appeared to 
directly mediate the transcription of several cytokines, many of which were also 



































Ingenuity pathway analysis of RNA sequencing data from three strains of 24-
hour TGF-β1-treated lung fibroblasts relative to vehicle-treated cells. Darker 
shades of green indicate higher gene downregulation compared to vehicle and 
darker shades of red indicate higher gene upregulation in TGF-β1 vs vehicle-
treated cells. Dashed lines signify indirect relationships between molecules (N.B. 
physical contact is required between two factors to represent direct 
interaction). A) Significant downstream targets of TGF-β1. Top activated cellular 
processes were identified by IPA and the genes involved in; adhesion of 













Figure 5. 3. Signalling pathways that regulate TGF-β1-induced genes in human lung fibroblasts. 
Ingenuity pathway analysis (IPA) software was used to determine which inflammation-associated pathways were active in TGF-β1 stimulated 
lung fibroblasts. Upregulated genes (red), downregulated genes (green) and unchanged genes (non-coloured) derive from the RNA 
sequencing analysis of three strains of lung fibroblasts. Darker shades of colour represent higher fold-change, log fold change and p-values 
are stated beneath each molecule. Lines connecting molecules are either dashed (indirect relationships) or solid (direct relationships). Inner 
circle represents the nucleus and outer square represents the cell plasma membrane. Image generated by IPA.  
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Although the analyses presented so far was performed on the combined dataset 
generated by HLF1, -2 and -3, overlapping genes were also common between the 
different lung strains. Figure 5.4 shows the same 99 differentially expressed genes 
were identified in both HLF1 and HLF3. Note, HLF2 was unusable for this analysis as 
only one biological repeat was completed, whereas at least two independent 
experiments were performed using strains HLF1 and HLF3. Although there was a 
disparity between the total numbers of differentially expressed genes found in each 
strain; 138 genes in HLF1 and 1162 in HLF3, these results show that lung fibroblasts 













Overall, RNA sequencing results demonstrated that only 24 hours of TGF-β1 exposure 
of healthy lung fibroblasts was sufficient to produce a gene signature reminiscent of 
a reactive stroma, with the potential to promote detrimental actions including 
angiogenesis, fibrosis and invasion.  
 
 
Differentially expressed (DE) genes were identified in TGF-β1 relative to vehicle-
treated lung fibroblasts. Ninety-nine common differentially expressed genes were 
identified in 2 strains of lung fibroblasts; strain 1 (HLF1) and strain 3 (HLF3).  




5.3. Discussion  
RNA-seq was conducted on TGF-β1-stimulated lung fibroblasts to examine which 
genes are significantly regulated by TGF-β1, in addition to those genes studied in my 
own qPCR experiments. Firstly, the results of the RNA-seq support the findings 
obtained by previous qPCRs, as genes such as ACTA2, CTGF, SERPINE1 and several 
integrin genes demonstrated similar levels of expression in response to TGF-β1. 
Ideally, RNA-seq would also be performed on skin and breast fibroblasts to determine 
the level of overlap of differentially expressed genes and heterogeneity that exists 
between fibroblasts derived from all three organs. From Figure 5.4, we can already 
confirm that some intra-tissue heterogeneity was present when comparing 
differentially expressed genes in lung strains HLF1 and HLF3, although 72% of TGF-
β1-regulated genes in HLF1 were also common to HLF3. 
RNA-seq was also performed to understand which biological networks TGF-β1-
regulated genes map to using various knowledgebase programs. Unsurprisingly, the 
‘TGF-β signalling pathway’ was a significantly regulated network and identified as a 
key upstream regulator, although TGF-β1-stimulated lung fibroblasts appear to 
involve negative feedback loops, as key TGF-β signalling components such as SMAD3 
and TGF-β1 receptor gene TGFBR2 were downregulated after 24 hours of TGF-β1 
exposure. However, determining the protein and phospho-protein levels of these 
genes would be required to confirm whether these results translate into biological 
effects. In addition, according to the analyses, TGF-β1 and TGF-β2 genes were 
significantly increased, suggesting if the encoded protein was secreted these 
molecules could act in a paracrine mechanism instead of autocrinally as their co-
receptor TGF-βRII was downregulated. It would be interesting to determine whether 
these feedback mechanisms in normal fibroblasts are also functioning in lung cancer-
associated fibroblasts, as several studies indicate TGFBR2 is a tumour 
suppressor[218].  
Recently, Busch and colleagues revealed that fibroblast-specific TGFBR2 expression 
is a biomarker for breast cancer prognosis, as expression positively correlated with 
recurrence-free survival[219], while loss of TGFBR2 in colon CAFs increased lymph 
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node metastases[220]. Moreover, xenograft tumours in mice where TGFBR2 was 
silenced in CAFs resulted in larger breast tumours. A potential mechanism for these 
effects was reported by Cheng and colleagues, who found that TGF-βRII knockdown 
in mammary fibroblasts resulted in increased secretion of TGF-α, HGF and 
macrophage-stimulating protein (MSP). In addition, the corresponding receptors of 
these factors, expressed by tumour cells, displayed enhanced phosphorylation, while 
pharmacologic inhibition of each pathway reduced tumour cell proliferation and 
motility in the presence of conditioned medium from TGF-βRII-knockout 
fibroblasts[221]. Furthermore, the authors noted when TGFBR2 was knocked down 
in normal unstimulated fibroblasts, there was no influence on the clonogenicity of 
co-cultured breast cancer cells, in contrast to the effects by TGFBR2-knockout CAFs, 
which promoted tumour cell survival in vitro[219]. This study highlighted the distinct 
differences between undifferentiated fibroblasts and CAFs, whilst in my own results, 
the downregulation of TGFBR2 indicates that TGF-β1-treated fibroblasts express a 
potentially tumour-promoting gene signature, similar to CAFs. Future studies 
involving RNA sequencing of primary lung fibroblasts from additional donors would 
validate these findings and perhaps also highlight TGFBR2 and other genes as clinical 
biomarkers in fibroblast-related lung pathologies.   
The ‘pathways in cancer’ network was also enriched in TGF-β1-treated lung 
fibroblasts. Surprisingly, HGF, a key fibroblast-secreted molecule known to promote 
tumour cell invasion[222] and chemoresistance[110] was downregulated in response 
to TGF-β1 in lung fibroblasts, though perhaps longer periods of TGF-β1 exposure 
would induce additional sets of genes. In addition, many extracellular matrix 
proteins, such as several collagens and collagen-crosslinking protein LOX were 
significantly increased. The genes regulated by TGF-β1 are reminiscent of those that 
contribute to wound repair[223], while excessive secretion of collagens and lysyl 
oxidases produces a fibrotic extracellular matrix, which is associated with promoting 
cancer cell growth and invasion[203]. Furthermore, lysyl oxidase-like 2 (LOXL2) was 
significantly upregulated by TGF-β1 in HLF3 by 2.3-fold. Immunohistochemical 
staining of several types of human tumour biopsies revealed LOXL2 localised to the 
tumour stroma, as opposed to healthy tissues. In addition, antibody-blockade of 
143 
 
LOXL2 significantly reduced the production of cross-linked collagen, breast tumour 
volume, the percentage of α-SMA-positive myofibroblasts and phospho-Smad2 
expression in fibroblasts. Moreover, the same monoclonal antibody diminished 
levels of cross-linked fibrillar collagen in a bleomycin-induced model of lung 
fibrosis[224]. Therefore, it appears these TGF-β1-activated lung fibroblasts could 
prime local fibroblasts for activation and encourage cancer progression by increasing 
the stiffness of the local microenvironment.  
The hedgehog signalling pathway also appeared to be activated in TGF-β1-treated 
HLFs. This pathway is known to mediate tumour-stroma interactions by paracrine 
activation, resulting in the expression of the hedgehog pathway transcription factor 
Gli1, collagen type I and fibronectin by fibroblasts, contributing to a desmoplastic 
stroma[225]. In addition, WNT5a, which was also upregulated in HLFs, is known to 
promote fibronectin expression, fibroblast proliferation and resistance to apoptosis, 
while WNT5a also displays higher expression in HLFs derived from fibrotic lung 
tissues[226], indicating TGF-β1 enhances hedgehog signalling, which together 
promote fibrosis.    
CAFs are also known to express pro-inflammatory gene signatures[227] and RNA-seq 
revealed that TGF-β1 also induced inflammation-associated genes, such as cytokine 
receptor IL21R, which was reported to enhance protease MMP expression by 
intestinal fibroblasts[228]. Although, whether this receptor serves the same function 
in lung fibroblasts is unknown. In addition, IL-6, which was also elevated, correlates 
with poor prognoses in prostate and ovarian cancers[229, 230], and promotes 
monocyte to macrophage differentiation[231]. Furthermore, when comparing 
fibroblasts from common sites of breast tumour metastases, such as the lung, bone 
and skin, levels of IL-6 secreted by fibroblasts directly correlated with tumour growth 
and invasion, which was mediated by activation of the STAT3 pathway in breast 
tumour cells[137]. As mentioned previously, the TGF-β1 gene was also increased in 
lung myofibroblasts, and it is well-documented that this cytokine is a paracrine 
stimulant of EMT in tumour tissues[91] and contributes to the population of 
activated fibroblasts in fibrotic organs[232]. These results suggest activated lung 
fibroblasts have the potential to promote an invasive tumour phenotype. In addition, 
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the role of many genes identified by RNA-seq have not been previously examined in 
the context of cancers, therefore their functions in fibroblasts are unknown.  
RNA-seq revealed subtypes of the TNF receptor superfamily were downregulated in 
response to TGF-β1 stimulation. The ligand for the type 1 receptor subtype is pro-
inflammatory cytokine TNF-α, which is associated with promoting tumour 
metastases[233]. Furthermore, mapping of signalling pathways involving 
inflammatory genes (Figure 5.3), showed key downstream transcription factor NF-κB 
exhibited no change in mRNA expression level, though NF-κB-regulated genes, such 
as IL-8 and MCP-1 displayed reduced expression, perhaps indicating they are 
negatively regulated by other transcription factors or by post-translational 
modifications of NF-κB[234]. Moreover, these effects also comply with role of 
fibroblasts during wound healing, where cytokines such as macrophage-secreted 
TNF-α is necessary to promote inflammation during the early stages of wound 
healing and negatively regulates myofibroblast activity. Abraham and colleagues 
have reported that TNF-α inhibits the expression of pro-fibrotic CTGF in TGF-β1-
activated skin fibroblasts. Hence, when wound healing transitions from the 
inflammatory phase into the remodelling phase, myofibroblast activity is required to 
stabilise the matrix, therefore perhaps the downregulation of TNF receptors removes 
the negative regulatory effect of this cytokine to permit the secretion of matrix 
proteins[235]. In addition, Figure 5.3 indicates additional receptor genes, including 
IL-6R and ET-BR (endothelin receptor type B) were each decreased by TGF-β1 
treatment, though their respective ligands (IL-6 and ET-1) were elevated, suggesting 
negative feedback may have resulted in receptor downregulation.  
It would also be interesting to determine whether integrins expressed by 
myofibroblasts regulate the expression of pro-inflammatory genes. Previous 
research suggests αvβ8 regulates chemokine CCL2 secretion from IL-1β-treated lung 
fibroblasts[185]. However, in this study β8 and CCL2 were each downregulated in 
response to TGF-β1, though perhaps other integrins are responsible for regulating 
pro-inflammatory genes in these cells. 
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IPA was used to identify TGF-β1-induced genes that would correspond to proteins 
localised to the plasma membrane of lung fibroblasts, as indicated by published 
reports. This analysis was performed to generate a top list of hits that if time 
permitted, could be further investigated to determine whether any of the proteins 
could regulate the myofibroblast phenotype. Integrin subunits α11 and β3 were 
included in this list, which were already examined in Results Part II. To note, RNA-seq 
also revealed the FERMT2 (kindlin-2) gene was upregulated by TGF-β1 in HLFs (Figure 
5.2B), which is known to mediate integrin activation[47].  
As RNA sequencing was conducted towards the end of the project, novel membrane-
associated hits could not be investigated. Nevertheless, published reports have 
shown genes, such as frizzled class receptor 8 (FZD8), which was increased 47.50-fold 
by TGF-β1 in my own experiments, was also upregulated in healthy and COPD lung 
fibroblasts by TGF-β1. FZD8 comprises the WNT/β-catenin pathway and is associated 
with fibroblast activation during organ fibrosis and tissue repair[236] and recent 
findings suggest this receptor may regulate the secretion of inflammatory 
mediators[237], though its role in lung myofibroblast biology is still undefined. 
Another highly upregulated gene, prostate transmembrane protein, androgen 
induced 1 (PMEPA1) was reported to display significantly higher expression in OSCC 
CAFs compared to healthy fibroblasts and correlated with reduced disease-free 
survival in cases of head and neck SCC[238]. In addition, the top gene elevated by 
TGF-β1 in HLFs was potassium voltage-gated channel subfamily H member 1 
(KCNH1); while its expression is associated with tumour cell growth and drug 
resistance, its role in fibroblasts has yet to be defined. Overall, the hits identified give 
rise to a new set of experiments to determine how they contribute to myofibroblast 
biology, and whether they exhibit any therapeutic potential.   
IPA software was also used to assess the top cellular processes associated with the 
dataset, and genes involved in fibroblast proliferation and cell cycle progression were 
overall, upregulated after stimulation. These included genes such as IL-11[239] and 
FGF-2, which previous reports show act in a paracrine manner, where ERK1/2 
activation by each of these factors promoted fibroblast proliferation. Furthermore, 
increased numbers of fibroblasts has been noted in diseases such as pulmonary 
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fibrosis[240]. Analysis by software IPA suggested the factors identified in Figure 5.2 
are not physically involved in proliferation and cell cycle functions (noted by the 
dashed lines in Figure 5.2), but are secreted mediators, indicating activated 
fibroblasts may promote growth in an autocrine manner, as described by Strutz[241], 
or perhaps support the proliferation of resident fibroblasts, amplifying their 
response.  
As mentioned throughout this section, the characterisation of TGF-β1-activated 
fibroblasts has the potential to identify genes associated with predicting the clinical 
outcome in cancer, which has previously been demonstrated using breast 
tumours[242]. Similarly, Chang and colleagues examined the transcriptional 
responses of breast, lung and gastric fibroblasts to foetal bovine serum to identify 
common genes expressed by fibroblasts from different anatomical sites. They 
identified 512 genes and named the wound-like signature the ‘core serum response’ 
and used published clinical and molecular data from breast carcinomas to examine 
overlapping genes. They found that tumour cells with the activated core serum 
response were more likely to progress to metastasis and patient death in the 5-year 
follow-up period. Furthermore, they validated microarray data by sub-selecting four 
genes linked to ECM remodelling and cell-cell interaction and confirmed their 
expression in fibroblasts using tissue microarrays containing hundreds of breast 
carcinoma tissues. The four molecules chosen were collagen cross-linking enzymes 
PLOD2 and LOXL2, urokinase-type plasminogen activator receptor PLAUR and SDFR1, 
a transmembrane protein belonging to the immunoglobulin superfamily[215]. These 
results are noteworthy because PLOD2, LOXL2 and PLAUR genes were also 
significantly upregulated in HLFs, per my own RNA-seq analysis. PLOD2 and ligand 
PLAU are displayed in Figure 5.2A, while the receptor PLAUR was increased by 1.8-
fold in HLFs, as was previously mentioned LOXL2. These results demonstrate that 
similar studies characterising TGF-β1-treated lung fibroblasts may also identify a core 
signature linked to prognosis and perhaps guide effective treatment plans in cancer 
and fibrosis.  
In summary, the global gene expression profiling of TGF-β1 activated lung fibroblasts 
has indicated these cells represent a gene signature similar to CAFs, as noted by the 
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downregulation of tumour suppressor TGFBR2 and the upregulation of genes 
encoding matrix proteins, collagen crosslinking proteins, integrins and pro-
inflammatory mediators. In addition, the results further highlight the potential 
benefits of interfering with TGF-β1 signalling in fibroblasts, which could reduce the 
expression of each of these factors, in addition to fibroblast proliferation. 
Furthermore, enriched cell surface-associated genes may represent novel regulators 





CHAPTER VI. RESULTS PART IV  
FDA-approved drug library screen using TGF-β1-treated human lung fibroblasts 
 
6.1. Background 
The overall aims investigated in Results Part I and Part II revolved around 
understanding the role of integrins in regulating myofibroblast activity and whether 
integrins exist as potential therapeutic targets to reduce the severity of cancer and 
fibrosis by inhibiting myofibroblast functions. In this section, the aim was to identify 
integrin-independent compounds and novel pathways that regulate TGF-β1-induced 
activation of lung fibroblasts, to gain a better understanding of fibroblast biology and 
generate additional potential therapeutic targets expressed by myofibroblasts. 
To do this I used a FDA-approved drug library containing 1,177 compounds with 
known mechanisms of action that are already used to treat a variety of diseases. The 
detailed method is described in Chapter II: Materials and Methods, but briefly, the 
concept was to test which, if any, drugs could prevent TGF-β1-induced differentiation 
of fibroblasts into myofibroblasts. To increase selectively I chose to examine the 
regulation of two, rather than one, myofibroblast activation marker. Thus, each 
compound of the FDA-approved drug library (10μM) was applied to lung fibroblasts 
plated in 96-well plates for 48 hours. Fibroblasts were then stimulated with TGF-β1 
(5ng/ml) in combination with the same drugs (10μM) for a further 48-hours. 
Subsequently, each well was fixed and stained for α-SMA and fibronectin using 
immunofluorescence and imaged on an IN Cell 1000 to enable high-throughput 
screening. The intensity of the fluorescence in drug + TGF-β1 treatment wells versus 
DMSO + TGF-β1 control was measured and compared. Drugs that reduced the 
expression of α-SMA and fibronectin, both key myofibroblast-associated proteins, 
were identified. 
Due to the high number of compounds, this assay could only be conducted on one 
strain of fibroblast. Lung fibroblasts were chosen over skin and breast, as the lung 
fibroblasts were provided by co-funding supporters GlaxoSmithKline, therefore the 
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identification of any hits could be further investigated with their high throughput 
resources and generate greater scope for the development of therapeutics.  
6.2. The optimisation of a 96-well plate phenotypic screen using 
immunofluorescent staining of TGF-β1-stimulated lung fibroblasts 
Before the screen was conducted in 96-well plates, preliminary tests were performed 
on coverslips using vehicle and TGF-β1-stimulated lung fibroblasts (5ng/ml) to select 
2 reliable primary antibodies for immunofluorescent staining. Markers were chosen 
according to the previous lung fibroblast qPCR results presented in Appendix Figure 
16 and the availability of antibodies in the group. The proteins examined were α-
SMA, fibronectin (FN1), myosin heavy chain 9 (MYH9) and connective tissue growth 
factor (CTGF) at three different primary antibody dilutions (1:100, 1:300, 1:500). 
Figure 6.1 shows the immunofluorescent staining of each marker in lung fibroblasts 
at one optimal primary antibody concentration. Note that, CTGF images are not 
presented due to poor staining, possibly as a result of the antibody used.  
Figure 6.1A-D shows the intensity of α-SMA and FN1 staining was clearly higher in 
TGF-β1-stimulated lung fibroblasts compared to vehicle-treated cells. In addition, 
Figure 6.1E and 6.1F shows MYH9 staining was present in both vehicle- and TGF-β1-
exposed fibroblasts, although interestingly MYH9 appeared to form fibres and align 
with F-actin in TGF-β1-activated cells. As a result of this assay, α-SMA and fibronectin 
were selected as the two markers to be used in the drug screen due to the clear 
differences in staining intensity in vehicle and TGF-β1-treated cells.  
Next, one strain of lung fibroblast needed to be chosen out of the three strains. 
Therefore, all three strains were first tested in preliminary runs of the screen by 
plating and stimulating each strain with TGF-β1 in 96-well plates. These preliminary 
experiments also enabled validation of α-SMA and fibronectin staining, as the 
protocol was adapted from staining on coverslips in 24-well plates and facilitated the 
optimisation of the number of fibroblasts to be seeded in each well (1000 cells). After 
repeat experiments, lung fibroblast strain 3 was selected as its performance was 
more reliable; the fibroblasts remained more adherent than strains 1 and 2 after the 
various wash steps were conducted during the staining procedure (data not shown). 
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Furthermore, the three lung strains exhibited similar responses to TGF-β1, as each 
strain significantly increased α-SMA (Figure 6.2A) and fibronectin (Figure 6.2B) 
expression compared to vehicle-treated cells, as expected. These results validated 





















Representative images from lung strain 1 fibroblasts plated on coverslips in a 24-
well plate and stimulated with vehicle or TGF-β1 (5ng/ml) for 48-hours and stained 
using anti-α-SMA (A, B), anti-fibronectin (C, D) or anti-myosin heavy chain 9 (E, F) 



































Figure 6. 1. Immunofluorescent staining of α-SMA, fibronectin and myosin heavy 













Figure 6.3 demonstrates how the analysis of α-SMA and fibronectin staining was 
quantified after imaging was completed. Figure 6.3A displays a representative image 
of merged α-SMA and fibronectin staining of TGF-β1-treated lung strain 3 fibroblasts 
plated in a 96-well plate and imaged using the IN Cell 1000. Figure 6.3B shows the 
same cells as Figure 6.3A, stained using whole-cell dye ‘CellMask’, which is a 
membrane-labelled fluorochrome used in phenotypic screening to visualise 
individual cells. The post-analysis was conducted using Developer Toolbox 2.3 
software, whereby a series of filters were applied to ensure the software only 
recognised α-SMA and fibronectin staining that was associated with both CellMask 
and DAPI. This was to prevent the software measuring background staining or 
extraneous clumps of α-SMA and fibronectin that were not associated with a whole 
adhered fibroblast. Figure 6.3C exhibits the use of a software-generated filter applied 
to roughly segment each cell using CellMask to identify the edges of each cell. Using 
this segmentation, the level of α-SMA (Figure 6.3D) and fibronectin (Figure 6.3E) 
staining in each cell could be quantified. Furthermore, additional filters were applied 
to ensure the software separated background staining within cells from true α-SMA 
Three strains of lung fibroblasts (HLF1, HLF2, HLF3) were plated in a 96-well plate 
and stimulated with vehicle or TGF-β1 (5ng/ml) for 48-hours and stained using anti-
α-SMA or anti-fibronectin antibodies, plus DAPI to identify nuclei. The mean 
immunofluorescence intensity of individual cells (≤7500) in each well was quantified 
(arbitrary units: A.U). *p<0.05, **p<0.01, ***p<0.001, Wilcoxon signed rank test. 
Data shown represents the median ± interquartile range of one independent 
experiment. 
A) B) 
Figure 6. 2. Expression of α-SMA and fibronectin in 3 strains of vehicle and 
TGF-β1-treated lung fibroblast stained in a 96-well plate. 
Fibronectin expression in lung fibroblasts
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and fibronectin expression. Hence, staining that presented under a certain threshold 
was labelled as background staining and the staining of individual α-SMA fibres 
(Figure 6.3F) and fibronectin strands (Figure 6.3G) per cell was measured, providing 
more accurate quantification. An example of excluded staining is shown inset in 






















































































































6.3. The effect of FDA-approved drugs on TGF-β1-induced lung fibroblast activation  
After the treatment, staining and imaging of lung fibroblasts was complete, various 
measurements of α-SMA and fibronectin staining were assessed in the first plate of 
the drug screen, including staining intensity, average fibre length, number of fibres 
and maximum fibre length per cell to compare in the absence and presence of each 
compound. Figure 6.4 shows TGF-β1-induced fibronectin expression was significantly 
reduced after the addition of drug axitinib compared to DMSO-treated cells when 
comparing staining intensity (Figure 6.4A), average strand length (Figure 6.4B) and 
the number of strands (Figure 6.4C). In contrast, the maximum fibronectin strand 
length did not significantly change between DMSO and axitinib-treated lung 
fibroblasts in the presence of TGF-β1 (Figure 6.4D). The measurement for staining 
intensity (Figure 6.4A) demonstrated the clearest reduction compared to the DMSO 
control, which was visible by the lower median and smaller upper quartile range. 
Similar results were also found using other compounds (data not shown), therefore 
fluorescence intensity was selected as the primary α-SMA and fibronectin 
measurement for the remainder of the drug screen. 
Computer programming software R-Studio was used to automate statistical and 
graphical analysis for the complete drug screen (the coding for the script was kindly 
conducted by bioinformatics PhD student William Cross at Barts Cancer Institute). As, 
Every well was stained with DAPI, CellMask, anti-α-SMA and anti-FN1. The IN Cell 
microscope imaged each relevant channel in each well in a 96-well plate and the 
staining was analysed by software Developer Toolbox 2.3. A) Representative 
image of merged DAPI (nuclei), α-SMA and FN1 staining of TGF-β1-treated lung 
fibroblasts. B) An image of the same field as A of cells dyed with CellMask to 
identify each cell. C) A software-generated filter was applied to segment cells using 
CellMask. Using this cell segmentation, the staining of α-SMA (D) and FN1 (E) in 
each cell could be quantified. On top of this, additional filters were applied to 
precisely identify α-SMA fibres (F) and FN1 strands (G) to avoid the inclusion of 
background staining and extraneous clumps (this can be observed as red filters 
inset (F), which were excluded from quantification).  
Figure 6. 3. Method of IN Cell image analysis of α-SMA and fibronectin (FN1) 
staining during the lung fibroblast drug screen. 
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cell numbers may have varied between some drug-treated wells and controls, a rule 
was incorporated into the script, whereby if less than 200 cells remained per well at 
the end of the screen (1000 cells were initially plated), then the results of these wells 
were disregarded. Cumulative frequency was used to determine the distributions of 
α-SMA and fibronectin in drug + TGF-β1-treated cells relative to DMSO + TGF-β1 by 
displaying the number of cells within each range of fluorescence intensity (Figure 6.5, 
x-axis). The Kolmogorov-Smirnov test was used to analyse the data as it is typically 
performed for cumulative frequency and is non-parametric. Note that the 












































Lung fibroblasts (strain 3) were plated in a 96-well plate and treated with DMSO 
or drug axitinib (10μM) for 48 hours and then TGF-β1 (5ng/ml) combined with 
either DMSO or drug axitinib (10μM) for a further 48 hours. Cells were stained for 
fibronectin and the immunofluorescent intensity (A), average strand length (B), 
number of strands (C) and maximum strand length (D) in individual cells (≤2000) 
was quantified (arbitrary units: A.U). ***p<0.001, Wilcoxon signed rank test. n.s = 
non-significant. Data shown represents the median ± interquartile range of one 
independent experiment. 
Figure 6. 4. Four measurements of fibronectin expression in TGF-β1-treated 






















































































































































To confirm which drugs significantly reduced the expression of α-SMA and 
fibronectin compared to DMSO in the presence of TGF-β1, R-studio was programmed 
so that drugs which significantly decreased marker expression reveal their true p-
value and drugs that increased marker expression were automatically assigned a 
value of 1, to easily distinguish between the different outcomes on the MS Excel 
output generated by R-studio. This method was applied as my primary aim was to 
only identify drugs that reduced the expression of α-SMA and/or fibronectin. One 
example of cumulative frequency analysis is shown in Figure 6.5 using α-SMA, 
whereby drug alfacalcidol significantly reduced α-SMA expression compared to 
DMSO and the p-value is 5.08E-33 (Figure 6.5A), whereas the drug bisoprolol 
increased α-SMA, hence the value generated was 1 (Figure 6.5B). This analysis was 
followed by the Wilcoxon signed rank test to compare the medians of fluorescence 
intensity of drug and DMSO-treated cells, demonstrating stringent statistical 










Lung fibroblasts (strain 3) were plated in a 96-well plate and treated with DMSO 
or drug Alfacalcidol (A) or Bisoprolol (B) (10μM) for 48 hours and then TGF-β1 
(5ng/ml) combined with either DMSO or drug (10μM) for a further 48 hours. 
Cells were stained using anti-α-SMA antibodies and the immunofluorescent 
intensity in individual cells was quantified. The cumulative frequency fraction 
(y-axis) represents the number of cells per fluorescence interval as a fraction of 
the total number of cells in the well. ***p<0.001, Kolmogorov-Smirnov test. 
Data shown represents mean fluorescence intensity per cell of one independent 
experiment. 
Figure 6. 5. Comparison of cumulative frequency results of α-SMA expressed 
by drug-treated lung fibroblasts. 








































































The results of the complete drug screen are shown in Table 6.1, whereby drugs that 
significantly inhibited both α-SMA and fibronectin intensity in the presence of TGF-
β1 compared to DMSO + TGF-β1-treated fibroblasts are presented. Only one set of 
p-values for each of these compounds are listed in Appendix Table 1, as calculated 
by the Kolmogorov-Smirnov test used for cumulative frequency, as it would be 
unfeasible to publish each graph and the second set of p-values measured by the 
Wilcoxon signed rank test. The drug library screen results shown represent one 
independent experiment, however a subset of drugs were tested in a second 
biological repeat and achieved the same results as the first experiment; these 
compounds are highlighted in Table 6.1 with an asterisk.  
As shown in Table 6.1, 46 FDA-approved compounds with various mechanisms 
significantly inhibited the expression of both α-SMA and fibronectin in TGF-β1-
activated lung fibroblasts. The classes of drugs were broad and included anti-
infective agents (i.e. antibiotics, antimycotics), tyrosine kinase inhibitors, ion channel 
blockers, phosphodiesterase inhibitors, non-steroidal anti-inflammatory drugs and 
hormones. In addition, the total number of cells in drug wells relative to DMSO are 
listed in Table 6.1, whereby most of the drugs did not exhibit toxicity, but increased 
cell numbers, indicating that reduced α-SMA and fibronectin was not a consequence 
of decreased numbers of cells in drug wells.   
In addition, as part of a collaboration with Dr Angus Cameron (Barts Cancer Institute), 
who studies the role of the GTPase Rho signalling pathway in fibroblasts, I received 6 
inhibitors of this pathway and included them in the same screen, though the Rho 
inhibitory drugs are non-FDA approved. Table 6.2 shows the inhibitors of RhoA and 
Rho-kinase (ROCK) also significantly inhibited α-SMA and fibronectin expression in 
TGF-β1-treated lung fibroblasts. 
A number of drugs also inhibited either α-SMA or fibronectin expression only. The 
overall results of the drug screen are summarised in Figure 6.6, which shows 184 
compounds reduced α-SMA expression only in TGF-β1-treated lung fibroblasts and 




Table 6.1. FDA-approved drugs that significantly reduced α-SMA and fibronectin 
expression in TGF-β1-treated lung fibroblasts during high throughput screening. 
Drug screen: one independent experiment, *two independent repeats. The 
percentage (%) of cells represents the number of cells in drug wells relative to DMSO.  
Drug name Mechanism of action/Targets Indication % Cells 
Anti-infectives 
Ofloxacin* 












Antimicrobial, binds the 50S 
ribosomal subunit 
Infection 144 
Cefaclor Antibiotic Infection 252 
Flucytosine* Antimycotic, pyrimide analog Infection 254 
Piperacillin sodium 
Antibiotic, binds penicillin-binding 
proteins 
Infection 183 
Toltrazuril Antiprotozoal agent  Infection 148 
Sulfacetamide 
sodium 
Antibiotic; inhibitor of bacterial para-
aminobenzoic acid 
Cardiovascular 237 
Atazanavir sulfate* HIV-1 protease inhibitor Infection 139 
Ritonavir HIV-1 protease inhibitor Infection 123 
Tyrosine kinase inhibitors 
Axitinib 
Tyrosine kinase inhibitor, i.e. VEGFR-
2 and -3, PDGFR 
Cancer 70 
Erlotinib HCl 




Selective tyrosine kinase EGFR 
inhibitor 
Cancer 104 
Ion channel blockers 
Carbamazepine Sodium channel blocker Neurological 155 
Nicardipine HCl Calcium-channel blocking agent Neurological 125 
Isradipine Calcium channel blocker Neurological 98 
Chlorpropamide 
Sulfonylurea; bind to ATP-sensitive 
potassium channels 
Endocrinology 140 
Tolperisone HCl Ion channel blocker Neurological 188 
Phosphodiesterase inhibitors 
Tadalafil Phosphodiesterase inhibitor Cardiovascular 242 
Pimobendan 







Nonsteroidal anti-inflammatory drugs (NSAID) 
Benzydamine HCl Inhibits prostaglandin biosynthesis Inflammation 149 
Sasapyrine Inactivates COX-1 and COX-2 Inflammation 170 
Hormones 
Estrone Estrogenic hormone Endocrinology 120 
Tiratricol Thyroid hormone analogue Endocrinology 170 
Various mechanisms 
Mesalamine 
Mechanism not fully understood, but 
may block cyclooxygenase 
Inflammation 115 
Trichlormethiazide* 
Diuretic, inhibits the sodium-chloride 
ion symporter 
Cardiovascular 127 
Rizatriptan benzoate Serotonin receptor agonist Neurological 234 








acetylcholine receptor agonist 
Neurological 200 
Biperiden HCl Cholinergic receptor antagonist Neurological 109 
Lamivudine 
Nucleoside analog reverse 
transcriptase inhibitor 
Infection 124 
Fludarabine Inhibits DNA synthesis, purine analog Cancer 125 
1-Hexadecanol 








Inhibits production of TNF-α, inhibits 
ubiquitin ligase activity 
Cancer 219 
Abiraterone 
Steroidal CYP17 inhibitor, i.e. 
cytochrome P450. 
Cancer 136 
Ramelteon  Selective melatonin receptor agonist Neurological 198 
Deoxyarbutin 




Prevents pyrimidine synthesis by 




Inhibits glycine transporter 2 
(GLYT2a) activity 
Neurological 176 
Misoprostol Synthetic analog of prostaglandin E1 Endocrinology 125 
Plerixafor 





Table 6.1; The drug library compounds, their mechanisms and indications were 
provided by SelleckChem (L1300). Abbreviations: VEGFR; vascular endothelial growth 
factor receptor, CYP17; cytochrome P450 17α-hydroxylase, HCl; hydrochloride, 
EGFR; epidermal growth factor receptor, HIV; human immunodeficiency virus, TNF-
α; tumour necrosis factor-α, 5-HT; 5-hydroxytryptamine, ACE; angiotensin-
converting-enzyme, COX; cyclooxygenase. 
 
Table 6. 2. RhoA pathway inhibitors that significantly reduced α-SMA and 
fibronectin expression in TGF-β1-treated lung fibroblasts during high throughput 
screening. 
Results shown represent one independent experiment. The percentage (%) of cells 









Figure 6.7A-B shows many of the drugs that reduced α-SMA or fibronectin expression 
alone are known as anti-infective drugs, as they target bacterial/viral proteins. In 
addition, various receptors (e.g. serotonin, histamine, cholinergic), enzymes, (e.g. 
tyrosine kinases, COX-1/COX-2) and ion channels (potassium, sodium) were also 
among the common targets that reduced each marker. 
Drug name Mechanism of action/Targets Indication % Cells 
Fasudil Rho kinase inhibitor Cardiovascular 160 




132Total number of drugs screened
Drugs that inhibited both α-SMA and 
fibronectin
Drugs that inhibited α-SMA only
Drugs that inhibited fibronectin only
The expression of α-SMA and fibronectin was measured during a high 
throughput screen using 1,177 FDA-approved drugs and 6 additional Rho 
signalling pathway inhibitors in TGF-β1-treated lung fibroblasts. 
Figure 6. 6. Summary of the total number of drugs screened and the effect on 
































Figure 6. 7. FDA-approved drugs and their targets that only reduced α-SMA (A) 
or fibronectin (B) expression in TGF-β1-treated lung fibroblasts relative to 
































Drug targets that resulted in decreased fibronectin 
only          
B) 
To note, microorganism-related targets are due to anti-infective agents, e.g. 
antibiotics, antifungal, antiviral drugs.  
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6.4. The validation of individual FDA-approved drugs on lung fibroblasts  
While I was establishing the best method to analyse the whole screen, I chose to re-
test hits from the first plate. According to a preliminary analysis assessing frequency 
distribution, three hits were identified; dasatinib, a BCR/ABL and Src kinase inhibitor, 
anastrozole; an aromatase inhibitor, and axitinib (listed in Table 6.1), which inhibits 
tyrosine kinase receptors VEGFR-1, -2 and -3[243]. (To note, more robust analysis of 
the drug screen completed after the following validation studies revealed dasatinib 
and anastrozole did not significantly reduce α-SMA and fibronectin). To validate and 
examine the potential of the hits identified, these three drugs were tested in 
experiments of cell viability, immunofluorescence, western blotting and collagen gel 
contraction. 
6.4.1. The cell viability of lung fibroblasts treated with dasatinib, anastrozole and 
axitinib 
The cell viability of unstimulated lung strain 3 fibroblasts in the presence of each drug 
(1-20μM) was assessed for 72 hours using a MTT assay. Figure 6.8A shows dasatinib 
significantly decreased cell viability below 50% at every concentration tested 
(p<0.001), which supported the results obtained during the drug screen, where 
dasatinib + TGF-β1 had similar effects at 10μM. As a result of dasatinib’s toxic effect 
on cell numbers during both the drug screen and then the MTT assay, it was not used 
in further experiments. 
In contrast, anastrozole increased viability relative to DMSO at 5μM and 20μM doses 
(Figure 6.8B), corresponding with the drug screen, as 10μM also increased cell 
number.  
In addition, axitinib significantly reduced fibroblast viability, particularly at 10μM (48 
± 17%) and 20μM doses (Figure 6.8C), which was to a higher degree compared with 
the screen results, where cell number was reduced to 70% compared with DMSO-


















6.4.2. The expression of α-SMA and fibronectin protein by lung fibroblasts treated 
with anastrozole and axitinib 
To validate the results of the drug screen, the changes in α-SMA and fibronectin 
protein expressed by lung fibroblasts were validated using immunofluorescent 
staining on coverslips in a 24-well plate and western blotting. To emulate the drug 
screen, fibroblasts were also treated with anastrozole or axitinib (10μM) first for 48 
hours and then in combination with TGF-β1 (5ng/ml) for a further 48 hours. 
Figure 6.9 shows the analysis of the average mean fluorescence intensity per lung 
fibroblast, which was seeded on coverslips and stained with the same anti-α-SMA 
and anti-fibronectin antibodies used during the drug screen. According to the more 
robust analysis of the drug screen data, anastrozole did not significantly affect the 
expression of either marker, which was also supported by the coverslip staining of α-
SMA (Figure 6.9A) and fibronectin (Figure 6.9B) compared to DMSO + TGF-β1. 
Surprisingly, axitinib significantly reduced α-SMA, but not fibronectin (Figure 6.9A-
B). This was also illustrated in representative images from this experiment (Figure 
6.9C) of drug + TGF-β1-treated lung fibroblasts.   
 
Lung strain 3 fibroblast viability was assessed using a MTT assay after 72 hours 
culture in dilutions (μM) of DMSO, dasatinib (A), anastrozole (B) or axitinib (C). 
**p<0.01, ***p<0.001, one-way ANOVA with Dunnet’s post-hoc to compare each 
concentration to DMSO control. Data shown represents the mean ± s.d of two 
independent experiments. 
A) B) C) 























































































Lung fibroblasts (strain 3) were plated on coverslips and treated with DMSO, 
anastrozole or axitinib (10μM) for 48-hours and then TGF-β1 (5ng/ml) combined 
with either DMSO or drug (10μM) for a further 48-hours. Cells were stained using 
anti-α-SMA (green) or anti-fibronectin (red) antibodies and the mean 
fluorescence intensity in each field was quantified (A, B) (arbitrary units: A.U) and 
imaged (C), approximately 20 fields were imaged per condition. **p<0.01, 
***p<0.001, Wilcoxon signed rank test. n.s: non-significant. Data shown 
represents the median ± interquartile range of one independent experiment. 
Scale bar: 50μM. 
A) B) 
DMSO + TGF-β1 
α-SMA   Fibronectin   Nuclei 
Anastrozole + TGF-β1 Axitinib + TGF-β1 
C) 
Figure 6. 9. Immunofluorescent staining of α-SMA and fibronectin in 






















































































































Next, α-SMA protein expression was investigated using western blotting (Figure 
6.10A). The same experimental design of the drug screen was again performed here, 
but cell lysates were subsequently collected. In addition, two concentrations of drug 
were tested (1μM and 10μM) to examine whether a lower concentration of 1μM 
would also reduce the expression of myofibroblast marker α-SMA.  
Densitometry in Figure 6.10B shows α-SMA expression in DMSO + TGF-β1-treated 
fibroblasts increased 5.7-fold compared to DMSO + vehicle treatment. The addition 
of 1μM anastrozole + TGF-β1 resulted in 3.3-fold α-SMA above vehicle, while the 
addition of 1μM axitinib upregulated only 1.6-fold α-SMA in response to TGF-β1. 
Figure 6.10C shows the use of 10μΜ treatment, where again axitinib produced less 
α-SMA in response to TGF-β1 than DMSO + TGF-β1. The 10μM anastrozole + vehicle 
sample could not be quantified here as the very faint band present would lead to 
inaccurate quantification and is therefore missing from the graph in Figure 6.10C. 
The levels of α-SMA were then directly compared in vehicle-treated samples only 
(Figure 6.10D) to determine whether the compounds stimulated baseline expression 
of α-SMA above the DMSO control. As shown in Figure 6.10D, anastrozole had no 
notable effect on α-SMA, while 1μM axitinib raised basal α-SMA expression, whereas 
10μΜ did not produce a change. Next, in Figure 6.10E α-SMA was directly compared 
in only TGF-β1 stimulated cells to validate the previous immunofluorescent staining 
results obtained in the drug screen and the coverslip staining. Figure 6.10E shows 
anastrozole reduced α-SMA at both 1μM and 10μM concentrations by 23% and 11%, 
respectively, while axitinib was only effective at the 10μM dose, which reduced α-
SMA expression by 34% in the presence of TGF-β1. Regrettably, I did not have time 
to perform western blotting for fibronectin on these samples.  
Taken together with previous immunofluorescent staining analysis, these results 
show that 10μM anastrozole did not affect α-SMA or fibronectin expression 
significantly, yet 1μΜ appeared to reduce α-SMA, though western blotting requires 
additional biological repeats. In addition, axitinib reduced α-SMA during staining and 
western blotting experiments, while there was no effect on fibronectin expression in 
TGF-β1-stimulated lung fibroblasts. To determine whether these effects had 

































Lung fibroblasts (strain 3) were treated with DMSO, anastrozole (anast) or 
axitinib (axit) at 2 different concentrations (1μM and 10μM) for 48-hours and 
then stimulated with vehicle or TGF-β1 (5ng/ml) combined with either DMSO or 
drug for a further 48-hours and lysates collected and immunoblotted for α-SMA 
(A). The analyses are presented as vehicle vs TGF-β1 for each concentration (B, 
C) and DMSO vs drug in only vehicle (D) or TGF-β1 samples (E). As there is no 
band for vehicle + anastrozole (10μM), densitometry could not be conducted 
(N/A). HSC70 serves as loading control. Data shown represents the mean of one 
independent experiment. 
Figure 6. 10. Western blot analysis of α-SMA expression in drug-treated lung 
fibroblasts with and without TGF-β1. 





















































































































































































6.4.3. Collagen gel contraction by lung fibroblasts treated with anastrozole and 
axitinib 
To examine whether anastrozole and axitinib affected myofibroblast activity, 
collagen gel contraction was studied. Lung strain 3 fibroblasts were first treated with 
10μM drug or DMSO for 48 hours in petri dishes and then plated inside collagen type 
I gels with fresh drug. The next day, gels were detached from the edge using a needle 
and vehicle or TGF-β1 (5ng/ml) was added on top of the gels. Figure 6.11A-C shows 
representative images taken of gels in each condition 10 days after the addition of 
vehicle/TGF-β1. The analysis in Figure 6.11D compares the surface area of only 
vehicle-treated gels and shows both anastrozole (Figure 6.11B) and axitinib (Figure 
6.11C) contracted gels 50% and 20% more than DMSO (Figure 6.11A), respectively.  
When examining the response of each drug-treated fibroblast to TGF-β1 (Figure 
6.11E), DMSO gels contracted by 60% in response to TGF-β1, visible in Figure 6.11A, 
while anastrozole contracted gels to a similar size in the absence and presence of 
TGF-β1 and did not inhibit gel contraction relative to DMSO + TGF-β1 gels. 
Interestingly, axitinib + TGF-β1-treated fibroblasts exhibited notably reduced gel 
contraction compared to DMSO + TGF-β1, hence the gels were much larger (Figure 
6.11C) and there was no difference in gel sizes between axitinib + vehicle and TGF-
β1-treated gels (Figure 6.11E).  
Overall, this drug library screen has generated 46 compounds of interest that 
inhibited two key markers of fibroblast activation, which now need to be examined 
further. In addition, this preliminary drug validation of dasatinib, anastrozole and 
axitinib demonstrated the reliability of the screen (marker expression studies 
summarised in Table 6.3), while tyrosine kinase inhibitor axitinib displayed promising 



























 α-SMA Fibronectin 
Anastrozole 
Drug screen No change No change 
IMF No change No change 
WB Reduced -- 
Axitinib 
Drug screen Reduced Reduced 
IMF Reduced No change 
WB Reduced -- 
Table 6. 3. Summary of anastrozole and axitinib effects on marker expression 
during drug screen, immunofluorescent staining (IMF) and western blotting (WB). 
TGF-β1-induced gel contraction


















































































Strain 3 lung fibroblasts were treated with DMSO, anastrozole or axitinib (10μM) 
for 48 hours in petri dishes and then trypsinised and plated inside collagen type I 
gels with fresh drug (10μM) and stimulated the next day with vehicle or TGF-β1 
(5ng/ml). Representative images of collagen gel contraction were taken at day 10 
after either vehicle of TGF-β1 addition (A-C). Analysis shown as gel area of drug + 
vehicle relative to DMSO + vehicle (D) and vehicle vs TGF-β1 per drug (E). Data 





The aim of this study was to identify novel pathways that regulate lung fibroblast 
activation by applying a library of 1,177 FDA-approved drugs and Rho signalling 
pathway inhibitors on to lung fibroblasts in the presence of TGF-β1. As a result, 
several drugs of varying mechanisms were identified that significantly reduced the 
expression of both α-SMA and fibronectin in TGF-β1-activated fibroblasts. These 
results suggested several unknown molecular pathways that may regulate TGF-β1-
induced myofibroblast activity.  
Further experiments for validation included MTT assays, which confirmed the 
cytotoxic effects of dasatinib and supported the results of anastrozole and axitinib 
also. Analysis of total cell numbers during the drug screen revealed many drug hits 
that significantly inhibited α-SMA and fibronectin expression, actually increased 
fibroblast numbers compared with DMSO + TGF-β1-treated wells. Although, it is 
unknown what effect these fibroblasts would have in diseased tissues if this 
translated in vivo. Repeated proliferation assays using the hits identified from the 
screen are first needed to confirm whether these drugs truly increase fibroblast 
numbers. Instead, it is possible that during the drug screen DMSO + TGF-β1-treated 
wells had consistently lower cell numbers than other wells, as these wells were at 
the edge of the 96-well plate, where higher levels of evaporation can occur, which 
may contribute to ‘edge effects’.  
In addition, protein expression studies validated the actions of anastrozole, which did 
not alter the expression of α-SMA or fibronectin in either the drug screen or post-
immunofluorescent staining experiments. Although, additional biological repeats of 
western blotting are needed to further validate these results. Treatment with axitinib 
also supported the results of the drug screen, as post-immunofluorescent staining 
and western blotting displayed decreased α-SMA in lung fibroblasts. However, 
fibronectin showed no significant change after the addition of axitinib in post-
immunofluorescent staining experiments, although perhaps more data points are 
required as axitinib also reduced fibroblasts numbers compared to DMSO controls, 
visible in Figure 6.9C. 
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To examine whether the selected drugs could affect the functional capacity of the 
TGF-β1-stimulated fibroblasts, gel contraction assays were conducted whereby only 
axitinib notably inhibited contraction. Axitinib was approved by the FDA in 2012[244] 
and is also currently used in the UK as second-line treatment for advanced renal cell 
carcinomas[245]. Axitinib primarily functions by inhibiting the autophosphorylation 
of VEGF receptors -1, -2 and -3 and has shown to reduce the phosphorylation of Akt 
and ERK1/2 in endothelial cells in vitro, although axitinib has also been described to 
target PDGF receptors[243]. The effects of axitinib on fibroblasts are supported by 
Lin and colleagues, who pre-treated hepatic stellate cells with TGF-β1 and then 
administered 50nM axitinib and found gel contraction was significantly prevented. 
This demonstrates axitinib had similar effects on cells pre-exposed to TGF-β1, which 
is an important feature of drugs that may be used to clinically treat fibroblasts 
already activated by TGF-β1 in the tumour microenvironment. Furthermore, Lin et 
al. also reported that axitinib-treated stellate cells secreted significantly less VEGF 
into culture medium and expressed less phosphorylated VEGFR-2 in the presence of 
TGF-β1, while the addition of VEGF increased gel contraction. This suggests that 
axitinib inhibited contraction as a result of VEGF receptor blockade and not by 
inducing alternative effects, such as cell death[246].  
Huang and colleagues recently demonstrated that axitinib reduced dermal fibroblast 
migration and proliferation during scratch wound assays. They also compared the 
effects of tyrosine kinase inhibitor nintedanib, which inhibits multiple key pathways, 
including PDGF, VEGF and FGF receptor signalling, and had more potent effects on 
fibroblast migration and TGF-β1-induced α-SMA and fibronectin expression than the 
selective inhibition of each pathway. Nintedanib is currently in Phase III clinical trials 
for cancer treatment and has been approved for the treatment of idiopathic 
pulmonary fibrosis[247], indicating the benefits of a multifaceted approach to drug 
targeting. Axitinib is also currently under-investigation for combination treatment in 
advanced non-small cell lung carcinoma[248], thyroid[249] and pancreatic 
cancers[250], demonstrating the therapeutic potential of tyrosine kinase inhibitors.  
Surprisingly, several effective drugs were classed as ‘anti-infective agents’, as their 
primary roles were described as targeting the DNA/RNA or protein components of 
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particular microorganisms. Although initially it was reported that many of these 
drugs target bacterial DNA gyrase to prevent DNA replication and thereby inhibit 
rapid bacterial proliferation, later studies demonstrated their mechanism of action 
includes inhibiting similar mammalian enzymes, such as topoisomerases I and II, 
therefore these drugs can also inhibit mammalian cell proliferation[251]. In 
consequence, these compounds have also been investigated for their anti-tumour 
activity. The anti-proliferative effect of norfloxacin was previously noted on a non-
small cell lung carcinoma cell line in vitro[252] and ofloxacin in bladder carcinoma 
cells[253], both of which also significantly downregulated α-SMA and fibronectin 
expression in HLFs. Moreover, norfloxacin has also shown to induce mitochondrial 
damage in dermal fibroblasts[254], however these drugs did not lower cell number 
during the drug screen, as detected by joint DAPI and CellMask staining, indicating 
they acted by an alternative, unknown mechanism in lung fibroblasts.  
ROCK inhibitors Fasudil and Y27632 also significantly inhibited α-SMA and fibronectin 
expression in HLFs. The Rho family of small GTPases transmits mechanical forces 
through the actin cytoskeleton by regulating actin reorganisation after RhoA 
activates downstream kinases, including ROCK and myosin light chain kinase, 
therefore this signalling pathway is important during cell motility and 
contraction[255]. In return, the Rho-activated pathway also responds to the 
detection of stiff matrices, as RhoA mediates stretch induced α-SMA expression and 
actin filament assembly in cardiac fibroblasts, via co-transcription factor MRTF-A, 
demonstrating the mechano-responsive nature of the Rho signalling pathway[256]. 
In addition, previous reports show TGF-β1 stimulation increases RhoA 
activation[257] and in human embryonic lung fibroblasts, Y27632 significantly 
reduced the expression of α-SMA protein and fibronectin detected in cell 
supernatents in the presence of TGF-β1, supporting the results of the drug screen.  
The Rho pathway may also mediate feedback loops, as RhoA, RhoC and Smad2 
exhibited reduced gene expression after inhibition of downstream ROCK, which 
indicates targeting this pathway may prevent continued myofibroblast activity[258]. 
It also appears Rho-ROCK signalling is required for fibronectin assembly in TGF-β1-
treated lung fibroblasts, as recent data suggests contractile activity may facilitate the 
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assembly of fibronectin. This is supported by siRNA-mediated knockdown of α-SMA, 
which attenuates fibronectin matrix formation, although this mechanism requires 
further investigation[259].  
RhoA appears to regulate myofibroblast differentiation via the generation of NADPH 
oxidase-derived reactive oxygen species (ROS), which conduct intracellular signals 
and promote TGF-β1-induced fibroblast differentiation in lung[260], cardiac[261] 
and prostate[262] tissues. The link between the Rho pathway and NADPH oxidase 
NOX4 was investigated in renal fibroblasts, where TGF-β1 increased NOX4 protein, 
NOX4 regulator Poldip2 and intracellular ROS levels. Each of these factors was 
abrogated by RhoA siRNA and ROCK inhibitor Y27632, indicating Poldip2-NOX4 
functions downstream of RhoA. Furthermore, inhibition of ROCK significantly 
decreased TGF-β1-induced α-SMA and fibronectin isoform EIIIA expression, which 
was rescued by the overexpression of Poldip2[263]. This indicates that Rho mediates 
fibroblast-myofibroblast differentiation via a RhoA-ROCK-Poldip2-NOX4 axis. 
Furthermore, in my own RNAseq experiments, NOX4 was upregulated by an average 
of 24-fold in TGF-β1-treated lung fibroblasts relative to vehicle, indicating the same 
pathway could exist in these cells.   
The potential therapeutic efficacy of ROCK inhibitor fasudil was demonstrated in a 
bleomycin-induced model of pulmonary fibrosis[264]. RhoA/ROCK signalling is 
activated in fibrotic tissues[265], while the in vivo administration of fasudil reduced 
collagen crosslinking, as measured by hydroxyproline content. Furthermore, the 
expression of TGF-β1-regulated genes implicated in pulmonary fibrosis were also 
examined in these fibrotic tissues. As expected, bleomycin increased TGF-β1, CTGF, 
PAI-1 and α-SMA mRNA and protein levels, while fasudil significantly downregulated 
the expression of each marker[264]. However, further studies are needed to 
determine the transcription factors activated downstream of ROCK, which may be 
involved in regulating these genes. 
The drug screen analysis also demonstrated overlap with the RNA sequencing results. 
The drug screen indicated several potassium and sodium ion channel blockers 
regulated α-SMA and fibronectin expression by HLFs. Coincidently, RNA sequencing 
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analysis of membrane-associated factors (Table 5.3) showed TGF-β1 significantly 
upregulated several types of potassium (up to 60-fold) and sodium ion channel genes 
(up to 12-fold) in HLFs derived from the same donor, as those used in the drug screen. 
Although it has previously been reported that potassium channels that were 
upregulated in HLFs (genes KCNN4, KCNH1) are also expressed by tumour cells and 
promote proliferation and migration, their role in lung fibroblasts is undefined[266]. 
In addition, non-steroidal anti-inflammatory drugs that target COX-1/COX-2 proteins, 
such as benzydamine and sasapyrine also prevented the expression of the two HLF 
activation markers, while RNA-seq showed the COX-2 gene (PTGS2) was increased 
2.5-fold in response to TGF-β1 stimulation.  
Previous reports suggest particular phosphodiesterase subtypes (PDE4B and PDE4D) 
regulate TGF-β1-induced lung fibroblast to myofibroblast conversion and collagen 
contraction[267, 268], while my own RNA-seq data revealed PDE4D was elevated 
2.9-fold after stimulation. Furthermore, PDE5 inhibitors prevented HLF activation 
during the drug screen, although whether they also target the PDE4 subtype is 
unknown. Overall, these results have identified targets that may be enriched in 
activated lung fibroblasts and concurrently, may have the potential to regulate their 
activity, though there is much still to discover about their mechanisms of action.   
During the drug screen analysis, it also became clear there were a number of drugs 
that specifically inhibited α-SMA expression, but not fibronectin, and vice versa. 
Although recent studies suggest fibroblast contractile activity is needed for 
fibronectin assembly[259], the results of the drug screen indicates separate 
mechanisms exist to regulate the contractile and ECM-secreting phenotype of 
myofibroblasts. Transcription factors myocardin and serum response factor promote 
α-SMA gene expression[269], therefore perhaps fibronectin-specific transcription 
factors also exist, which account for the drug-induced inhibition of fibronectin and 
not α-SMA. Unpicking the mechanisms by which these drugs act would provide a 
more detailed understanding of contractile and matrix-secreting fibroblasts and 
potentially allow manipulation of fibroblasts towards either phenotype.  
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Overall, these results have demonstrated that examining α-SMA and fibronectin 
expression by high throughput phenotypic screening is an effective method for 
identifying drugs that modulate TGF-β1-induced fibroblast activation. The reliability 
of the assay was also validated in later experiments, albeit using three selected drugs. 
To further identify potential drug targets, hits should be sub-selected by examining 
their effects during functional assays, such as fibroblast gel contraction and 3D 
invasion. To establish the mechanism by which these drug hits are acting, likely target 
molecules as indicated in online drug databases and key signalling molecules should 
be studied using siRNA-mediated knockdown and western blotting to define the 
downstream pathways activated in lung fibroblasts. This is in the hope that select 
pathways, which effectively regulate the myofibroblast phenotype can provide novel 







CHAPTER VII. CONCLUSION 
TGF-β1 has a key role in activating fibroblasts during tissue injury to promote wound 
repair via the secretion of matrix proteins and growth factors, in addition to 
fibroblast-mediated contraction to induce wound closure[270]. However, in the 
presence of tumours that secrete excessive amounts of TGF-β1, fibroblasts can 
become chronically activated and promote tumour progression by the exploitation 
of their wound healing properties[215]. Therefore, although previous studies have 
documented fibroblast intra- and inter-tissue heterogeneity[134, 165], it was 
surprising that few studies had compared the responses of fibroblasts from different 
tissues to TGF-β1 stimulation. This study has shown fibroblasts derived from skin, 
lung and breast tissues exhibited differences in gene expression when activated with 
TGF-β1. Common genes, such as ACTA2, TIMP3, FN1 and CTGF were differentially 
expressed between fibroblasts from the three tissues, though fibroblasts derived 
from the same tissue, but different donors also displayed some heterogeneity. 
Future studies involving fibroblasts from additional donors would determine if these 
differences are characteristic of skin, lung and breast tissues and perhaps aid the 
identification of tissue-specific markers of fibroblast activation. The evidence of 
differential responses by fibroblasts to TGF-β1 is supported by Lygoe and colleagues, 
who also found α-SMA was differentially expressed in three tissue fibroblasts in 
response to TGF-β1[64]. This study has extended these findings by comparing eight 
markers of fibroblast activation in cells derived from additional tissues.  
Although previous studies described individual integrin subunits that are upregulated 
by TGF-β1[60, 191], few studies had characterised the complete TGF-β1-induced 
integrin expression profile in fibroblasts. This study provides evidence of differential 
integrin expression in skin, lung and breast fibroblasts, particularly at the mRNA level 
of subunits including, α1, α4 and α11. However, I am aware that further 
experimentation is required to determine the levels of integrin protein, particularly 
using flow cytometry before and after TGF-β1 stimulation. This new information 
would indicate whether heterogeneity of myofibroblasts extends to integrins 
expressed on the cell surface. Additionally, experiments involving the 
characterisation of phosphorylated signalling proteins downstream of activated 
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integrins, such as FAK, Src and ERK1/2 would determine whether changes in integrin 
activity occur alongside or instead of increases in integrin expression.  
Myofibroblasts appear to maintain their own autocrine signalling after initial 
activation. A recent study by Eberlein and colleagues demonstrated that although 
αvβ6-dependent activation of TGF-β1 by lung tumour cells was necessary to induce 
a myofibroblast phenotype, once fibroblasts were activated only direct TGF-β 
receptor inhibition of myofibroblasts reduced α-SMA expression[87]. This suggested 
that targeting myofibroblasts directly in established tumours may be an effective 
therapeutic strategy to reduce progression, while previous studies suggest particular 
fibroblast integrins are capable of mediating the TGF-β1-induced phenotype[64]. In 
this study, the use of small-molecule integrin inhibitors and siRNA-mediated 
knockdown indicates different integrins are involved in regulating the same 
myofibroblast functions depending on the tissue of origin. In particular, the invasion 
assays performed with pan-αv, cilengitide and αvβ1 integrin inhibitors significantly 
reduced skin myofibroblast invasion, whereas cilengitide promoted the invasion of 
lung and breast myofibroblasts, perhaps suggesting αvβ3 and αvβ5 integrins have 
distinct mechanisms of action in these cells. In addition, these inhibitors were unable 
to modulate myofibroblast-induced collagen contraction, in contrast to siRNA-
mediated silencing of, particularly, the β5 subunit which prevented collagen 
contraction by skin, lung and breast myofibroblasts. Although knockdown of integrin 
protein at the cell surface was not confirmed, these results suggest that integrins 
may regulate contraction by intracellular signalling or physical contact with the 
actomyosin network, as blockade of the extracellular ligand binding site was 
ineffective. In addition, integrin inhibition was limited to the peptide inhibitors 
supplied by my sponsor GSK. With additional time and money, I would like to have 
also used integrin-blocking antibodies. 
Collagen contraction also was regulated by different integrins in skin, lung and breast 
myofibroblasts. Collagen receptor α1β1 integrin appeared to be a potent regulator 
of breast fibroblast-mediated contraction in the presence of TGF-β1, but not in skin 
or lung. Although α1β1 has previously demonstrated a role in cardiac fibroblast-
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mediated collagen contraction[271], additional biological repeats are essential to 
determine whether these are strain- or tissue-specific responses.  
Modulation of integrin subunits α11, β3 and β5 also exhibited roles in regulating TGF-
β1-induced gel contraction and gene expression. These results are supported by 
additional research suggesting α11β1 regulates corneal myofibroblast 
differentiation[61] and collagen contraction in vitro[74], and tissue stiffness in vivo, 
which was associated with promotion of lung tumour growth and invasion. Previous 
studies of αvβ3 and αvβ5 integrins revealed contraction mediated by these integrins 
in cardiac[125] and lung fibroblasts[272] was necessary for the activation of latent 
TGF-β1. In addition, in my own studies it is unknown whether integrin silencing of 
collagen receptors α1 and α11 prevented adhesion of fibroblasts to collagen during 
contraction assays (Figure 4.6-4.9), which could be resolved using adhesion assay 
experiments by plating fibroblasts on collagen-coated Transwells in combination 
with integrin inhibitors and siRNA.  
In addition, though my findings indicate β3 and β5 integrins modulate TGF-β1 
signalling in skin, lung and breast fibroblasts, Henderson and colleagues 
demonstrated that fibroblast-specific knockout of β3 and β5 integrins in hepatic 
stellate cells did not affect collagen expression and collagen cross-linking in mouse 
models of liver fibrosis[130]. In 2015, Sheppard and colleagues revealed that αvβ1 
may have been the integrin responsible for significantly reducing organ fibrosis in the 
Henderson study[38], potentially demonstrating heterogeneity between fibroblasts 
of different tissue types. In addition, in my own experiments using the same small-
molecule αvβ1 inhibitor used by Sheppard, skin fibroblast invasion was significantly 
reduced in two strains of skin fibroblasts. Therefore, additional functional assays 
using skin fibroblasts are warranted where the effects of αvβ1 blockade are further 
explored to understand the function of this integrin, as much is still unknown about 
its biology, as there are no αvβ1-specific antibodies to interrogate cells and tissue 
samples.  
Due to lack of time, the mechanism by which integrins regulated the myofibroblast 
phenotype in these TGF-β1-activated skin, lung and breast fibroblasts was not 
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investigated. According to previous research, potential molecules that may mediate 
both TGF-β1 and integrin signalling includes focal adhesion kinase[28] and integrin-
linked kinase[67], although additional mechanisms may exist, including the physical 
association of TGF-β receptors and integrins and interaction via novel intermediary 
proteins. Further research into this area is required to establish this mechanism and 
to determine whether fibroblasts from different tissues utilise the same pathways.  
The ability of integrins to regulate TGF-β1-induced functions, as found in this study 
provides the foundation to continue the investigation into the role of integrins in 
myofibroblast activation and activity. Better reagents to integrins such as α11 and β8 
are required to facilitate their characterisation in both untreated and TGF-β1-
exposed fibroblasts. The findings revealed in this study also support the hypothesis 
that α11β1 integrin may regulate myofibroblast activity[210], particularly in those 
derived from skin and lung tissue, though development of a blocking antibody or 
small-molecule inhibitor targeting α11 is needed to better evaluate its role in 
myofibroblast biology. This is in the hope that this research could progress to the use 
of in vivo models of fibroblast-specific α11 and β5 knockout (which also modulated 
collagen contraction), where their potential as therapeutic targets in cancer and 
organ fibrosis could be further assessed, as these studies are lacking in the current 
literature.  
In addition, the invasion assays conducted using integrin inhibitors involved 
Transwells coated with a thin layer of Matrigel. The next step to develop this data 
would involve the use of mini-organotypic invasion assays (as displayed in Figure 3.9), 
to examine the effects on co-cultured tumour cells, when targeting fibroblasts in a 
3D environment that better models tumour-stromal cell interactions. Furthermore, 
the effects of fibroblast culture on softer matrices, such as an organ-derived ECM 
could be examined, as the cells used in the experiments performed were all cultured 
on plastic. It is known that fibroblasts are responsive to the tension held in matrices 
they are adhered to[176], therefore it is possible that culture on plastic primed these 
skin, lung and breast fibroblasts towards activation, as noted by the α-SMA protein 
expressed in untreated skin strain 2 fibroblasts. Therefore, in vitro systems that 
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better mimic the normal tissue and tumour microenvironment would better 
represent TGF-β1-induced changes in fibroblast biology.  
RNA sequencing of TGF-β1-stimulated lung fibroblasts revealed a variety of genes 
were up- and downregulated by this cytokine, many of which were similar to those 
identified in wound healing signatures of fibroblasts[223], which could be exploited 
in the presence of transformed epithelial cells[215]. Perhaps then unsurprisingly, 
these activated lung fibroblasts expressed genes associated with cancer-related 
networks, including various collagens and collagen cross-linking genes that were 
upregulated by TGF-β1. These factors are also relevant to organ fibrosis, whereby 
fibroblast activation is mediated by integrin-dependent activation of latent-TGF-
β1[124]. This suggests that the availability of active TGF-β1 in these tissues may 
dictate the level of fibrosis that occurs, while the stiffened matrix may further 
promote integrin expression and myofibroblast-mediated ECM contraction, thereby 
activating additional TGF-β1, resulting in a continuous cycle of uncontrolled TGF-β1 
activation[16]. Therefore, perhaps dampening myofibroblast activity could reduce 
features such as matrix stiffness and subsequent tumour progression/organ 
fibrosis[95].  
Previous studies demonstrate CAFs express pro-inflammatory genes, which are 
associated with promoting cancer cell invasion. RNA sequencing revealed TGF-β1 
exposed fibroblasts also upregulated several pro-inflammatory genes, such as 
IL6[137] and TGFB1[89], which are reported to promote cancer cell growth and EMT. 
Additionally, previous research suggests αvβ8 regulates chemokine CCL2 secretion 
from IL-1β-treated lung fibroblasts[185]. However, in this study β8 and CCL2 were 
each downregulated in response to TGF-β1, though it is unknown whether 
alternative integrins regulate inflammation-associated genes in TGF-β1-treated 
fibroblasts. 
In addition, although RNA-seq revealed the TGFB1 gene was increased after 
stimulation, TGF-β1 signalling genes, including TGFBR2 and SMAD3 were 
downregulated, suggesting a negative feedback loop. These results coincide with 
cancer-associated fibroblasts[219] and fibroblasts derived from chronic 
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wounds[273], which also exhibit downregulated type II TGF-β receptors, 
demonstrating TGF-β1 stimulation of healthy fibroblasts mimics the phenotype of 
fibroblasts in the presence of tumours. Moreover, it is currently unknown whether 
TGF-β receptor downregulation is compensated for by the activation of non-
canonical signalling pathways, which would render the use of TGF-β receptor 
targeted inhibitors ineffective.  
In the context of tumour tissues, fibroblasts are genetically more stable cells 
compared with cancer cells, as they are less likely to mutate[274], making them 
better drug targets. Overall, this study has begun the groundwork needed to move 
this investigation into further translational research. In addition to the identified 
integrins capable of regulating the myofibroblast phenotype, RNA sequencing 
identified membrane-associated factors upregulated in myofibroblasts, while the 
drug screen conducted on lung fibroblasts demonstrated several distinct 
mechanisms may converge with the TGF-β1 signalling pathway to mediate a 
contractile and/or matrix-secreting phenotype. Of interest are the several anti-
microbial drugs identified, as the mechanism by which they regulate TGF-β1 
activation has yet to be defined. Moreover, various tyrosine kinase and 
phosphodiesterase inhibitors were effective in reducing α-SMA and fibronectin 
expression; drugs that have also been shown to regulate activated fibroblasts in 
published studies[247, 275], validating some of the potential hits identified. In 
addition, successful clinical trials using the pan-tyrosine kinase inhibitor nintedanib, 
which was recently approved for the treatment of IPF, demonstrates the potential 
translational benefits of targeting myofibroblasts, in addition to epithelial cells. 
Further investigation into the mechanisms of these already FDA-approved drugs may 
reveal novel druggable targets and expand the current strategies under investigation 
to regulate the activity of activated fibroblasts.  
Although many studies have established myofibroblasts promote tumour 
progression[86], recent findings using pancreatic cancer models where fibroblasts 
were depleted showed that although fibrosis was reduced, the cancer condition was 
aggravated, as observed by immune suppression (decreased effector T cells and 
increased regulatory T cells), enhanced EMT and reduced survival of mice[276]. 
181 
 
Furthermore, inhibited hedgehog signalling in stromal pancreatic cells led to reduced 
numbers of α-SMA-positive myofibroblasts, which also led to accelerated pancreatic 
tumour progression[277]. However, the data are conflicting, as other studies 
demonstrate inducing quiescence in activated pancreatic stellate cells overcomes 
chemotherapeutic drug resistance, reduces tumour volume and increases 
survival[278]. These studies may show differences due to the in vivo models used, 
but highlight the potential detrimental effects of completely removing fibroblasts 
from the tumour stroma and indicate pathways, such as stromal hedgehog signalling 
may prove to be tumour-suppressive. Nevertheless, these implications perhaps 
demonstrate the need to characterise tissue-specific effects of fibroblasts, in addition 
to their functions, in 3D microenvironments that mimic the cancer.   
To add to the complexity of cancer biology, it is reported that CAFs may not only 
derive from resident fibroblasts, but from vascular smooth muscle cells, 
pericytes[279], adipocytes[280], bone marrow[281] and tumour cells via EMT[282], 
though, it is unclear how many of these subtypes exist within specific tumour types 
at one time. In addition, Costea and colleagues examined the functional significance 
of two different subpopulations of OSCC CAFs and found they exhibited different 
levels of motility and utilised distinct mechanisms to promote tumour cell invasion. 
Though, whether these subsets derived from different sources was unclear[238]. 
While the origin of fibroblasts constituting the tumour stroma is still under 
contention, studies characterising the functional heterogeneity of fibroblasts 
populations within single tumours are required to determine how to effectively 
target CAFs within each patient. 
In summary, I have shown that fibroblasts derived from skin, lung and breast tissue 
display heterogeneity in their response to TGF-β1, while different integrins appear to 
modulate TGF-β1 signalling, as measured by markers of fibroblast activation, invasion 
and collagen gel contraction. In addition, enhanced characterisation of fibroblasts 
from each tissue may improve therapeutic efficacy by identifying tissue fibroblast-
specific biomarkers and drug targets. Further studies are required to investigate the 
mechanisms by which integrins, such as α11 and the FDA-approved drugs identified 
in this study influence TGF-β1 signalling, in the hope that these data can propel these 
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studies into translational in vivo research to evaluate potential therapeutic targets. 
These studies are particularly needed to expand the approach for targeting stromal 
fibroblasts, which are currently very limited. Lastly, RNA sequencing of healthy lung 
fibroblasts suggested TGF-β1 activation increases the expression of genes which 
seem to ultimately support a tumour-promoting microenvironment. Therefore, 
reversing the myofibroblast phenotype in particular tissues by means of small-
molecule inhibitors and antibodies to key membrane markers of the myofibroblast 
phenotype, is likely to reduce the severity of cancer and organ fibrosis and improve 









Appendix Figure 1. Gene expression of markers of myofibroblast activation 
after TGF-β1 addition to skin strain 1 and strain 2 fibroblasts. A preliminary 
experiment where skin strain 1 and 2 fibroblasts were exposed to TGF-β1 
(5ng/ml) for 24 hours. ACTA2 is missing due to primer contamination. The qPCR 
data shows fold-change of TGF-β1 relative to vehicle-treated cells and data was 
normalised to housekeeping gene beta-2 microglobulin. Data shown represents 










































































































































Appendix Figure 2. qPCR analysis comparison of α-SMA and MMP-1 during 4-
24-hour TGF-β1 (5ng/ml) exposure in 3 skin, lung and breast fibroblast strains. 
Graphs show skin strain 1 (N1 FSF), strain 2 (N2 FSF) and strain 3 (HDF), lung 
strain (HLF) 1, 2, 3 and breast fibroblast strain (BF) 1, 2 and 3. Data of TGF-β1 
relative to vehicle-treated cells and normalised to housekeeping genes. Linear 
regression analysis, significance measured as deviance of slope from 0. *p<0.05, 
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Appendix Figure 3. qPCR analysis comparison of COL1A2 and FN1 during 4-24-
hour TGF-β1 (5ng/ml) exposure in 3 skin, lung and breast fibroblast strains. 
Graphs show skin strain 1 (N1 FSF), strain 2 (N2 FSF) and strain 3 (HDF), lung 
strain (HLF) 1, 2, 3 and breast fibroblast strain (BF) 1, 2 and 3. Data of TGF-β1 
relative to vehicle-treated cells and normalised to housekeeping genes. Linear 
regression analysis, significance measured as deviance of slope from 0. *p<0.05, 





























































































































































































































































































Appendix Figure 4. qPCR analysis comparison of TIMP3 and MYH9 during 4-24-
hour TGF-β1 (5ng/ml) exposure in 3 skin, lung and breast fibroblast strains. 
Graphs show skin strain 1 (N1 FSF), strain 2 (N2 FSF) and strain 3 (HDF), lung strain 
(HLF) 1, 2, 3 and breast fibroblast strain (BF) 1, 2 and 3.  Data of TGF-β1 relative to 
vehicle-treated cells and normalised to housekeeping genes. Linear regression 
analysis, significance measured as deviance of slope from 0. *p<0.05, **p<0.01. n = 
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Appendix Figure 5. qPCR analysis comparison of CTGF and PAI-1 during 4-24-hour 
TGF-β1 (5ng/ml) exposure in 3 skin, lung and breast fibroblast strains. Graphs 
show skin strain 1 (N1 FSF), strain 2 (N2 FSF) and strain 3 (HDF), lung strain (HLF) 1, 
2, 3 and breast fibroblast strain (BF) 1, 2 and 3. Data of TGF-β1 relative to vehicle-
treated cells and normalised to housekeeping genes. Linear regression analysis, 
significance measured as deviance of slope from 0. *p<0.05, **p<0.01. n = 3. See 









































































































































































































































































Appendix Figure 6. Gene expression in TGF-β1-treated strain 1 skin fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH and PPIA housekeeping genes. *p<0.05, **p<0.01 Linear regression 
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Appendix Figure 7. Gene expression in TGF-β1-treated strain 2 skin fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH and PPIA housekeeping genes. *p<0.05, **p<0.01 Linear regression 
analysis, significance measured as deviance of slope from 0.  
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Appendix Figure 8. Gene expression in TGF-β1-treated strain 2 skin fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH and PPIA housekeeping genes. *p<0.05, **p<0.01 Linear regression 
analysis, significance measured as deviance of slope from 0.  
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  Appendix Figure 9. Gene expression in TGF-β1-treated strain 3 skin fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH and HPRT-1 housekeeping genes. *p<0.05, **p<0.01 Linear 
regression analysis, significance measured as deviance of slope from 0. 
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Appendix Figure 10. Gene expression in TGF-β1-treated strain 1 lung fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH & TRIM27 housekeeping genes. *p<0.05, **p<0.01 Linear 
regression analysis, significance measured as deviance of slope from 0. 
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Appendix Figure 11. Gene expression in TGF-β1-treated strain 2 lung fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH & TRIM27 housekeeping genes. *p<0.05, **p<0.01 Linear 
regression analysis, significance measured as deviance of slope from 0. (Asterisks 
next to legend to identify which repeat is significant). 
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Appendix Figure 12. Gene expression in TGF-β1-treated strain 3 lung fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to B2M, GAPDH & TRIM27 housekeeping genes. *p<0.05 Linear regression analysis, 
significance measured as deviance of slope from 0. (Asterisks next to legend to 
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Appendix Figure 13. Gene expression in TGF-β1-treated strain 1 breast fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to HPRT-1, B2M & PPIA housekeeping genes. *p<0.05, **p<0.01 Linear regression 
analysis, significance measured as deviance of slope from 0. MMP-1 uncompleted.  
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  Appendix Figure 14. Gene expression in TGF-β1-treated strain 2 breast fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to HPRT-1, B2M & TRIM27 housekeeping genes. Linear regression analysis, 
significance measured as deviance of slope from 0. MMP-1 uncompleted.  
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Appendix Figure 15. Gene expression in TGF-β1-treated strain 3 breast fibroblasts. 
qPCR analysis of 8 myofibroblast-associated genes during 4-24-hour TGF-β1 
(5ng/ml) exposure. Data of TGF-β1 relative to vehicle-treated cells and normalised 
to HPRT-1, B2M & PPIA housekeeping genes. *p<0.05, Linear regression analysis, 
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Appendix Figure 16. Gene expression of 8 markers of myofibroblast activation 
after TGF-β1 addition to 3 strains of skin, lung and breast fibroblasts. Data is 
presented from the 16-hour or 24-hour time-point of TGF-β1 (5ng/ml) 
stimulation, according to which time-point induced peak gene expression. This 
was to establish which markers were most highly upregulated by TGF-β1 to 
facilitate the selection of markers to be analysed by western blot. Skin fibroblast 
strains 1 & 2 (24-hours) and strain 3 (16-hours). Lung fibroblast strain 1 and 3 (16-
hours) and lung strain 2 (24-hours). Breast fibroblasts strain 1 and 3 (24-hours) 
and strain 2 (16-hours). Housekeeping genes listed in Materials and Methods. 
Graphs show TGF-β1-induced genes significantly upregulated relative to vehicle-
cell stimulation. *p<0.05, **p<0.01, Paired students t-test. Data shown 
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Appendix Figure 17. Comparison of integrin subunit genes after TGF-β1 addition in skin, lung and breast fibroblasts. Fibroblasts were exposed to TGF-β1 
(5ng/ml) at varying times due according to peak expression during time course. Foreskin fibroblast strains 1 & 2 (24-hours), strain 3 HDF (16-hours). HLF1, 
HLF3 (16-hours) and strain 2 (24-hours). Breast fibroblasts strain 1 and 3 (24 hours), strain 2 was treated for 16-hours. Housekeeping genes listed in Materials 
and Methods. Fold-change of TGF-β1-treated relative to vehicle stimulation. *p<0.05, **p<0.01, Paired students t-test. Data represented as mean ± s.d.  
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  TGF-β1 
Appendix Figure 18. Mini-organotypic invasion assay and western blot of αv 
and β5 integrin expression in TGF-β1-treated breast fibroblasts. A) H & E and 
immunofluorescent staining of breast cancer cells admixed with breast 
fibroblasts in a 1:2 ratio plated above organotypic gels in transwell inserts and 
cultured for 7 days. The cancer cell layer was thinner when plated with breast 
fibroblast strain 2 (BF2) compared to breast cancer cells plated with strain 3 
(BF3). B) Western blots: BF2 and BF3 were stimulated with either vehicle (-) or 
TGF-β1 (+) (5ng/ml) for 48-hours. Strain 3 fibroblasts expressed more αv and β5 
than strain 2. HSC70 serves as loading control.  
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Drug name α-SMA p-value Fibronectin p-value 
Axitinib 7.85E-08 1.26E-09 
Abiraterone 5.77E-43 9.54E-51 
Erlotinib HCl 7.57E-07 6.39E-16 
Gefitinib 3.33E-05 1.29E-26 
Atazanavir sulfate 1.66E-250 1.19E-221 
Ofloxacin 2.65E-239 3.66E-59 
Marbofloxacin 4.06E-209 1.95E-22 
Zolmitriptan 1.76E-162 1.39E-12 
Flurdarabine 3.65E-210 1.55E-163 
Cefaclor 5.43E-87 5.50E-24 
Flucytosine 3.24E-122 0.000685314 
Trichlormethiazide 2.83E-171 1.34E-05 
Norfloxacin 1.10E-185 8.84E-229 
Tadalafil 8.81E-156 7.92E-25 
Pimobendan 1.86E-130 1.87E-124 
Pomalidomide 7.58E-95 2.04E-12 
Rizatriptan benzoate 5.23E-113 1.14E-11 
Lamivudine 1.17E-11 6.96E-17 
Enalaprilat dihydrate 1.02E-78 6.08E-07 
Isradipine 6.47E-52 2.95E-16 
Estrone 2.65E-63 4.89E-110 
Chloramphenicol 1.08E-50 1.45E-14 
Mesalamine 1.09E-47 1.63E-12 
Carbamazepine 4.77E-61 1.05E-37 
Appendix Figure 19. qPCR confirming integrin knockdown using integrin siRNA in 
lung strain 3 fibroblasts. Fibroblasts were pre-treated with TGF-β1 (5ng/ml) for 48 
hours and then 15nM integrin siRNA for 72 hours. Only 30% knockdown was achieved 
of α1 and β3 integrin and 50% knockdown of β5. Data shown represents mean ± s.d 
















































































































































1-Hexadecanol 8.84E-05 1.85E-06 
Tiratricol 4.26E-08 4.22E-35 
Sevelamer HCl 9.03E-06 6.93E-11 
Toltrazuril 8.88E-05 0.000428613 
Sulfacetamide sodium 0.000269903 5.66E-16 
Ritonavir 0.000183239 0.000123 
Chlorpropamide 4.08E-06 0.001947822 
Plerixafor 0.000132417 1.32E-38 
Misoprostol 2.89E-06 1.32E-12 
Teriflunomide 7.59E-06 0.001765107 
Deoxyarbutin  0.00012313 8.51E-08 
Ramelteon  0.000428992 1.85E-99 
Biperiden HCl 6.02E-86 0.000458 
Amoxapine 1.28E-05 0.000103919 
Tolperisone HCl 1.20E-07 4.03E-06 
Piperacillin sodium 4.84E-08 5.21E-15 
Benzydamine HCl 1.00E-26 1.06E-05 
Nicardipine HCl 1.79E-05 2.96E-06 
Sasapyrine 7.59E-11 1.76E-05 
Pilocarpine HCl 2.27E-17 2.24E-24 
Fasudil 1.23E-05 1.77E-16 
Y27632 0.000286166 3.31E-24 
Appendix Table 1. FDA-approved drugs that significantly reduced α-SMA and 
fibronectin expression in TGF-β1-treated lung fibroblasts. Statistical test 
Kolmogorov-Smirnov was used to compare cumulative frequency of drug & TGF-





#To show plate list: 
plateList <- 
read.table(file="C:\\Users\\Zareen\\Desktop\\drugTestingStats\\plateList.txt", 
sep="\t", header = FALSE, stringsAsFactors = FALSE) 
#wells containing drug data 
drugsWells <- expand.grid(seq(2,10,2), c("A", "B", "C", "D", "E", "F", "G", "H")) 
#loop though each plate and perform statistics,  
for(currPlate in 1:nrow(plateList)){ 
#make results table 
mainFNTab <- data.frame(matrix(NA, ncol=7, nrow=40)) 
names(mainFNTab) <- c("well", "type", "NorCells", "DrugCells", "meanNorm", 
"meanDrug", "p.value") 
mainFNTab[1:40, 2] <- "FN" 
#plate locations 
SMAplateTemp <- paste("C:\\Users\\Zareen\\Desktop\\drugTestingStats\\", 
as.character(plateList[currPlate,1]), "\\", as.character(plateList[currPlate,1]), 
".SMA.A.csv", sep="") 
FNplateTempA <- paste("C:\\Users\\Zareen\\Desktop\\drugTestingStats\\", 
as.character(plateList[currPlate,1]), "\\", as.character(plateList[currPlate,1]), 
".FN.A.csv", sep="") 
FNplateTempB <- paste("C:\\Users\\Zareen\\Desktop\\drugTestingStats\\", 
as.character(plateList[currPlate,1]), "\\", as.character(plateList[currPlate,1]), 
".FN.B.csv", sep="")   
#make output directory 
#system(command = paste("mkdir ", 
"C:\\Users\\Zareen\\Desktop\\drugTestingStats\\", 
as.character(plateList[currPlate,1]), sep="")) 
#### FN analysis #### 
Appendix Figure 20. RStudio script used to analyse IN Cell drug screen data. The 
script presented below was used to assess fibronectin (FN) staining intensity of 
lung fibroblasts in drug + TGF-β1 compared to DMSO + TGF-β1 treated wells. For 
α-SMA analysis, ‘FN’ was substituted for ‘SMA’ to access the correct data file.  
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#read in tables 
FNtab <- read.csv(file=FNplateTempA, stringsAsFactors = FALSE) 
#remove NA rows 
FNtab <- FNtab[FNtab[[1]] != "", ] 
 #remove unwanted spaces from cell names 
 for(currStr in 1:nrow(FNtab)){FNtab[currStr,1] <- 
paste(strsplit(as.character(FNtab[currStr,1]), split = " ")[[1]][1], 
strsplit(as.character(FNtab[currStr,1]), split = " ")[[1]][3], sep = "") 
  } 
#separate control from plate 
normalFN <- FNtab[FNtab[[1]]=="A12" | FNtab[[1]]=="B12", ] 
meanNormal <- mean(normalFN[["Levels.FN_NM.Cells"]]) 
#plot graphs as grid  
graphName <- 
paste("C:\\Users\\Zareen\\Desktop\\drugTestingStats\\",as.character(plateList[cur
rPlate,1]), "\\", as.character(plateList[currPlate,1]), ".FN.pdf", sep="") 
pdf(file=graphName, height = 40, width = 20) 
par(mfrow=c(10, 4), mar=c(2,2,2,2)) 
#status message during running of the script 
for(currTest in 1:nrow(drugsWells)){ 
currentWell <- paste(drugsWells[currTest, 2], drugsWells[currTest, 1], sep="") 
print(paste("#### analyzing plate", currPlate, "drug well", currentWell, "####")) 
#save current well name to main table 
mainFNTab[currTest, "well"] <- currentWell 
mainFNTab[currTest, "NorCells"] <- nrow(normalFN) 
mainFNTab[currTest, "meanNorm"]<- meanNormal 
#show current drug data 
currDrugData <- FNtab[FNtab[["Section"]]==currentWell, ] 
#test to see if current well has drug 
if(nrow(currDrugData) < 200){ 
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#do not perform statistical test 
mainFNTab[currTest, "DrugCells"] <- nrow(currDrugData) next 
    } 
#perform a Kolmogorov Smirnov test or Wilcoxon signed rank test (‘wilcox.test’) 
tempStats <- ks.test(x = normalFN[["Levels.FN_NM.Cells"]], y = 
currDrugData[["Levels.FN_NM.Cells"]], alternative = "less") 
#save the statistics to a main table (MS Excel) 
mainFNTab[currTest, "meanDrug"] <- mean(currDrugData[["Levels.FN_NM.Cells"]]) 
mainFNTab[currTest, "p.value"] <- tempStats["p.value"] 
mainFNTab[currTest, "DrugCells"] <- nrow(currDrugData) 
#plot cumulative frequency graph to compare distribution* 
plot(ecdf(x=normalFN[["Levels.FN_NM.Cells"]]), cex=0.5, col=rgb(0,0,1,0.5), 
main=paste(as.character(plateList[currPlate,1]), " ", currentWell)) 
plot(ecdf(x=currDrugData[["Levels.FN_NM.Cells"]]), cex=0.5, col=rgb(1,0,0,0.5), 
add=TRUE) 
legend("bottomright", legend = c("drug", "normal"), col=c(rgb(1,0,0,0.5), 
rgb(0,0,1,0.5)), lty=1, lwd=5, cex=1.5) 
text(x=600, y=0.8, labels = paste("p =", round(as.numeric(tempStats["p.value"], 
digits = 10))), cex=3)  } 
dev.off() 
#save main table to chosen directory location  
outFNfile <- paste("C:\\Users\\Zareen\\Desktop\\drugTestingStats\\", 
as.character(plateList[currPlate,1]), "\\", as.character(plateList[currPlate,1]), 
".FN.cumulfreq.csv", sep="") 
write.table(mainFNTab, file=outFNfile, sep=",", row.names = FALSE, quote = FALSE)} 
*#or instead to a plot a box and whiskers plot to compare medians 
graphName <- paste("C:\\Users\\Zareen\\Desktop\\drugTestingStats\\FN\\", 
as.character(plateList[currPlate,1]), "\\", as.character(plateList[currPlate,1]), 
".boxplot.", currentWell, ".pdf", sep="") pdf(file=graphName, height = 5, width = 5) 
boxplot(normalFN[["Levels.FN_NM.Cells"]], currDrugData[["Levels.FN_NM.Cells"]], 
main=paste(as.character(plateList[currPlate,1]), currentWell), ylab="Fluorescence", 
names = c("Normal", "Drug")) 
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